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ABSTRACT  
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease 
characterized by microangiopathic hemolytic anemia and 
thrombocytopenia with renal impairment or neurologic abnormalities due 
to the deposition of thrombi rich in platelets and von Willebrand factor 
(VWF) in the microcirculation. ADAMTS13 regulates the size, and 
therefore the thrombogenic potential, of VWF by cleaving a single peptide 
bond in VWF. Congenital or acquired ADAMTS13 deficiency is the major 
risk factor for TTP. Autoantibodies against ADAMTS13 are believed to 
cause ADAMTS13 deficiency in acquired idiopathic TTP. The main 
objective of this work was to study the pathophysiologic and prognostic 
value of anti-ADAMTS13 antibodies in a cohort of 76 patients with 
acquired TTP. To achieve this goal, enzyme-linked immunosorbent assays 
were established to detect and quantify IgG1-4, IgA, and IgM anti-
ADAMTS13 antibodies as well as circulating ADAMTS13-specific immune 
complexes (ICs). The surveyed antibody profile revealed the presence of 
anti-ADAMTS13 antibodies of the IgG, IgA, and IgM class in 92%, 17% 
and 7% of the patients, respectively. IgG4 (90%) was the most prevalent 
IgG subclass, followed by IgG1 (52%), IgG2 (50%), and IgG3 (33%). 
ADAMTS13-specific immune complexes formed by IgG1-4 and IgA were 
found in 82 and 25% of the patients, respectively. Notably, the complexes 
contained antibodies of the same Ig (sub)classes as the free antibodies 
present in most of the samples, being IgG4-ICs the most prevalent (87%) 
ICs found. Anti-ADAMTS13 IgG antibodies associated with a high inhibitor 
titer at disease presentation were associated with persistence of 
undetectable ADAMTS13 activity in clinical remission. TTP patients with 
high IgG4 and undetectable IgG1 levels were more prone to relapse than 
patients with low IgG4 and detectable IgG1 levels suggesting that IgG4 
could be a useful biomarker for identification of patients at risk of disease 
recurrence. Circulating ADAMTS13-specific immune complexes may 
contribute to progression and severity of the disease, because they may 
continuously deplete ADAMTS13 from circulation inducing organ damage 
due to tissue deposition. The comprehensive characterization of anti-
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ADAMTS13 antibodies as well as circulating ADAMTS13-specific ICs is 
expected to contribute to a better understanding of the mechanisms 
leading to the autoimmune form of TTP. 
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ZUSAMMENFASSUNG 
Thrombotische thrombozytopenische Purpura (TTP) ist eine 
lebensbedrohliche Erkrankung, die durch eine mikroangiopathische 
Anämie und Thrombozytopenie mit eingeschränkter Nierenfunktion oder 
neurologischen Auffälligkeiten durch die Ablagerung von Thromben (reich 
an Thrombozyten und von Willebrand Faktor (VWF)) in der 
Mikrozirkulation gekennzeichnet ist. ADAMTS13 regelt die Größe und 
damit das thrombogene Potenzial von VWF durch die Spaltung einer 
einzigen Peptidbindung in VWF. Angeborener oder erworbener ADAMTS13 
Mangel ist der wichtigste Risikofaktor für die TTP. Autoantikörper gegen 
ADAMTS13 führen  vermutlich zum erworbenen ADAMTS13 Mangel in der 
idiopathischen TTP. Das Hauptziel dieser Arbeit war es, die 
pathophysiologischen und prognostischen Werte von Anti-ADAMTS13 
Antikörpern in einer Kohorte von 76 Patienten mit erworbener TTP zu 
untersuchen. Deshalb wurden Enzym-gekoppelte Immun-Assays etabliert, 
die IgG1-4, IgA, IgM-und Anti-ADAMTS13 Antikörper sowie die 
zirkulierenden ADAMTS13-spezifische Immunkomplexe (ICs) erkennen 
und quantifizieren können. Das untersuchte Antikörper Profil zeigte die 
Anwesenheit von anti-ADAMTS13 Antikörper der IgG, IgA, IgM-Klasse in 
92%, 17% und 7% der Patienten. IgG4 (90%) war die häufigste IgG 
Unterklasse gefolgt von IgG1 (52%), IgG2 (50%) und IgG3 (33%). 
ADAMTS13-spezifische Immunkomplexe, bestehend aus IgG1-4-und IgA, 
wurden in 82 und 25% der Patienten gefunden. Es ist bemerkenswert, 
dass diese Immunkomplexe Antikörper der gleichen Ig (sub-) Klassen 
enthielten wie die in den meisten Proben gefundenen freien Antikörper, 
wobei IgG4-ICs am häufigsten (87%) ICS vorkamen. Anti-ADAMTS13 IgG-
Antikörper, die mit einem hohen Inhibitor-Titer bei 
Krankheitserscheinung einhergingen, wurden mit nicht nachweisbarer 
ADAMTS13 Tätigkeit in klinischer Remission assoziiert. TTP Patienten mit 
hohen IgG4 und nicht nachweisbaren IgG1-Spiegeln waren anfälliger für 
Krankheitsrückfälle als Patienten mit niedrigen IgG4 und nachweisbaren 
IgG1-Spiegeln, was darauf hindeutet, dass IgG4 ein nützlicher Biomarker 
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für die Identifizierung von Patienten mit Rezidiv-Risiko sein könnte. 
Zirkulierende ADAMTS13-spezifische Immunkomplexe können zur 
Progression und Schwere der Krankheit beitragen, weil sie kontinuierlich 
ADAMTS13 aus der Blutzirkulation entfernen, was zu 
Gewebeablagerungen und nachfolgenden Organschädigungen führt. Die 
umfassende Charakterisierung von anti-ADAMTS13 Antikörpern sowie 
zirkulierenden ADAMTS13-spezifischen ICs kann zu einem besseren 
Verständnis der Mechanismen beitragen, die zu der 
Autoimmunerkrankungsform der TTP führen. 
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1- INTRODUCTION 
1. Introduction 
ADAMTS13 is the thirteenth member of the ADAMTS (A Disintegrin-like 
And Metalloprotease with ThromboSpondin type-1 repeats) family of 
metalloproteases. Its function is to regulate the size of the hemostatic 
protein von Willebrand factor (VWF) (Porter et al, 2005). VWF is released 
from intracellular storage compartments in the form of multimers 
containing a portion of very high molecular weight multimers referred to 
as ultra-large VWF (ULVWF) multimers (Sporn et al, 1986). These ULVWF 
multimers bear a high prothrombotic potential, but usually they are 
proteolyzed by ADAMTS13 immediately after secretion, thereby reducing 
the size and by consequence the prothrombotic properties of VWF while 
maintaining its hemostatic function. This function confers to ADAMTS13 
an important role in the maintenance of a balanced hemostasis. 
 
1.1 Overview of Hemostasis 
Hemostasis is a protective physiological mechanism by which the body 
prevents loss of blood at the site of injury while maintaining normal blood 
flow elsewhere in the circulation. Hemostasis is a dynamic and complex 
system, involving cells, coagulation proteins and the vascular wall to keep 
the blood in a fluid state, but the same players form a barrier when 
trauma or pathologic conditions cause vessel damage. When the 
continuity of the vascular endothelium is disrupted, components of the 
subendothelial layers of the vessel wall are exposed to flowing blood 
allowing circulating platelets to adhere thereby initiating blood arrest. 
Activated platelets stimulate the activation of plasma coagulation factors 
leading to the generation of fibrin that stabilizes the platelet plug. Fibrin 
also provides a matrix for cell migration and wound healing. In the latter 
case, the platelet aggregate and fibrin clot are dissolved and removed by 
the fibrinolytic system which completes the process of hemostasis (Arnout 
et al, 2006). 
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Hemostasis is a tightly regulated process. In the absence of injury, 
regulatory mechanisms ensure the maintenance of blood fluidity. After 
tissue damage the system is immediately activated. As a consequence a 
thrombus is generated that remains localized to the site of injury and is 
proportional to the size of injury (Gale, 2011). A balance between 
procoagulant and anticoagulant pathways is critical to achieve a regulated 
hemostasis (Gale, 2011). Disturbances of the natural balance due to 
genetic or acquired factors may result in either bleeding (not enough 
clotting) or thrombosis (too much clotting).  
Hemostasis can be divided into primary and secondary hemostasis. 
Primary hemostasis is mediated by platelets which aggregate to form a 
hemostatic plug at the site of injury. Secondary hemostasis is the 
generation of insoluble fibrin by the coagulation cascade. Both processes 
occur simultaneously and are mechanistically intertwined (Furie & Furie, 
2008;Gale, 2011). 
 
1.1.1 Primary Hemostasis 
The intact vascular endothelium is a non-adhesive surface with which 
platelets are not interacting under normal blood flow. However, when the 
endothelium is disrupted by mechanical damage (traumatic wounds) or 
pathogenic stimuli (e.g. chronic vascular diseases), extracellular matrix 
(ECM) components become exposed to circulating blood triggering events 
of primary hemostasis. Platelet adhesion is the first response to vascular 
injury and is an important host defense mechanism to avoid bleeding. 
Platelet adhesion requires the synergistic and coordinated function of 
different plasma proteins and receptors on platelets together with ECM 
components (Ruggeri, 2009). 
The initial platelet tethering to the vessel wall is mediated by the 
interaction between two platelet surface receptors (glycoprotein (GP) VI 
and integrin α2β1) and subendothelial collagen. Subendothelial VWF also 
mediates platelet adhesion by binding to the platelet receptors GPIbα 
(platelet membrane GPIb-IX-V complex) (Andrews et al, 2003) and integrin 
αIIbβ3 (Ruggeri & Mendolicchio, 2007). Soluble plasma VWF can also be 
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immobilized to ECM components via direct binding to sudendothelial 
collagen or self-association with other VWF multimers, thus acting as a 
bridge between tissue and platelets (Savage et al, 2002;Ruggeri, 2009).  
After platelets are firmly adhered to ECM components, they can 
translocate on the injured vessel wall and on the surface of the developing 
thrombus. This step is critical for the regulation of the rate and extent of 
thrombus growth. Platelet translocation also generates signals that induce 
platelet morphological changes like rearrangement of the membrane with 
exposure of negatively charged phospholipids and development of 
tethers/pseudopodia that increase the platelet potential to establish 
multivalent adhesive interactions (Dahlback, 2005;Jackson, 2007). The 
exposition of negatively charged phospholipids (mainly 
phosphatidylserine) on the outer membrane layer of platelets is 
particularly critical for platelet procoagulant activity. Platelet activation 
and granule content release are responsible for activation of additional 
platelets (Dahlback, 2005). Platelet activation also stimulates integrin 
αIIbβ3 activation, enhancing its affinity for adhesive proteins such as 
soluble fibrinogen, VWF, fibronectin and thrombospondin (Tao et al, 
2010). Fibrinogen physically bridges adjacent activated platelets 
promoting cell arrest and stable platelet aggregation. Platelet aggregation 
mediated by binding of soluble fibrinogen to platelet integrin αIIbβ3 is the 
dominant mechanism supporting platelet aggregation under low wall 
shear rate conditions (0 to 1000 s-1). With increasing wall shear rates 
(1000 to 10 000 s-1), the initiation of aggregation becomes more dependent 
on VWF and fibrinogen only supports the stabilization of the formed 
aggregates (Jackson, 2007). Nevertheless, fibrinogen and VWF have a 
synergistic role supporting platelet aggregation and both are required to 
ensure a stable primary plug. Primary hemostasis is coordinated with the 
activation of the coagulation system (secondary hemostasis) which will 
generate thrombin and deposition of an insoluble fibrin net stabilizing and 
anchoring the primary thrombus to the vessel wall.   
 - 14 - 
1.1.2 Secondary Hemostasis 
The original waterfall/cascade model of coagulation depicted as a Y-
shaped scheme was described in 1964 independently by Davie and Ratnoff 
(DAVIE & RATNOFF, 1964) and Macfarlane (MACFARLANE, 1964). This 
model describes a complex series of sequential enzymatic reactions in 
which several inactive plasma coagulation zymogens are converted to 
active serine proteases along either an extrinsic or an intrinsic pathway 
that converge at a common pathway that ends with the generation of 
thrombin and a fibrin clot (Fig.1).  
The activation of the extrinsic pathway is triggered by the exposition of 
tissue factor (TF) to flowing blood, which occurs after vascular damage or 
activation of the endothelium. Tissue factor is a transmembrane protein 
constitutively expressed on cells that are not in contact with blood. TF 
binds to activated plasma factor (F) VII (FVIIa, with the lower case “a” 
indicating active clotting factor), about ~1% of which circulates as active 
enzyme. Circulating FVIIa displays a weak catalytic activity that is 
enhanced only when bound to TF, calcium ions and membrane surfaces to 
form the catalytic TF/FVIIa tenase complex. TF/FVIIa complex activates 
the zymogens FIX (belonging to the intrinsic pathway) and FX to their 
active forms (IXa and Xa, respectively) (Butenas et al, 2009). At this initial 
stage, trace amounts of thrombin are generated by the minute quantities 
of FXa produced. The small amount of thrombin generated is not 
sufficient to induce clot formation but will partially activate platelets and 
the cofactors FV and FVIII to their active forms allowing the propagation 
and amplification of the coagulation to generate a fibrin clot (Butenas & 
Mann, 2002) (Fig.1).  
Initiation of the intrinsic pathway is triggered by the autoactivation of 
plasma coagulation factor XII upon contact with negatively charged 
biological or artificial surfaces (e.g. platelet membrane, collagen, glass) by 
a process called “contact activation”. In the presence of high-molecular-
weight kininogen (HMWK), a platelet-derived cofactor, small amounts of 
FXIIa can convert prekallikrein into active kallikrein which reciprocally 
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activates more FXII thereby amplifying the activation signal. Factor XIIa, 
in the presence of HMWK, proteolytically cleaves FXI to FXIa which in turn 
activates FIX to FIXa (Renne & Gailani, 2007;Muller & Renne, 2008). 
 
Figure 1. Schematic representation of the coagulation cascade.  
The intrinsic and extrinsic pathways are depicted. Plasma coagulation 
zymogens are indicated by roman numbers and activated factors by a lower 
case “a”. Non-enzymatic cofactors are indicated in green. The red line 
indicates a reaction that does not belong to the standard waterfall cascade 
described in 1964. 
Factor IXa assembles with activated FVIII (FVIIIa) and calcium ions into a 
complex on negatively charged platelet membranes. This so called tenase 
complex catalyzes the activation of FX to FXa (Fig.1).  
The extrinsic and intrinsic pathways converge at the step of FX activation. 
In the common pathway, FXa forms a complex with FVa, calcium ions and 
phospholipid membranes (prothrombinase complex) which activates 
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prothrombin to thrombin (FIIa). Thrombin converts fibrinogen to fibrin 
monomers that spontaneously polymerize in a soft and friable clot (Fig.1). 
Furthermore, thrombin activates FXIII to FXIIIa which catalyzes the 
formation of covalent cross-links between fibrin polymers to form a fibrin 
mesh thus enhancing clot stability and resistance (Lorand, 2001).  
The waterfall/cascade model of coagulation supports the in vitro 
evaluation of coagulation function but may not explain coagulation in 
vivo. The catalytic reactions of blood coagulation are localized on 
phospholipid surfaces mainly provided by platelets, but cells also play a 
key role in controlling and directing the coagulation event to avoid its 
spreading throughout the vascular system. A modified cell-based model of 
coagulation has been proposed which describes the interaction of clotting 
factors with specific cell surfaces in an overlapping manner and not only 
in a sequential cascade of reactions (Hoffman, 2003;Monroe & Hoffman, 
2006).  
In this cell-based model, coagulation occurs in three overlapping phases: 
initiation, amplification and propagation (Hoffman, 2003;Monroe & 
Hoffman, 2006). The initiation of coagulation is driven in vivo by the 
extrinsic or TF-dependent pathway that includes the FVIIa/TF and the 
FXa/FVa complexes and operates exclusively on TF-bearing cells. During 
this phase, the FVIIa/TF complex activates FIX and FX. FIXa is able to 
migrate to other cellular surfaces whereas FXa remains on TF-bearing 
cells, where it activates FV to form the FXa/FVa or prothrombinase 
complex, which in turn produces small amounts of thrombin. These small 
quantities of thrombin suffice to activate platelets, FV, FVIII and FXI, 
thereby initiating the amplification phase. This phase occurs mainly on 
platelets and ends with the binding of FVa and FVIIIa to the surface of 
activated platelets. In the propagation phase, the tenase complex 
(FVIIIa/FIXa) bound to platelet membranes activates FX, which will form 
the prothrombinase complex (FXa/FVa) on the platelet surface. This 
complex generates a large amount of thrombin, which finally converts 
fibrinogen to fibrin and activates FXIII leading to a stabilization of the 
forming clot (Hoffman, 2003;Monroe & Hoffman, 2006). 
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On the other hand, contact activation does not play any physiological role 
in that process. The intrinsic pathway is only operating on platelet 
surfaces and is driven by FXIa and the tenase (FVIIIa/FIXa) and 
prothrombinase (FXa/FVa) complexes. According to this model, both 
pathways are required to achieve hemostasis because they work on 
different cell surfaces having different functional roles. 
 
1.2 Von Willebrand Factor  
The von Willebrand factor is a large plasma multimeric glycoprotein that 
exerts two important biological functions. In primary hemostasis, VWF 
supports platelet adhesion and aggregation (Ruggeri, 2009). The second 
relevant function of VWF relates to its role in secondary hemostasis, as it 
serves as a carrier protein for the procoagulant plasma factor VIII. VWF 
forms a complex with FVIII via non-covalent interactions increasing the 
plasma half-life of FVIII and conferring protection from proteolytic 
degradation (Terraube et al, 2010). 
VWF is synthesized exclusively in megakaryocytes (Nachman et al, 1977) 
and endothelial cells (Jaffe et al, 1974). The VWF precursor protein 
(denoted as pre-pro-VWF) consists of a monomeric polypeptide of 2813 
amino acids with a molecular weight of about 350 kDa. The structure of 
pre-pro-VWF is based on a 22 amino acid signal peptide, a pro-peptide 
comprising 741 residues and a mature subunit of 2050 amino acids. The 
pro-VWF is composed of four types of repeated domains (A to D) displaying 
considerable internal homology and linked in the order: NH2-D1-D2-D’-
D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK-COOH. Each domain contains 
different physiological binding functions. Domains D1 and D2 correspond 
to the VWF propeptide whereas mature VWF is composed of domains D’ to 
CK (Wagner, 1990;Sadler, 1998). 
Pro-VWF is extensively post-translationally modified to produce 
multimeric VWF. In the endoplasmic reticulum, pro-VWF monomers 
dimerize in a ‘tail-to-tail’ manner through disulfide bonds within the C-
terminal domains. In the Golgi apparatus, pro-VWF dimers polymerize via 
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additional N-terminal ‘head-to-head’ disulfide bonds yielding high 
molecular weight multimeric VWF species, the sizes of which can reach 
molecular weights up to 20.000 kDa or even higher. Multimer assembly is 
promoted by the VWF-propeptide which is proteolytically cleaved from the 
VWF subunits inside the trans-Golgi. The VWF-propeptide is also required 
to direct and package VWF multimers into specialized storage organelles, 
the so-called Weibel-Palade bodies of endothelial cells and the α-granules 
of megakaryocytes and platelets. 
In endothelial cells, VWF multimers are secreted immediately after 
synthesis from both cellular sides (apical and basal) via a constitutive 
pathway or stored in the Weibel-Palade bodies and released after 
induction with secretagogues via a regulated pathway (Wagner, 1990) or, 
probably, by an unstimulated basal pathway (Giblin et al, 2008). In 
contrast, VWF stored in megakaryocytes and platelets is secreted only 
upon activation via the regulated pathway (Sporn et al, 1985). 
VWF is released from the stored compartments in the form of multimers 
containing a portion of very high molecular weight multimers referred to 
as ultra-large VWF (ULVWF) multimers (Sporn et al, 1986). These highest 
molecular weight VWF species are the hemostatically most active forms 
with a propensity to promote spontaneous platelet adhesion and 
aggregation under high shear. As this aggregation can occur even in the 
absence of endothelial damage ULVW multimers bear a significant 
prothrombotic potential (Moake et al, 1986). 
VWF multimer size is regulated by ADAMTS13 (A Disintegrin-like And 
Metalloprotease with ThromboSpondin type-1 repeats), a metalloprotease 
that specifically cleaves the peptide bond between the amino acids 
Tyr1605 and Met1606 within the central A2 domain of VWF (Furlan et al, 
1996;Tsai, 1996). This conversion of the ULVWF multimers to smaller and 
less active forms is thought to predominantly occur immediately after 
secretion of VWF.  
The first association between the presence of circulating ULVWF 
multimers and thrombosis was made in 1982 (Moake et al, 1982) in a 
description of patients suffering of chronic relapsing thrombotic 
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thrombocytopenic purpura (TTP), a life-threatening thrombotic 
microangiopathy characterized by thrombocytopenia, microangiopathic 
hemolytic anemia and renal impairment or neurological abnormalities. 
The ULVWF multimers were present in the plasma only during the 
remission phase of the disease, disappearing after fresh plasma 
replacement or during the acute phase. This led to the speculation that 
ULVWF multimers are responsible for the widespread thrombus formation 
observed in the microvasculature of the patients and that a plasma 
deficiency of a VWF depolymerase (today known as ADAMTS13) could be 
the cause of the accumulation of ULVWF multimers. 
On the other hand, deficiency of VWF can cause a bleeding disorder called 
von Willebrand disease (VWD). VWD is the most common autosomally 
inherited bleeding disorder due to quantitative (type 1 and 3) or qualitative 
(type 2) deficiencies of VWF (Sadler et al, 2006). In type 1 VWD, VWF levels 
are partially reduced, whereas in type 3 VWD are undetectable. Type 2 
VWD is characterized by qualitative defects in VWF that lead to impaired 
protein function and can be divided into four different subclasses (2A, 2B, 
2M and 2N) based on specific functional and structural defects. Patients 
with type 2A VWD have decreased VWF-dependent platelet adhesion due 
to a selective deficiency of high-molecular-weight VWF multimers. A VWF 
with increased affinity for platelet GPIb characterize type 2B VWD. 
Patients with type 2M VWD have decreased VWF-dependent platelet 
adhesion without a selective deficiency of high-molecular-weight VWF 
multimers. Finally, a VWF with markedly decreased binding affinity for 
FVIII characterize type 2N VWD (Sadler et al, 2006). 
 
1.3 ADAMTS13  
1.3.1 ADAMTS13 identification and cloning  
Two independent groups partially purified a ~200 kDa plasma protease in 
1996 that was capable of cleaving VWF at a single specific site producing 
the same cleavage fragments of 140 and 176 kDa as observed in normal 
human plasma (Furlan et al, 1996;Tsai, 1996). The newly identified 
protease cleaved VWF only after exposure to mild denaturation with 
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chaotropic agents such as urea (Furlan et al, 1996) and guanidine-HCl 
(Tsai, 1996) or to high fluid shear stress (Tsai, 1996). The VWF-cleaving 
protease (VWFCP) was found to be activated by divalent cation ions and 
low ionic strength, strongly inhibited by chelating agents and insensitive 
to serine and cysteine proteinase inhibitors. Later on, deficiency of the 
VWFCP was found in patients suffering from chronic relapsing TTP 
(Furlan et al, 1997) and it was shown that in some cases, an isolated IgG 
from plasma of TTP patients inhibited the proteolytic activity of the 
VWFCP, suggesting that a constitutional or acquired deficiency of the 
VWFCP has led to development of TTP (Furlan et al, 1998;Tsai & Lian, 
1998). 
In 2001, the VWFCP was isolated, cloned and identified as a new member 
of the ADAMTS (A Disintegrin-like And Metalloprotease with 
ThromboSpondin type-1 repeats) metalloprotease family, designed 
ADAMTS13 (Gerritsen et al, 2001;Fujikawa et al, 2001;Soejima et al, 
2001;Zheng et al, 2001;Levy et al, 2001;Plaimauer et al, 2002).  
The human ADAMTS13 gene contains 29 exons encompassing 
approximately 37kb on human chromosome 9q34. The 4.7 kb transcript 
encoded by the ADAMTS13 gene is predominantly expressed in the liver 
and a short 2.4 kb transcript was also found in placenta and skeletal 
muscles (Soejima et al, 2001;Zheng et al, 2001;Levy et al, 2001). 
 
1.3.2 ADAMTS13 biosynthesis, secretion and catabolism 
ADAMTS13 is synthesized in the hepatic stellate cells of the liver (Uemura 
et al, 2005;Zhou et al, 2005), platelets (Suzuki et al, 2004), endothelial 
cells (Turner et al, 2006) and podocytes and renal tubular epithelial cells 
from the kidney (Manea et al, 2007;Manea et al, 2010). In contrast to 
other ADAMTS proteases, ADAMTS13 is secreted into the circulation as an 
active enzyme (Majerus et al, 2003) with a plasma half-life of 
approximately 2-3 days (Furlan et al, 1999). The estimated normal plasma 
concentration of ADAMTS13 is ~1 µg/ml (5 nM) (Gerritsen et al, 
2001;Rieger et al, 2006). A small percentage (~3%) of ADAMTS13 
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circulates bound to native VWF without exerting substrate proteolysis 
(Feys et al, 2009). 
Full length ADAMTS13 is the major plasma circulating species, however, 
truncated forms have also been identified (Gerritsen et al, 2001;Soejima et 
al, 2006). Mature ADAMTS13 is highly posttranslationally modified with 
glycosylation accounting for ~20% of its molecular weight. N-glycosylation 
(Zhou & Tsai, 2009) and O-fucosylation of the TSP1 repeats (Ricketts et al, 
2007) seem to be critical for ADAMTS13 secretion based on studies in cell 
culture with recombinantly expressed ADAMTS13. Moreover, N-
glycosylation seems to be important for promoting a correct protein folding 
rendering ADAMTS13 proteolytically more active. N-glycans are however 
not required for protease activity once ADAMTS13 is correctly folded and 
secreted (Zhou & Tsai, 2009). Using purified plasma-derived ADAMTS13 
(pADAMTS13), Hiura et al (Hiura et al, 2010) showed that ADAMTS13 
contains α2-6 and α2-3-linked sialic acid residues at the non-reducing 
terminus and β-galactose residues on the N- and O-linked sugar chains 
penultimate to sialic acid. 
The mechanism by which ADAMTS13 is cleared or metabolized in vivo is 
unknown. Recent findings indicate that all sugar chains of pADAMTS13 
are capped by sialic acids with no exposure of galactose residues. This 
could suggest that the hepatic asialoglycoprotein receptor is involved in 
ADAMTS13 clearance (Hiura et al, 2010). It has been reported that 
thrombin, plasmin and factor Xa can inactivate ADAMTS13 in vitro 
(Crawley et al, 2005). Leucocyte elastase also cleaves pADAMTS13 but at 
sites different from those of thrombin and plasmin (Hiura et al, 2010). 
These results suggest that ADAMTS13 activity might be locally regulated 
by coagulation proteinases. 
 
1.3.3 ADAMTS13 structure and domain organization 
ADAMTS13 is a protein with a multidomain structure (Fig. 2). The primary 
ADAMTS13 sequence consists of a polypeptide with 1427 amino acid 
residues sharing common domains with other members of the ADAMTS 
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family. At its N-terminus, ADAMTS13 harbors a 33 amino acid signal 
peptide and a short propeptide (residues 34-74). The mature sequence 
consists of a reprolysin-like metalloprotease domain (residues 75-289), a 
disintegrin-like domain (residues 290-385), a central thrombospondin type 
1 (TSP1-1) motif (residues 386-439), a cysteine-rich domain (residues 440-
555), a spacer domain (residues 556-685) followed by a unique 
combination of seven additional TSP1 repeats (TSP1 2-8; residues 686-
1131) and two CUB domains (residues 1192-1408) which were first 
identified in complement components C1r and C1s, embryonic sea urchin 
protein (uEGF) and bone morphogenetic protein (Bmp1).  
 
Figure 2. Schematic diagram of the ADAMTS13 domain structure and 
proposed VWF interaction sites.  
The domains are indicated from the N-terminus as follows: signal peptide (S), 
propeptide (P), metalloprotease domain (M), disintegrin-like domain (Dis), the first 
thrombospondin type 1 motif (TSP1-1), cysteine-rich domain (Cys-R), spacer 
domain (Spa), the second to eighth TSP1 repeats (2-8) and two CUB domains (C1 
and C2). In the metalloprotease domain resides the active site responsible for VWF 
cleavage. The contributions of the different domains to the binding of ADAMTS13 to 
folded and unfolded VWF are also depicted. 
The crystal structure of full-length ADAMTS13 has not yet been resolved, 
but that of a fragment comprising the disintegrin-like, TSP1-1, cysteine-
rich and spacer domains, all of which are relevant for ADAMTS13 activity, 
was published recently (Akiyama et al, 2009). In some of these domains 
peripheral loops were identified that are not conserved among the different 
members of the ADAMTS family. Identification of these non-conserved 
domains not only helped to better understand the various interactions 
between ADAMTS13 and VWF but also suggested that these may confer 
specific functions to each ADAMTS member (Akiyama et al, 2009). 
The ADAMTS13 propeptide lacks the cysteine-switch motif present in all 
other ADAMTS members (Zheng et al, 2001). Since this motif confers 
enzyme latency its absence might be responsible for the secretion of 
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ADAMTS13 as an active enzyme (Majerus et al, 2003). The propeptide is 
also not required for protein folding and secretion, and its cleavage is not 
critical for proteolytic activity (Majerus et al, 2003). 
The metalloprotease or catalytic domain of ADAMTS13 is responsible for 
the specific cleavage of VWF and contains the conserved active site motif 
224HEXXHXXGXXHD235 (“X” represent any amino acid). The active site 
pocket has three histidine residues coordinating a Zn2+ ion and a glutamic 
acid coordinating a water molecule being essential for ADAMTS13 catalytic 
activity (Bode et al, 1999). In addition, the active site has also a conserved 
Met249 in a proposed “Met turn” (Bode et al, 1999) and a predicted high-
affinity Ca2+ -binding site adjacent to the active site cleft (Gardner et al, 
2009). 
The Cys-rich domain of ADAMTS13 has an RGD sequence that is usually 
used for recognition of integrins on cellular membranes and could 
therefore act as a potential anchor to cell surfaces, but this possibility has 
not yet been investigated. 
The thrombospondin-like repeats are homologous to the type I repeats of 
thrombospondin 1 and 2. The TSPs contain six potential CD36 binding 
motifs and preliminary in vitro studies showed that ADAMTS13 binds to 
CD36 via its TSPs without affecting its proteolytic activity suggesting that 
TSPs may localize ADAMTS13 to the cell surface of endothelial cells (Davis 
et al, 2009). 
The CUB domains are unique for ADAMTS13 (Zheng et al, 2001) and seem 
to be involved in apical sorting of ADAMTS13 in human endothelial cells 
and Madin-Darby canine kidney fibroblasts (a well-established cell line for 
polarized cell) by interacting with membrane lipid rafts (Shang et al, 
2006). Moreover, CUB domains seem to be critical for recognition and 
cleavage of VWF under flow conditions (Tao et al, 2005a;Zhang et al, 
2007). Four of five cysteine residues in the CUB-1 domain seem to have a 
critical role in ADAMTS13 secretion and stability (Zhou et al, 2011). 
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1.3.4 ADAMTS13 - VWF interactions and ADAMTS13 activity 
regulation 
VWF is the only known substrate of ADAMTS13 thus conferring to 
ADAMTS13 a highly selective role. ADAMTS13 cleaves VWF at a single site 
between amino acids Tyr1605 and Met1606 in the central part of the A2 
domain. VWF circulates in a native globular-shaped conformation where 
the ADAMTS13 cleavage site inside the A2 domain is buried, rendering it 
inaccessible for ADAMTS13 (Zhang et al, 2009). Partial or complete VWF 
A2 domain unfolding is required for ADAMTS13 to cleave VWF. In vitro, 
unfolding is obtained by the use of mild denaturing agents such as urea 
or guanidine-HCl. In vivo, unfolding is induced by flow under high shear 
stress as found in small arteries and capillaries. Under flow conditions, 
newly released ULVWF from Weibel-Palade bodies or endothelial cells 
remains anchored to the cellular surface via P-selectin (Padilla et al, 2004) 
or αVβ3 integrin (Huang et al, 2009) in the form of string-like structures 
that are rapidly cleaved by ADAMTS13. Recent in vitro findings suggest 
that this type of VWF hardly requires shear stress (Turner et al, 2009;Jin 
et al, 2009). Cleavage of endothelial cell-anchored ULVWF multimers by 
ADAMTS13 appears to be the prevalent mechanism in vivo (Dong et al, 
2002;Dong et al, 2004), but a portion of VWF is likely to be also cleaved in 
the microcirculation. 
ADAMTS13 can also act as disulfide bond reductase of VWF multimers 
(Yeh et al, 2010). This novel activity of ADAMTS13 selectively targets inter-
molecular disulfide bonds formed between VWF multimers under 
conditions of high fluid shear stress without affecting bonds that maintain 
the VWF multimeric structure. This reductase activity seems to be 
independent of the proteolytic activity of ADAMTS13 and might prevent 
covalent lateral VWF multimer association, a mechanism that in the 
absence of ADAMTS13 may lead to an enhanced binding to platelets.  
Many cofactors can positively or negatively modulate ADAMTS13 
proteolytic activity against VWF by binding to the enzyme itself or to VWF. 
Cations like Zn2+ and Ca2+ individually and cooperatively enhance 
ADAMTS13 proteolytic activity in static assays (Anderson et al, 2006). 
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Under high shear stress conditions, both platelets (Shim et al, 2008) and 
coagulation FVIII (Cao et al, 2008) independently, or synergistically when 
added together (Skipwith et al, 2010), accelerate and enhance VWF 
cleavage by ADAMTS13 in vitro. On the other hand, anions (ClO4- > Cl- > 
F-) may negatively modulate ADAMTS13 activity by binding to VWF under 
both static and flow conditions (De Cristofaro et al, 2005;De Cristofaro et 
al, 2006). 
During systemic inflammation, several reactive oxygen species are 
generated which cause oxidative stress that may oxidize the methionine 
residue at the VWF peptide bond cleavage site (Met1606) rendering VWF 
more resistant to ADAMTS13 proteolysis (Chen et al, 2010;Lancellotti et 
al, 2010). This effect may generate a prothrombotic state with 
accumulation of ULVWF multimers in circulation without altering their 
interaction with platelets.  
Multiple interactions between ADAMTS13 and the unfolded VWF A2 
domain are required for an efficient and specific proteolysis. The unfolded 
VWF A2 domain exposes different exosite-binding regions (adjacent and 
also distant to the cleavage site) that are recognized by counterpart 
exosites localized within different ADAMTS13 domains favoring a precise 
positioning of the ADAMTS13 active site next to the target VWF peptide 
bond.  
The contribution of the different domains to the proteolytic activity of 
ADAMTS13 has been investigated using C-terminally truncated 
ADAMTS13 fragments. The metalloprotease domain alone showed no 
proteolytic activity against VWF, and truncations upstream of the spacer 
domain cleaved full-length VWF with only very low efficacy under static 
(Zheng et al, 2003;Ai et al, 2005;Gao et al, 2006) and also under flow 
conditions (Tao et al, 2005b). Addition of the spacer region restored 
activity to levels similar to those of full-length ADAMTS13 (Zheng et al, 
2003;Tao et al, 2005b;Ai et al, 2005;Gao et al, 2006), highlighting the 
functional importance of the spacer domain for ADAMTS13 activity. 
Addition of domains C-terminal to the spacer domain do not further 
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increase the proteolytic activity of ADAMTS13 against VWF (Zheng et al, 
2003;Ai et al, 2005). 
The minimal functional VWF substrate identified for ADAMTS13 
comprises 73 amino acid residues (Asp1596 to Arg1668) of the C-terminal 
region of the A2 domain (abbreviated VWF73) (Kokame et al, 2004). 
Upon unfolding of the VWF A2 domain the ADAMTS13 spacer domain is 
docking to residues localized at the C-terminal end of the VWF A2 domain. 
Amino acids Arg658, Arg660, Tyr661 and Tyr665 within the spacer 
domain interact with residues between Glu1660 and Arg1668 in the VWF 
A2 domain (Gao et al, 2006;Gao et al, 2008;Akiyama et al, 2009;Jin et al, 
2010;Pos et al, 2010). This step seems to be critical for recognition and 
subsequent cleavage of VWF. Docking of the spacer domain is followed by 
the binding of residues within the ADAMTS13 disintegrin-like domain 
close to the VWF cleavage site, thus positioning the VWF cleavage site next 
to the ADAMTS13 active site (de Groot R. et al, 2009). Before proteolysis of 
VWF can finally occur, subsites within the metalloprotease domain of 
ADAMTS13 need to interact with VWF residues adjacent to the cleavage 
site to ensure a highly specific cleavage of the VWF peptide bond (Ai et al, 
2005;Gao et al, 2008;de Groot R. et al, 2010). Finally, stable interactions 
between the metalloprotease and the disintegrin-like domain appear to be 
essential for ADAMTS13 activity (Akiyama et al, 2009). The combined 
observations suggest that efficient substrate recognition, binding and 
cleavage require multiple N-terminal domains of ADAMTS13.  
A productive proteolysis additionally depends on interactions of VWF with 
the C-terminal domains of ADAMTS13. The first CUB domain (CUB-1) or 
peptides derived thereof were shown to partially inhibit the docking and 
cleavage of VWF by ADAMTS13 under static and flow conditions (Tao et al, 
2005a). Moreover, removal of the distal TSP1 2-8 and CUB domains also 
reduced the binding and cleavage of VWF under flow conditions, 
suggesting a critical role of these domains in VWF recognition (Majerus et 
al, 2005;Zhang et al, 2007). Studies conducted with congenic mice 
expressing a shorter version of ADAMTS13 that lacks the TSP1 7-8 and 
CUB domains have demonstrated that these mice were more prone to 
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thrombosis than mice carrying the wild type ADAMTS13 gene, suggesting 
an impaired capacity of the C-terminally truncated ADAMTS13 to regulate 
thrombus formation (Banno et al, 2009). In vivo studies using ADAMTS13 
knockout mice showed that injection of murine (m) ADAMTS13 variants 
lacking the two CUB domains abolished proteolysis of platelet-decorated 
VWF strings (De Maeyer et al, 2010). Additional injection of truncated 
mADAMTS13 variants lacking the TSP1 2-8 repeats restored proteolysis. 
These studies stressed the relevant role of the TSP repeats and CUB 
domains for ADAMTS13 binding and cleavage of VWF in vivo (De Maeyer 
et al, 2010). 
 
1.4 Measurement of ADAMTS13 activity, functional inhibitor 
and antigen  
The normal plasma ADAMTS13 activity in healthy individuals ranges from 
50-150%. The most widely used laboratory assays to measure ADAMTS13 
activity in plasma employ multimeric VWF (purified plasma-derived or 
recombinant) as substrate and measure directly (by electrophoresis) or 
indirectly (platelet aggregation, enzyme-linked immunosorbent assay 
(ELISA)) the degraded VWF products generated after incubation with 
ADAMTS13 (Furlan et al, 1996;Tsai, 1996;Gerritsen et al, 1999;Obert et 
al, 1999;Böhm et al, 2002). Overall, these assays have moderate 
sensitivity but they are cumbersome, time-consuming, call for expert 
laboratory handling and importantly, they measure ADAMTS13 activity 
under static and non-physiological conditions requiring long incubation 
times and denaturing conditions (urea or guanidine hydrochloride) to 
unfold VWF and to mimic the role of the physiological blood shear stress.  
Assays using as substrate recombinant VWF domains or short VWF A2 
domain-derived peptides have also been developed (Cruz et al, 
2003;Whitelock et al, 2004). Most of these assays use the 73 amino acid 
sequence of VWF (VWF73) shown to be the minimal functional ADAMTS13 
substrate (Kokame et al, 2004). The main advantage of this type of assays 
is that it does not require denaturing conditions. Currently, the most 
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widely used assay is a fluorescence resonance energy transfer (FRET)-
based assay employing a fluorogenic VWF73 as substrate (FRETS-VWF73) 
(Kokame et al, 2005). The FRETS-VWF73 assay, although using a non-
physiological VWF substrate, showed good agreement with ADAMTS13 
activity assays employing full-length VWF (Groot et al, 2006;Mahdian et 
al, 2006;Kremer Hovinga et al, 2006). It shows high reproducibility and 
accuracy and requires short incubation times (~1 h). 
The measurement of ADAMTS13 functional inhibitor is based on the 
principle of the Bethesda method originally described for anti-factor VIII 
antibodies (Kasper et al, 1975). Heat-inactivated patient and pooled 
normal plasmas are mixed in a 1:1 proportion and incubated for 2 hours 
at 37°C. After incubation, the residual ADAMTS13 activity in the mixture 
is assayed by any of the conventional assays described above. A patient is 
considered to have an ADAMTS13 functional inhibitor if the residual 
ADAMTS13 activity in the mixture is less than 75% of a control mixture 
made with pooled normal plasma and buffer.  
A method for measuring ADAMTS13 activity in vitro under flow conditions 
uses ULVWF multimers secreted by histamine-stimulated endothelial cells 
as VWF source (Dong et al, 2002). This assay seems to be reliable in 
discriminating ADAMTS13 activity only at levels higher than 20% (Tripodi 
et al, 2004). Although this assay mimics the in vivo situation more closely 
as it takes into consideration the endothelial cells and the fluid shear 
stress, expert laboratory handling is required making it unsuitable for 
routine testing.  
Recently, a vortex-based assay to quantify ADAMTS13 activity and 
inhibitors has been proposed (Han et al, 2011). According to the authors, 
the vortex rotation generates a shear stress similar to that found in 
arteries and appears to be sufficient to unfold and cleave VWF thus 
mimicking more closely the in vivo situation.  
ELISA-based assays to quantify ADAMTS13 antigen levels have been 
developed using polyclonal (Rieger et al, 2006) or monoclonal (Feys et al, 
2006;Yagi et al, 2007) anti-ADAMTS13 antibodies. When comparing the 
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performance of two of these assays in a multicenter study (Tripodi et al, 
2008), a good reproducibility and linearity could be demonstrated, with a 
limit of detection of 10% and 5%, using monoclonal (Feys et al, 2006) and 
polyclonal (Rieger et al, 2006) antibodies, respectively.  
 
1.5 Thrombotic thrombocytopenic purpura and the role of 
ADAMTS13 
Thrombotic microangiopathies (TMA) are a group of syndromes that share 
the common features of thrombocytopenia and microangiopathic 
hemolytic anemia with erythrocyte fragmentation (schistocytes) and 
increased serum levels of the intracellular enzyme lactate dehydrogenase 
(LDH) (Moake, 2009). The classical diseases associated with TMA are 
thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic 
syndrome (HUS) although TMA is also observed in a wide range of other 
diseases such as systemic lupus erythematosus (SLE), malignancy, 
disseminating intravascular coagulopathy, pre-eclampsia, and endothelial 
damage due to drug toxicity (Copelovitch & Kaplan, 2008;Benz & Amann, 
2010).  
The HUS is characterized by a triad of renal failure, thrombocytopenia and 
non-immune hemolytic anemia with schistocytes. The common form of 
HUS, called typical HUS, is triggered by infection with shiga toxin-
producing bacteria and is associated with a favorable outcome. The 
atypical HUS is a less common form (about 10% of the cases) and is 
associated with poor prognosis. In 50% of the cases, the atypical HUS is 
associated with genetic deficiency of the complement regulator protein 
factors H, I, and B or of membrane cofactor proteins. In the remaining 
cases, the etiology is unknown (Copelovitch & Kaplan, 2008;Benz & 
Amann, 2010). 
TTP is a rare but life-threatening TMA first described by Moschcowitz in 
1924 (Moschcowitz, 1924). The clinical presentation of TTP is 
characterized by a pentad of signs and symptoms including fever, 
thrombocytopenia, microangiopathic hemolytic anemia with red cell 
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fragmentation and renal failure and/or fluctuating neurological 
abnormalities (Moake, 2002). A deficiency in plasma ADAMTS13 is the 
currently accepted pathophysiological mechanism of TTP (Fig. 3). 
ADAMTS13 deficiency leads to the accumulation of ULVWF multimers 
under the high shear stress of the microcirculation with subsequent 
spontaneous platelet adhesion and aggregation and occlusive 
microvascular thrombosis. The presence of widespread hyaline VWF- and 
platelet-rich thrombi in the microcirculation causing multiple organ 
ischemia are the main histopathological features found in TTP patients 
(Moake, 2002) (Fig. 3). 
Even if the pentad of clinical symptoms was originally required as 
diagnostic criterion for TTP, in the current practice, only the presence of a 
non-immune microangiopathic hemolytic anemia and thrombocytopenia 
without any alternative etiology are often sufficient criteria to suggest TTP 
and prompt initiation of treatment to reduce fatal outcomes (Moake, 
2002;George, 2006). Since the introduction of plasma exchange (PEX) with 
plasma replacement in 1991 (Rock et al, 1991) as first choice therapy, the 
mortality rate of TTP has been reduced from 90% to 10-20% (Fontana et 
al, 2006). The mortality is mainly due to treatment refractoriness. Relapse 
occurs in 30-50% of the patients who survive an initial episode of TTP, 
being more often during the first year after the onset (George, 2009). 
TTP has an estimated annual incidence in the adult population of 4-11 
cases per million (Terrell et al, 2005;Scully et al, 2008). TTP occurs more 
frequently in adults than in children and it affects both sexes with an 
increased incidence for women and black race (Terrell et al, 2005).  
Congenital and acquired TTP are the two clinically recognized forms of 
TTP. Distinction at clinical presentation between these two forms is 
important because of differences in treatment modalities. Congenital TTP, 
also known as Upshaw-Schulman Syndrome, is caused by a genetic 
deficiency of ADAMTS13 (Levy et al, 2001;Kokame et al, 2002), whereas 
autoantibody-mediated ADAMTS13 deficiency is considered to be the 
principal cause of acquired idiopathic TTP (Furlan et al, 1998;Tsai & Lian, 
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1998) and is often associated with a severe ADAMTS13 deficiency (<10%) 
(Zheng et al, 2004;Peyvandi et al, 2004). 
 
 
Figure 3. Role of ADAMTS13 in hemostasis 
(A) Physiological role of ADAMTS13 in hemostasis. VWF multimers bind to endothelial 
cells (P-selectin) or to exposed extracellular matrix components. Platelets adhere to VWF 
through glycoprotein GPIb forming a platelet-rich thrombus the growth of which is 
limited by the proteolytic activity of ADAMTS13. (B) Pathogenesis of thrombotic 
thrombocytopenic purpura (TTP) caused by ADAMTS13 deficiency. In the absence of 
ADAMTS13, VWF-dependent platelet accumulation proceeds and eventually causes 
microvessel occlusion.  This will lead to thrombosis and multiorgan failure, features 
characteristic of TTP. 
A secondary, non-idiopathic acquired form of TTP occurs in association 
with pregnancy, certain drugs (e.g. ticlopidine, clopidogrel, quinine, 
chemotherapeutic and immunosuppressive agents), autoimmune 
disorders, infections, cancer and after hematopoietic stem cell 
transplantation (George, 2006;Zakarija et al, 2009). These cases are rarely 
associated with severe ADAMTS13 deficiency except for those associated 
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with pregnancy, autoimmune diseases or ticlopidine/clopidogrel treatment 
(Sadler, 2006). 
Distinguishing TTP from atypical HUS is not always possible due to the 
overlap of symptoms. In the last years a differential diagnosis according to 
the underlying molecular defect was proposed (Tsai, 2010). In the case of 
atypical HUS, genetic mutations of genes regulating the complement 
system and for TTP, deficiency of ADAMTS13 are the proposed patho-
mechanisms (Copelovitch & Kaplan, 2008;Benz & Amann, 2010). 
Congenital TTP is uncommon (2-3% of TTP patients) and it has an 
autosomal recessive mode of inheritance. Deficiency of ADAMTS13 (levels 
5-10% of normal) is due to homozygous or double heterozygous mutations 
in the ADAMTS13 gene resulting in constitutional plasma deficiency or in 
a non-functional protein (Levy et al, 2001;Kokame et al, 2002). Until now, 
more than 70 mutations including missense and nonsense mutations, 
deletions, insertions, and splice site mutations have been reported (Lotta 
et al, 2010). Mutations are not clustered in one gene region, they are 
spread along the entire length of the gene encoding different protein 
domains (Levy et al, 2001). Single nucleotide polymorphisms of the 
ADAMTS13 gene, influencing ADAMTS13 secretion and activity have also 
been described in patients with congenital TTP (Kokame et al, 
2002;Plaimauer et al, 2006). Congenital TTP generally presents in infancy 
or childhood, however some patients may develop clinical symptoms of 
TTP at later age (e.g. during first pregnancy, infections) (George, 2008).   
Acquired idiopathic TTP is an autoimmune disease with an estimated 
incidence of ~4 cases/million people (Terrell et al, 2005), occurring mainly 
in previously healthy individuals. Idiopathic TTP is associated in most of 
the cases with severe ADAMTS13 deficiency (<10% of normal) and in 60-
90% of the patients, inhibitory antibodies that block and reduce 
ADAMTS13 activity are identified by in vitro functional assays (Peyvandi et 
al, 2004). In a reduced number of cases, the presence of non-inhibitory 
antibodies was detected by ELISA (Scheiflinger et al, 2003;Shelat et al, 
2006). Non-inhibitory antibodies may be involved in immune complex 
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formation increasing ADAMTS13 clearance or interfering with ADAMTS13 
binding to cells or other plasma proteins. Antibodies against ADAMTS13 
are predominantly of the IgG and IgM classes (Rieger et al, 2005;Tsai et al, 
2006).  
Epitope mapping of anti-ADAMTS13 antibodies in TTP patients has 
demonstrated that the major binding site on ADAMTS13 is located within 
the cysteine-rich/spacer domains (Klaus et al, 2004;Luken et al, 2005). 
More specifically, amino acids inside the spacer domain (Arg568, Phe592, 
Arg660, Tyr661 and Tyr665 on the outer surface of the spacer domain), 
which are directly involved in the interaction with the VWF A2 domain, are 
the major targeted amino acids by autoantibodies suggesting that 
autoantibodies may impair the binding of ADAMTS13 to VWF and by 
consequence inhibit its proteolysis (Jin et al, 2010;Pos et al, 2010;Pos et 
al, 2011). However, epitopes on different domains of the ADAMTS13 
molecule have also been identified, mostly within the TSP1 2-8 and CUB 
domains (Klaus et al, 2004;Zheng et al, 2010;Pos et al, 2011).  
Genetic factors also play a role in the etiology of acquired TTP. The 
presence or reduced levels of the antigens HLA-DRB1*11 and HLA-
DRB1*04, respectively was identified as a risk factor for development of 
acquired TTP (Coppo et al, 2010;Scully et al, 2010). 
 
1.6 Treatment of thrombotic thrombocytopenic purpura 
The treatment modalities in patients with TTP differ if the patient suffers 
from congenital or acquired TTP. Patients with congenital TTP are treated 
with infusion of normal fresh frozen plasma (FFP) that contains normal 
levels of ADAMTS13. Potential relapses in these patients can be prevented 
or reduced by regular infusions of FFP every 2-3 weeks (Fontana et al, 
2006).  
The first line therapy for acquired TTP is daily PEX. During the 
plasmapheresis or PEX procedure, the patient´s plasma is extracorporeally 
separated from the blood cells followed by its replacement by a normal 
FFP or cryosupernatant and then re-infused together with the blood cells 
into the blood. The efficacy of PEX therapy has been attributed to the 
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combination of the infusion of normal FFP which supplies ADAMTS13 and 
the apheresis which removes circulating ULVWF multimers and 
ADAMTS13 autoantibodies when present (Fontana et al, 2006). Although 
PEX is the standard treatment for TTP, it is not safe and adverse events 
are reported to complicate about 5-12% of the PEX procedures (Nguyen et 
al, 2009). Immunosuppressive drugs (mainly the steroid 
methylprednisone) are often added as supportive therapy to improve 
outcomes.  
More recently, the administration of rituximab, a chimeric monoclonal 
antibody, has been proven to be effective in the treatment of refractory 
(failure to respond to standard treatment) or relapsing acquired TTP 
mediated by autoantibodies. Rituximab is an antibody directed against 
CD20, a surface antigen on B-lymphocytes. Rituximab specifically 
depletes premature and mature B-cells thus increasing the clearance of 
antibody-producing cells and by consequence reducing the autoantibody 
titers (Elliott et al, 2009). Although there is still limited clinical experience 
and only few reports outline the advantage of rituximab in patients with 
TTP, its use appears to be promising and patients seems to benefit 
through long-lasting remission. 
Splenectomy is another therapeutic option indicated in patients suffering 
of refractory or relapsing TTP. The diagnosis of refractory TTP is 
considered when incomplete, delayed or no clinical/laboratories responses 
are obtained with standard treatments within 7 days. Splenectomy has 
been used with a varying degree of success with its efficacy in preventing 
relapses remaining controversial (Dubois & Gray, 2010). Patients suffering 
from relapsing TTP seem to have more benefit from the splenectomy than 
those suffering of refractory TTP (Dubois & Gray, 2010). When 
splenectomy is performed on patients suffering from the relapsing form, it 
is associated with minimal morbidity and mortality and response rates 
greater than 80% are achieved (Dubois & Gray, 2010). 
 
 - 35 - 
1.7 Anti-CD36 antibodies in TTP patients 
CD36 (originally identified in platelets as glycoprotein VI) is an integral 
membrane protein of 471 amino acids that belongs to the class B 
scavenger receptor family. CD36 is expressed mainly in professional 
phagocytes, platelets, microvascular endothelium and fat and muscle cells 
(Silverstein & Febbraio, 2009). CD36 has multiple physiologic ligands 
including oxidized low-density lipoprotein (LDL), phosphatidyl serine (PS) 
and oxidized PS expressed on the surface of apoptotic cells, long-chain 
fatty acids and the TSP-1 domains on thrombospondin 1 (Silverstein & 
Febbraio, 2009). Based on the wide variety of ligands having diverse and 
complex functions CD36 could be a critical factor  in different diseases 
such as cancer, atherosclerosis, malaria and insulin resistance (Febbraio 
& Silverstein, 2007). 
Recent in vitro experiments using recombinant proteins showed that 
CD36 is able to also bind to ADAMTS13 without inhibiting its activity 
(Davis et al, 2009). The authors suggest that the binding may be mediated 
via its TSP-1 domains and could be responsible for localizing ADAMTS13 
to the surface of endothelial cells (Davis et al, 2009).  
Homozygous or compound heterozygous CD36 deficiency has been 
reported with variable incidence between different ethnic groups (Rac et al, 
2007). In addition, a polymorphism in the blood group antigen Naka is 
associated with a selective deficiency of platelet CD36 (Yamamoto et al, 
1990). Interestingly, no clinical symptoms appear to be associated to any 
type of CD36 deficiency. Patients carrying the platelet CD36 deficiency 
have no bleeding or thrombotic diatheses but anti-CD36 antibodies were 
reported in the plasma of some patients due to iso- or alloimmunization 
against the protein (Saw et al, 2010). 
Interestingly, in about 70% of the patients with acquired TTP, 
autoantibodies directed against CD36 were detected but their pathological 
or clinical significance was not investigated (Tandon et al, 1994;Schultz et 
al, 1998;Wright et al, 1999). The presence of autoantibodies against CD36 
has also been described in patients suffering from autoimmune diseases 
such as SLE (al-Shahi et al, 1997) and antiphospholipid syndrome (Pelegri 
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et al, 2003). More recently, Rock et al (Rock et al, 2005) described the 
concomitant presence of anti-CD36 and anti-ADAMTS13 antibodies in 
16/35 patients analyzed, suggesting a possible pathogenic role of these 
antibodies in TTP. 
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2- AIM OF THE THESIS 
The main goal of the thesis was to characterize the antibody response 
against the metalloprotease ADAMTS13 in patients suffering from 
acquired thrombotic thrombocytopenic purpura (TTP). Our group was the 
first to describe the presence of anti-ADAMTS13 IgG and IgM antibodies in 
TTP patients. These findings prompted a further characterization of the 
immune response in a cohort of adult patients with acute acquired TTP to 
better understand the patho-mechanism leading to acquired TTP. In 
addition, we attempted to investigate possible prognostic or predictive 
marker/s that could help to identify patients at risk of recurrence or fatal 
outcome.  
 
DESIGN OF THE RESEARCH STUDY 
The following aspects shall be investigated in a cohort of 76 patients 
diagnosed with acute acquired TTP: 
• Evaluation of ADAMTS13-specific activity, functional inhibitors and 
antigen levels.  
The quantification of these parameters will be performed using 
standard assays. 
• Detection of total IgG, IgG subclasses, IgM, IgA and IgE anti-
ADAMTS13 antibodies.  
The detection of IgG and IgM antibodies in plasma will be performed 
using a pre-established in-house enzyme-linked immunosorbent 
assay (ELISA). For detection of IgG subclasses, IgA and IgE 
antibodies, specific ELISA systems will be established. 
• Detection of circulating ADAMTS13-anti-ADAMTS13 antibody immune 
complexes (IC).  
For detection of ADAMTS13-specific IC in plasma two different 
assays will be developed. (1) A co-immunoprecipitation of plasma 
ADAMTS13 with IgG, IgM, and IgA antibodies. (2) ELISA-based 
systems to detect and characterize the immunoglobulin type and 
subclass involved in the IC formation. 
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• Detection of anti-CD36 antibodies.  
For detection of anti-CD36 antibodies in plasma a specific ELISA 
will be established. 
• Correlation of the different parameters evaluated with the clinical 
outcome of the patients 
The different parameters evaluated will be correlated with the 
clinical outcome of the patients using standard statistical tests and 
software. 
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3- METHODOLOGY  
3.1 Patients 
3.1.1 Plasma samples 
Frozen plasma samples from TTP patients were obtained from three 
European Reference Centers: the Central Hematology Laboratory, 
University of Bern, Switzerland (Center 1), Service d´Hematologie 
biologique, Hôspital Antoine Béclère, Paris, France (Center 2) and 
Department of Medicine 1, Medical University of Vienna, Vienna, Austria 
(Center 3). Patients were enrolled after giving consent according to The 
Declaration of Helsinki. This study was approved by the institutional 
review board.  
Plasma samples from healthy donors were collected at plasma collection 
centers of Baxter Innovations in Austria. 
 
3.1.2 Sample collection 
Before any therapeutical treatment was initiated, venous blood samples 
were collected into tubes containing 3.8% (w/v) sodium citrate and 
platelet-poor plasma was obtained by centrifugation at 2500 x g for 15 
minutes. Plasma aliquots were stored at –80°C until tested. For one 
patient, daily plasma samples (time course samples during 2 months 
follow-up (death)) were collected before initiation of therapeutic PEX in 
which patient´ plasma is replaced by normal fresh frozen plasma. 
 
3.1.3 Inclusion criteria 
Patients had to meet the following inclusion criteria: (i) presence of 
microangiopathic hemolytic anemia (hemoglobin level <12 g/dL), direct 
antiglobulin test negative, at least 2 schistocytes per high-power field in 
the peripheral blood smear, LDH levels >450 IU/L and undetectable 
serum haptoglobin; (ii) thrombocytopenia (platelet count <150 x 109/L); 
(iii) severely reduced (<10%) plasma ADAMTS13 activity levels. Fever, 
neurological symptoms or renal failure were not obligatory.  
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3.1.4 Clinical definition 
Idiopathic TTP was defined as TTP occurring in patients with no apparent 
preexisting disease. Patients are described as having secondary TTP if 
other conditions are identified that may cause thrombotic 
microangiopathy such as pregnancy, other autoimmune diseases, HIV 
infection and cancer. Remission was defined as a normal platelet count 
(>150 x 109/L) and no plasma exchange treatment for 30 consecutive days 
(day 1 of remission) or more. Relapse or recurrence was defined as the 
reappearance of clinical manifestation and/or laboratory data compatible 
with TTP after remission had been achieved. Refractory TTP is considered 
when incomplete, delayed or no clinical and laboratories responses are 
obtained with standard treatments within 7 days. 
 
3.2 Measurement of the ADAMTS13 activity and inhibitor  
3.2.1 Measurement of the ADAMTS13 activity 
The measurements of residual ADAMTS13 activity (ADAMTS13:Ac) and 
anti-ADAMTS13 inhibitory activity in patients´ plasma were carried out in 
the participant centers at the moment when the patient was admitted to 
the hospital. 
In Center 1, the ADAMTS13 activity and inhibitor was tested according to 
Studt et al (Studt et al, 2003) using a quantitative immunoblotting assay 
and in Center 2 according to Veyradier et al (Veyradier et al, 2001) using a 
two-site ELISA assay. Both methods measure ADAMTS13 activity under 
static conditions, employing multimeric/full-length VWF as substrate and 
indirect quantification of the VWF cleavage products by immunoblotting or 
ELISA. Both methods have similar sensitivities (Tripodi et al, 2004).  
 
3.2.2 Measurement of the ADAMTS13 activity by FRETS-VWF73 assay 
Samples received from Center 3 were tested in our laboratory using the 
FRETS-VWF73 assay performed essentially as described (Kokame et al, 
2005) with minor modifications. Plasma samples were diluted 1 to 25 in 
assay buffer (5 mM Bis-Tris, 25 mM CaCl2, 0.005% v/v Tween 20, pH 6.0) 
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supplemented with a protease inhibitor cocktail (Sigma, St. Louis, MO, 
USA) in a final concentration of 2 µL/ 100 µL of reaction buffer and 2% 
v/v heat-inactivated pooled normal human plasma (NHP) (George King 
Bio-Medical, Overland Park, KS, USA) to correct for a plasma matrix effect 
in the dilution. The heat-inactivation of the plasmas was achieved by 
incubating the plasma at 56°C for 30 min followed by 15 min of 
centrifugation at 15000 x g. A calibration curve was made diluting a 
pooled NHP (George King Bio-Medical) 1 to 25 and by serial dilutions in a 
ratio of 3 to 4 (75%), 1 to 2 (50%), 1 to 4 (25%), 1 to 8 (12.5%), 1 to 16 
(6.25) and 1 to 32 (3.12%) in supplemented assay buffer. The FRETS-
VWF73 substrate (Peptide Institute Inc., Osaka, Japan) was re-suspended 
in 25% v/v dimethylsulfoxide, leading to 100 µM FRETS-VWF73 stock 
solution and subsequently diluted to a final concentration of 1.67 µM in 
assay buffer without supplementation. 100 µL/well of each diluted plasma 
sample or standard was added to a 96-well white plate (Costar, Corning 
Inc., NY, USA) followed by the addition of 100 µL/well FRETS-VWF73 
substrate. The fluorescence was measured at 37°C every 5 min for 90 min 
in a SAFIRE II reader (Tecan, Zürich, Switzerland) equipped with a 340 
nm excitation filter and 440 nm emission filter. The reaction rate was 
calculated by linear regression analysis of fluorescence over time and 
compared with that of a pooled NHP used as calibration curve. 
 
3.2.3 Anti-ADAMTS13 inhibitor activity assay 
The ADAMTS13 functional inhibitor titers were measured according to the 
Bethesda method originally described for anti-factor VIII antibodies 
(Kasper et al, 1975). Briefly, patient´ plasma and pooled NHP were heat-
inactivated (as described in chapter 3.2.2) to inactivate any endogenous 
ADAMTS13 activity. Afterwards, a mixture of equal volumes of heat-
inactivated patient´ plasma and pooled NHP as well as a control mixture 
made of buffer and pooled NHP were incubated for 2 hours at 37°C. After 
incubation, the residual ADAMTS13:Ac in both mixtures was assayed. The 
residual ADAMTS13:Ac is defined as the percentage between the residual 
ADAMTS13:Ac of the patient´ mixture compared with the control mixture. 
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A patient was considered to have inhibitors of ADAMTS13 if the residual 
ADAMTS13:Ac in the patient´ mixture was less than 75% of the control 
mixture. When the residual ADAMTS13:Ac of the mixture with the 
undiluted sample was below 25%, samples were retested by diluting until 
a residual ADAMTS13:Ac between 25% and 75% was obtained. The 
inhibitor titers are expressed in Bethesda Units per milliliter (BU/mL) and 
one BU is defined as the amount of inhibitor that results in 50% residual 
ADAMTS13:Ac. The inhibitor titer of the patient´ plasma is read from a 
semi-logarithmic plot representing the correlation between residual 
ADAMTS13:Ac (logarithmic) and the inhibitor titer in BU/mL (linear). The 
regression line is defined by 100% residual ADAMTS13:Ac when no 
inhibitor is present (0 BU/mL) and 50% residual ADAMTS13:Ac when 1 
BU/mL inhibitor is present. 
The procedure described above was followed by all the participant Centers 
with a minor modification in the incubation time done by Center 2 (30 min 
at room temperature (RT) instead of 2 hours at 37°C). The residual 
ADAMTS13:Ac was measured by the FRETS-VWF73 assay or the 
immunoblotting assay (Studt et al, 2003) (Center 1) or by ELISA (Veyradier 
et al, 2001) (Center 2). 
There was a difference in the expression of inhibitor titers between 
Centers. Center 1 reported the exact inhibitor titers when the BU/mL were 
up to 2. When the residual ADAMTS13:Ac was between 11% and 25% 
(titers greater than 2 BU/mL), titers were reported as >2 BU/mL. When 
the residual ADAMTS13:Ac was equal or less than 10%, titers are reported 
as >>2 BU/mL. Center 2 expressed the titers semi-quantitatively; they 
were arbitrarily defined as high, medium or low for a residual 
ADAMTS13:Ac less than 10% in a 1:1, 2:1 or 3:1 volume/volume mixture 
of patient and pooled NHP, respectively.  
Due to these differences in the expression of the ADAMTS13 functional 
inhibitor titers between Centers 1 and 2, a harmonization of the titer 
results was arbitrarily done to express them by a single measure. Inhibitor 
titers from Center 1 were assigned as low, medium or high when the BU 
were up to 2 BU/mL, >2 BU/mL and >>2 BU/mL, respectively.  
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3.3 Measurement of ADAMTS13 protein (antigen) levels  
ADAMTS13 antigen (ADAMTS13:Ag) levels were analyzed in patients´ 
plasma by ELISA according to Rieger et al (Rieger et al, 2006). Microtiter 
plates (Nunc-Immuno Maxisorp, Roskilde, Denmark) were coated with 100 
µL/well of a polyclonal rabbit anti-human ADAMTS13 IgG (2 µg/mL; 
Baxter Innovations, Vienna, Austria) in 0.1 M bicarbonate solution, pH 9.6 
for 5 hours at RT. The non-specific binding sites were blocked with 0.5% 
w/v non-fat dry milk (Blotting Grade Blocker Non-Fat Dry Milk, Bio-Rad 
Laboratories, CA, USA) diluted into phosphate-buffered saline (PBS), pH 
7.4, containing 0.1% v/v Tween-20 (Biorad) (PBS-T). Plasma and standard 
samples (100 µL/well) were incubated overnight at RT. Plates were washed 
and incubated with 100 µL/well of a horseradish peroxidase (HRP)-
conjugated polyclonal rabbit anti-human ADAMTS13 IgG (Baxter) at 20 
ng/mL and developed using 100 µL/well of the chromogenic 3,3',5,5'-
tetra-methylbenzidine substrate (TMB; Sure BlueTM TMB Microwell 
Peroxidase Substrate, KPL, Maryland, USA). The color reaction was 
stopped by the addition of 50 µL/well of 1 N HCl and the absorbance was 
read at 450 nm with a reference filter of 620 nm on an iEMS microplate 
reader (Labsystems, Helsinki, Finland). Between each step, the plates were 
washed with PBS-T in an auto strip washer (Elx50 Bio-Tek instruments, 
Germany).  
ADAMTS13:Ag levels in the samples were calculated extrapolating the 
corresponding OD value from a standard curve using purified 
recombinant ADAMTS13 (rADAMTS13, Baxter Innovations) diluted to final 
concentrations of 20, 10, 5, 2.5, 1.25, 0.625 and 0.5 ng/mL in 
ADAMTS13-depleted human plasma (Baxter Innovations). The reference 
interval for the ELISA (calculated with 100 individual healthy donors) was 
740–1420 ng ADAMTS13/mL and the limit of quantification was 62.5 ng 
ADAMTS13/mL. Samples with antigen levels under the limit of 
quantification were expressed as <62.5 ng ADAMTS13/mL.  
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3.4 Detection of anti-ADAMTS13 antibodies  
3.4.1 ELISA to detect total IgG, IgG subclass, IgM, IgA and IgE anti-
ADAMTS13 antibodies 
The presence of total IgG (IgGtot) and IgG subclasses, IgM, IgA and IgE 
anti-ADAMTS13 antibodies in patient plasmas was tested by ELISA as 
described (Rieger et al, 2005) with minor modifications. Microtiter plates 
(Nunc) were coated with an anti-His tag antibody (2 µg/mL; Penta-His, 
Qiagen, Hilden, Germany) by overnight incubation at 4ºC. The non-
specific binding sites were blocked with PBS containing 2% w/v bovine 
serum albumin (BSA, Sigma) (PBS-BSA) and thereafter, 100µL/well 
recombinant His-tagged ADAMTS13 (Baxter Innovations) was added in a 
concentration of 2 µg/mL diluted in PBS-BSA. Diluted patients’ plasma 
and negative controls (pooled NHP of 30 healthy donors, Baxter 
Innovations) were incubated overnight at 4ºC. Bound antibodies were 
detected using an alkaline-phosphatase (AP)-conjugated goat anti-human 
IgG, IgM, IgA or IgE antibody (Sigma) or mouse monoclonal anti-human 
IgG1, IgG2, IgG3 or IgG4 antibodies (Zymed Laboratories, San Francisco, 
CA, USA). Finally, the enzyme substrate p-nitrophenylphosphate (pNPP; 
Sigma) was added, and the absorbance was read at 405 nm with a 
reference filter of 620 nm on a microplate reader (Labsystems). Between 
each step, the plates were washed with PBS-T in an auto strip washer 
(Bio-Tek instruments).  
 
3.4.2 Cross-reactivity assay 
The specificity in the detection of the AP-conjugated mouse monoclonal 
anti-human IgG1-IgG4 and the goat anti-human IgA and IgE antibodies 
used in the ELISAs was tested in an ELISA-based cross-reactivity assay. 
Briefly, microtiter plates (Nunc) were coated with 100 µL/well of purified 
human IgG1-4, IgM, IgA and IgE (Sigma) diluted in a concentration range 
between 4 and 0.1 µg/mL using PBS. After overnight incubation at 4ºC, 
the plates were washed and incubated with 100 µL/well of an AP-
conjugated goat anti-human IgA or IgE antibody (Sigma) or monoclonal 
AP-conjugated mouse anti-human IgG1, IgG2, IgG3 and IgG4 antibodies 
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(Zymed). The enzyme substrate pNPP (Sigma) was added, and the 
absorbance was read at 405 nm with a reference filter of 620 nm on a 
microplate reader (Labsystems). No cross-reactivity was observed at any 
concentration with any class or subclass of antibodies analyzed. 
 
3.4.3 Data analysis and cut-off calculations 
IgGtot and IgG subclass, IgM, IgA and IgE anti-ADAMTS13 antibodies 
detected by the ELISA described in chapter 3.4.1 were expressed as 
antibody titers. For calculation of the anti-ADAMTS13 antibody titers, the 
ELISA read out (optical density, OD) from 100 healthy donors diluted in a 
range between 1 to 20 up to 1 to 6400 was used to calculate the ratio of 
sample OD to background OD for each sample at each dilution. As 
background OD the signal derived from a pooled NHP was used. To 
achieve an approximate normal distribution, the OD ratio values of the 
100 control plasmas were transformed by the function y=log(1+log(x)). 
Normal distribution was assessed by quantile-quantile plots and Shapiro-
Wilk tests. The means and standard deviations of the resulting 100 ratios 
were calculated. The thresholds for each dilution were obtained by back-
transformation of the means plus two standard deviations of the 
transformed data. Samples with ratios below or above the cut-off levels 
were judged as negative or positive, respectively. When a sample was 
judged positive, sample dilutions were compared with the corresponding 
cut-off value and the last dilution above the cut–off value was taken as 
positive. 
For the IgG subclass ELISA, the OD values were additionally normalized 
by the corresponding normalization factor and calculated as described 
below.  
 
3.4.4 Quantification and normalization of the absorbances measured 
in the IgG subclass ELISA  
An ELISA with subclass-specific antibodies was used to estimate the 
relative amount of the different IgG subclasses, first because of the 
absence of a true standard, and second because of the differences in the 
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development time between the IgG subclasses due to differences in the 
detection sensitivities of the secondary antibodies used. To minimize these 
differences, the relative OD values of the IgG subclass ELISA were 
compared under standardized conditions.  
Each IgG subclass (purified human IgG1-IgG4, Sigma) was coated on an 
ELISA plate in a concentration range of 0.125 to 1 µg/mL and the time-
dependent OD signal generated was analyzed. The corresponding OD 
values generated were recorded every 5 min up to 75 min, and plotted 
against time. Slopes for each concentration and subclass were calculated. 
The corresponding means ± standard deviations of the slopes from 4 
independent experiments were plotted and analyzed by linear regression 
for each individual IgG subclass. The regression parameters obtained were 
used to calculate the OD values of each subclass at a coating 
concentration of 0.5 µg/mL (linear range). The OD value of IgG4 was set to 
“1”, resulting in normalization factors for IgG1, IgG2 and IgG3 of 9, 0.7 
and 0.4, as compared with IgG4. Coating efficiency was evaluated in each 
experiment by ELISA using an AP-conjugated goat anti-human lambda 
light chain antibody (Sigma) to ensure uniform IgG1-IgG4 concentrations. 
The calculated normalization factors were used to normalize the OD 
values in patients with more than one IgG subclass of anti-ADAMTS13 
antibodies. Samples were normalized by multiplying the OD values 
corresponding to each positive subclass by the corresponding calculated 
normalization factor. With this approach, an estimate of the relative 
contributions of the different IgG subclasses to the total anti-ADAMTS13 
IgG in patient plasma was obtained. Without the normalization procedure, 
IgG1 levels would have been underestimated as compared to IgG2, IgG3 
and IgG4 levels. Samples with normalized OD values above the linear 
range were excluded (six patients) from analyses.  
Positive normalized OD values of each subclass were summed up (IgGsum, 
total absorbance) and the proportion of each individual subclass was 
calculated as a percentage of the total absorbance (assumed to be 100%) 
to obtain the IgG subclass percentage distribution in a single patient. 
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3.4.5 Competitive inhibition of antibody binding with recombinant 
ADAMTS13 
To ensure specificity of the anti-ADAMTS13 antibody detection, 
competitive inhibition experiments with rADAMTS13 in solution were 
carried out. Diluted patient and pooled NHP plasmas were pre-incubated 
with 100 µg/mL of purified rADAMTS13 at 37°C for 2 hours to allow 
binding of ADAMTS13-specific antibodies to rADAMTS13 in solution. 
Afterwards, the binding of anti-ADAMTS13 antibodies was assayed by the 
ELISA as described above (chapter 3.4.1). As negative control, plasma 
samples were pre-incubated with BSA (100 µg/mL). A sample was judged 
as positive when addition of rADAMTS13 decreased the antibody binding 
by at least 30% when compared to the decrease of the negative control. 
 
3.5 Detection of IgG anti-ADAMTS13 antibodies by a 
commercial ELISA kit 
The measurement of IgG anti-ADAMTS13 antibodies was also performed 
using a commercially available kit (TECHNOZYM ADAMTS-13 INH; 
Technoclone GmbH, Vienna, Austria) according to the manufacturer´s 
instructions. Briefly, 100 µL/well of diluted plasma samples or calibrators 
were added to wells coated with rADAMTS13 and incubated for 1 hour at 
RT. Thereafter, 100 µL/well of a HRP-conjugated anti-human IgG were 
added followed by 100 µL/well of the chromogenic substrate TMB. The 
color reaction was stopped by the addition of 1.9 M H2SO4 and the 
absorbance was measured at 450 nm with a reference filter of 620 nm on 
a microplate reader (Labsystems).  
The antibody titers of a sample were obtained by extrapolating from the 
corresponding OD value of a standard curve using standards provided 
with the kit in concentrations ranging between 0.8-98.8 U/mL of anti-
ADAMTS13 antibodies. Standards are calibrated against a plasma with a 
very high titer of IgG anti-ADAMST13. A 1 to 200 dilution of this reference 
plasma is defined to contain an antibody concentration of 100 U/mL 
(arbitrary units). 
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The positive cut-off value of the assay is 15 U/mL, samples with results 
between 12-15 U/mL are judged as borderline and samples with values 
below 12 U/mL are judged as negative. 
 
3.6 Detection of circulating immune complexes by co-
immunoprecipitation and Western blotting 
Patient plasma (200 µL) was incubated with 100 µL protein G Sepharose 
(Protein G HP SpinTrapTM columns, GE Healthcare, Buckinghamshire, 
England) or anti-IgA or anti-IgM specific affinity matrixes (BAC 
CaptureSelect, Naarden, The Netherlands) for 30 min (IgG) and 120 min, 
respectively at RT on a rotator. The immunoprecipitated IgG-, IgA-, or IgM 
containing material was washed 6 times with binding buffer (20 mM 
sodium phosphate, 150 mM NaCl; pH 7.0) and the antigen-antibody 
complexes were eluted from the beads by adding sample loading buffer 
(Thermo, Rockford, IL, USA) and heating at 95°C for 10 min. The resulting 
supernatants were loaded on a 4–12% gradient tris-glycine SDS 
polyacrylamide pre-cast gel (Invitrogen, Caramillo, CA, USA) and subjected 
to electrophoresis under reducing conditions. The separated proteins were 
transferred to a polyvinyldifluoride membrane using an iBlot® Dry Blotting 
System (Invitrogen), and ADAMTS13 was detected with an affinity-purified 
polyclonal rabbit IgG anti-human ADAMTS13 antibody (1 µg/mL; Baxter 
Innovations) in combination with a HRP-conjugated goat anti-rabbit IgG 
(27 ng/mL; Jackson Immunoresearch, West Grove, PA, USA) and addition 
of a chemiluminescent substrate (Thermo). Immunoreactive bands were 
visualized with the Fusion FX7 image system (Vilber Lourmat, Germany). 
The ADAMTS13 luminograms were scanned and the relative amount of 
immune complexes (ICs; expressed in arbitrary units (AU)) was quantified 
by densitometry using the BIO-1D software (Vilber Lourmat) and 
rADAMTS13 (1 ng) as standard. 
To evaluate for unspecific binding to the matrix, human serum albumin 
(HSA) in a final concentration of 50 µg/mL was spiked with 2 µg/mL 
rADAMTS13 and processed as the plasma samples. For the anti-IgA 
matrix, a minimal unspecific binding was observed with the negative 
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controls. In this case, the mean background signal generated by the 
pooled NHP and ADAMTS13-spiked samples was subtracted from the 
signal of the plasma samples. 
 
3.7 Detection of circulating immune complexes by ELISA 
Microtiter plates (Nunc) were coated with 100 µL/well of a polyclonal 
rabbit anti-human ADAMTS13 IgG (2 µg/mL; Baxter Innovations) in 0.05 
M carbonate-bicarbonate buffer, pH 9.6 by overnight incubation at 4°C. 
The non-specific binding sites were blocked with 0.5% w/v non-fat dry 
milk (Bio-Rad) diluted into PBS-T buffer. A 100 µL/well of diluted patient 
and normal plasmas (dilution range: 1 to 20, 1 to 50 and 1 to 100) were 
incubated overnight at 4°C. Thereafter, plates were washed and incubated 
with 100 µL/well of an AP-conjugated goat anti-human IgA (Sigma) or 
mouse monoclonal anti-human IgG1, IgG2, IgG3 and IgG4 antibodies 
(Zymed Laboratories). Finally, the enzyme substrate 5-bromo-4-chloro-3-
indoyl phosphate (BCIP) (KPL) was added, and the absorbance was read at 
620 nm on an iEMS microplate reader (Labsystems). Between each step, 
the plates were washed with PBS-T in an auto strip washer (Elx50 Bio-Tek 
instruments).  
For cut-off calculation, 60 healthy donors diluted in the same range as the 
samples were used to calculate the ratio of sample OD to background OD 
(signal derived from a pooled NHP). Normal distribution was assessed by 
the Shapiro-Wilk test and the means plus three standard deviations of the 
resulting 60 ratios were calculated for each dilution. Samples with ratios 
below or above the cut-off levels were judged as negative or positive, 
respectively. 
 
3.7.1 Detection of complement fixing immune complexes by C1q 
binding ELISA 
Complement fixing immune complexes (ICs) were analyzed using a C1q 
binding ELISA kit (Bühlmann Laboratories, Schönenbuch, Switzerland) 
according to the manufacturer´s instructions. Briefly, patient plasma, 
calibrators and controls were incubated with human C1q adsorbed on a 
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microtiter plate. After incubation, AP-conjugated Protein A was added, 
followed by the enzyme substrate pNPP. The color reaction was stopped 
after 30 min of incubation by the addition of 1 N NaOH and the 
absorbance was measured at 450 nm with a reference filter of 620 nm on 
a microplate reader (Labsystems).  
The concentration of ICs present in the plasma samples was determined 
by extrapolating the corresponding OD value to a standard curve using 
standards provided with the kit. Results were expressed as heat 
aggregated human gamma globulin equivalents per mL (μg Eq/mL). The 
negative cut-off value of the assay is 3.2 µg Eq/mL, samples between 3.2-
5.0 μg Eq/mL are judged as borderline and samples with values above 5.0 
μg Eq/mL are judged as positive. 
 
3.7.2 Competitive inhibition of the binding of human IgG4 to rabbit 
anti-ADAMTS13 antibody 
To confirm unspecific binding of human IgG4 to rabbit anti-ADAMTS13 
antibody coated on the plate, a competitive inhibition experiment was 
performed. Diluted normal plasma (dilution range: 1 to 20, 1 to 50, 1 to 
100, 1 to 200, 1 to 400 and 1 to 800) was pre-incubated with 11 µg/mL 
monoclonal mouse anti-human IgG4 antibody (Sigma) at 37°C for 30 min. 
After incubation, the binding of human IgG4 was assayed by ELISA as 
described in chapter 3.7. As negative control, diluted plasma samples 
were pre-incubated with 11 µg/mL of BSA diluted in PBS.  
 
3.7.3 Binding of rabbit IgG to human antibodies 
Microtiter plates (Nunc) were coated by overnight incubation at 4°C with 
100 µL/well of purified human IgG1-4 (Sigma), IgM (Sigma) and IgA 
(Calbiochem, Darmstadt, Germany) in a concentration of 4 µg/mL diluted 
in 0.05 M carbonate-bicarbonate buffer, pH 9.6. The non-specific binding 
sites were blocked with 0.5% non-fat dry milk (Bio-Rad) diluted in PBS-T 
buffer. Thereafter, plates were washed and incubated with 100 µL/well of 
HRP-conjugated rabbit IgG (whole molecule) or rabbit IgG Fc fragment or 
rabbit IgG F(ab)2 fragment (Alpha Diagnostic, San Antonio, TX, USA), in a 
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concentration range between 1 and 4 µg/mL. After 4 hours of incubation, 
plates were developed with TMB substrate (KPL) and the color reaction 
was stopped by the addition of 1 N HCl. The absorbance was read at 450 
nm with a reference filter of 620 nm on a microplate reader (Labsystems). 
Between each step, the plates were washed with PBS-T in an auto strip 
washer (Bio-Tek instruments).  
 
3.8 Detection of anti-CD36 antibodies by ELISA 
Microtiter plates (Half area, high binding; Costar, Corning Inc., NY, USA) 
were coated with 50 µL/well of recombinant full-length CD36 (1.5 µg/mL; 
Origene, Rockville, USA) diluted in 0.05 M carbonate-bicarbonate buffer, 
pH 9.6 by overnight incubation at 4°C. The non-specific binding sites were 
blocked with Protein-Free blocking buffer (Thermo). Afterwards, 50 
µL/well of patient and normal plasmas (diluted 1 to 50 in LowCross buffer 
(Candor Bioscience, Weissensberg, Germany) were added and incubated 
for additional 3 hours at RT. Plates were washed and incubated for 90 min 
at RT with 50 µL/well of biotin-conjugated goat anti-human IgG antibody 
(Rockland Immunochemicals, Gilbersville, PA, USA) at 10 ng/mL in 
LowCross buffer followed by the addition of streptavidin-peroxidase 
polymer conjugate (Sigma) diluted 1 to 5000 in PBS. Plates were developed 
by the addition of 50 µL/well of the TMB substrate (KPL) and the color 
reaction stopped with 50 µL/well of 1 N HCl. Absorbance was read at 450 
nm with a reference filter of 620 nm on a microplate reader (Labsystems). 
Between each step, the plates were washed with PBS-T in an auto strip 
washer (Bio-Tek instruments).  
As a positive ELISA control, a monoclonal rat anti-human CD36 antibody 
(R&D Systems, Minneapolis, MN, USA) was tested in a concentration 
range between 0 and 60 ng/mL and detected with HRP-conjugated rabbit 
anti-rat IgG (whole molecule, 100ng/mL, Sigma). 
For cut-off calculation, 60 healthy donors were used to calculate the ratio 
of sample OD to background OD (signal derived from a pooled NHP). 
Normal distribution was assessed by the Shapiro-Wilk test after log-
transformation of the data and the means and standard deviations of the 
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resulting 60 ratios were calculated. The thresholds for each dilution were 
obtained by back-transformation of the means plus three standard 
deviations of the transformed data. Samples with ratios below or above the 
cut-off levels were judged as negative or positive, respectively. 
To ensure that the detected anti-CD36 antibodies are specific, positive 
samples were subjected to competitive inhibition using an excess of rCD36 
(11 µg/mL) in solution. Following pre-incubation with soluble rCD36 at 
37°C for 2 hours, patient and pooled NHP plasma samples were assayed 
for anti-CD36 antibodies by the ELISA as described above. 
 
3.9 Statistical analysis 
Statistical analyses were done with SigmaStat version 3.5 (Systat 
Software, San Jose, CA, USA). Demographic and clinical data are 
presented as the median and the interquartile range (IQR). Cut-off values 
for the different established ELISAs were calculated as described in the 
corresponding chapter. The statistical significance of the differences 
between OD ratios of healthy donors and TTP patients were assessed by 
the Mann-Whitney rank sum test. The statistical significance of the 
differences between medians of IgG1 and IgG4 values were assessed by 
the Mann-Whitney rank sum test and the correlation by the Spearman 
rank test. To assess the strength of the relation between IgG4 levels and 
recurrence, 40 patients were divided into three groups according to 
clinical outcome. The first group comprised 18 patients who had 
experienced only a single TTP event, the second comprised nine patients 
who relapsed during the 36 months of follow-up and the third comprised 
13 patients who had had relapse(s), five of whom had had no further 
relapses during follow-up and eight of whom were lost to follow-up after 
the acute relapsing event. Deceased patients, patients lost to follow-up 
after the first TTP event and patients with IgG4 OD values above the linear 
range were excluded from this analysis (18 patients). P-values less than 
0.05 were considered to be statistically significant. 
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4- RESULTS  
4.1 Demographic and clinical features of the patients enrolled 
Seventy-six adult patients diagnosed with acute acquired TTP were 
included in the study. All of them met the inclusion criteria described in 
chapter 3.1.3. Demographic, clinical and standard biological features of 
the 76 patients enrolled are summarized in Table 1. The median age was 
37 year-old (range 16-75) and the sex ratio was 2F/1M (50 women and 26 
men). Sixty-three had idiopathic TTP and thirteen had TTP associated with 
pregnancy (n = 6), the postpartum state (n = 1), psoriasis (n = 1), 
antiphospholipid syndrome (n = 1), SLE (n = 1), renal disease (n = 2) or 
cancer (n = 1). 
 
Table 1. Demographic and clinical features of the patients with acute 
acquired thrombotic thrombocytopenic purpura (TTP) included in the 
study 
Sex, F/M 50/26 
Median age, years (range) 37 (16-75) 
Median platelet count, x109L-1 (range) 15 (2-96)  
Median hemoglobin levels, g/dL (range)# 9.6 (4.2-14.7) 
No of patients / total  
Idiopathic TTP 63/76 
TTP with associated conditions 13/76 
First episode 57/76 
Relapse 19/76 
Renal involvement* 9/68  
Neurological symptoms# 52/58  
* data were not available for 8 patients 
# data were not available for 17 patients 
Renal involvement was considered when plasmatic creatinine values were 
above 120 µmol/L. Neurological involvement included: aphasia, headache, 
confusion, paresthesia, altered mental status and seizure.  
Fifty-seven patients were analyzed during the first acute episode of TTP 
and 19 during relapse. Four of the 57 (7%) patients analyzed during the 
first episode died of acute multivisceral thrombotic microangiopathy, 10 
patients were lost to follow-up and 12/43 who achieved clinical remission, 
relapsed during a minimum of 48-months follow-up (follow-up performed 
in a range of 48 to 109 months). The 19 patients studied during an acute 
 - 54 - 
relapse had a documented positive history of TTP with at least one 
previous TTP episode. Seven of the 19 patients were included in the 48-
months follow-up and they had no new relapses and 12/19 patients were 
lost to follow-up. 
At inclusion during the acute episode, anemia (hemoglobin median levels 
9.6 g/dL; range 4.2–14.7 g/dL; data available only for 59/76 patients) and 
thrombocytopenia (median 15X109/L; range 2-96X109/L) were present in 
the patients. Neurologic symptoms including headache, altered mental 
status, aphasia, paresthesia, transitory ischemic attack or convulsions 
were observed in 27/68 (40%) patients. Renal involvement, considered 
when plasmatic creatinine values were higher than 200 µmol/L, was 
present only in 9/68 (13%) patients whereas the mean creatinine level was 
101 ± 31 µmol/L in the remaining 59 patients. For 8 patients, the 
neurological and renal data were not available.  
 
4.2 ADAMTS13 activity, functional ADAMTS13 inhibitor and 
ADAMTS13 antigen levels in patients with acquired TTP 
As a result of our inclusion criteria, all patients (n=76) had ADAMTS13:Ac 
values <10%. A functional inhibitor was found in 69/76 (91%) patients; 
with 26 patients having a low, 23 patients a medium and 20 patients a 
high titer. In 7 (9%) patients a functional inhibitor was not detected by the 
assays used at the respective reference center. 
Analysis of ADAMTS13:Ag levels in TTP patients showed a variable 
distribution similar to earlier findings (Rieger et al, 2006). Eighteen 
patients had undetectable levels (<65 ng/mL), 10 patients had severely 
reduced antigen levels (65-100 ng/mL), 42 patients had reduced levels 
(100-740 ng/mL) and 6 patients had normal levels. There were no 
differences when the antigen levels between patients with single or 
relapsing TTP events were compared (Fig. 4). Three of the four deceased 
patients had undetectable antigen levels and the fourth one a borderline 
level (83 ng/mL) (Fig. 4). 
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Figure 4. ADAMTS13 antigen levels in patients with acquired TTP. 
Box plot of the distribution of the ADAMTS13 antigen levels in 76 patients with 
acute acquired TTP. Patients are divided into 3 categories according to the clinical 
outcome. The lower normal value (740 ng/mL) and the limit of quantification (<65 
ng/mL) are indicated by dashed lines. The bottom, median and top lines of the box 
mark the 25th, 50th, and 75th percentiles, respectively. The vertical line shows the 
range of values comprised between the 5th and 95th percentiles and the dots 
represent outlier values. 
 
4.3 Anti-ADAMTS13 antibody profile in patients with acquired 
TTP 
To investigate the presence of anti-ADAMTS13 antibodies, in-house ELISA 
assays were employed. These ELISAs use immobilized recombinant 
ADAMTS13 and bound plasma antibodies are visualized by means of 
specific secondary, enzyme-labeled antibodies. 
For detection of IgG and IgM anti-ADAMTS13 antibodies, previously 
established in-house ELISA assays were used (Rieger et al, 2005). For 
detection of IgA, IgE and IgG subclasses, new ELISA assays were 
developed introducing a single modification to the pre-established ELISA 
at the level of the secondary antibody.  
 
4.3.1 Anti-ADAMTS13 antibody profile in the acute episode 
Analysis of the anti-ADAMTS13 antibody profile in the acute episode 
showed the presence of anti-ADAMTS13 antibodies in 71/76 (93%) 
patients.  
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IgG anti-ADAMTS13 antibodies were detected by our in-house ELISA in 
52/76 TTP patients. In patients whose anti-ADAMTS13 IgG titers were 
lower than the detection limit of our ELISA (IgG negative, 18 patients), 
plasma samples were retested for anti-ADAMTS13 IgG antibodies using a 
commercial kit with improved sensitivity due to the use of a horseradish 
peroxidase-conjugated secondary antibody instead of an alkaline-
phosphatase-conjugated one. Using this kit, 12/18 patients tested positive 
for IgG anti-ADAMTS13 antibodies and 6 patients were confirmed 
negative. 
Taking together the results of both ELISA assays (in-house and 
commercial), 70/76 (92%) patients with acute TTP had a specific IgG 
against ADAMTS13 with titers ranging from 20 to 6400 (Fig. 5). 
 
Figure 5. ADAMTS13 inhibitor and anti-ADAMTS13 IgG/IgM/IgA antibodies 
in patients with acquired TTP. 
Seventy-six patients with acute acquired TTP were analyzed for the presence of 
ADAMTS13 inhibitor and the different classes of anti-ADAMTS13 antibodies. 
Patients are grouped in 4 categories according to their ADAMTS13 inhibitor titers 
(semi-quantitative): negative (7 patients), low (26 patients), medium (23 patients) 
and high (20 patients). Each patient is represented by a symbol. Gray circles are 
for patients with positive IgG, green circles for IgM, blue circles for IgA and red 
circles for patients with no detectable IgG/IgM/IgA (undetectable). Only positive 
patients are depicted for IgM and IgA antibodies.  
IgM and IgA classes of anti-ADAMTS13 antibodies were investigated in 
addition to the IgG class. Low titers (ranging from 20-100 with exception 
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of one patient with 3200) of IgM anti-ADAMTS13 antibodies were detected 
in 5/76 (7%) patients (Fig. 5). IgA anti-ADAMTS13 antibodies were found 
in 13/75 (17%) patients with variable titers from 200 to 51200 (Fig. 5). In 
one patient, the IgA anti-ADAMTS13 antibody titer could not be 
determined due to the lack of a sufficient amount of plasma.  
A trend toward increasing inhibiting activity with increasing anti-
ADAMTS13 titers was observed, especially in those patients positive for 
more than one class of antibodies (Fig. 5). 
Isolated IgG anti-ADAMTS13 antibodies were detected in 57 patients. IgM 
was not detected alone and only one patient had low titer of IgA 
antibodies. The combination of IgG and IgM was detected in 2 patients, 
the combination of IgG and IgA in 8 patients and the combination of the 3 
classes of antibodies in 3 patients. Taken together, 71 out of 76 (93%) 
patients tested positive for anti-ADAMTS13 antibodies. 
The presence of non inhibitory antibodies was detected in 6 out of 7 
patients with no measurable functional inhibitor (Fig. 5). Five patients 
tested positive only for IgG antibodies and the sixth one for IgG in 
combination with high IgA antibodies. One patient tested negative for both 
ADAMTS13 functional inhibitor and classes (IgG, IgM or IgA) of anti-
ADAMTS13 antibodies. The overall prevalence of non inhibitory antibodies 
in this study was 8%.  
An interesting finding is that the plasma from 4 patients inhibited 
ADAMTS13 activity in the absence of any detectable class (IgG, IgM or IgA) 
of anti-ADAMTS13 antibodies.  
 
4.3.2 Correlation between ADAMTS13 antibodies at presentation and 
ADAMTS13 activity at initial clinical remission 
The ADAMTS13 activity was analyzed at initial clinical remission in only 
32 out of the 76 patients studied. The ADAMTS13 activity showed 3 
distinct courses: it either remained undetectable (<5%) in 13 patients 
(41%), became detectable but partially decreased (15 to 40%) in 12 
patients (38%), or normal (50 to 100%) in 7 patients (21%). ADAMTS13 
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inhibitors in remission were detectable only in patients whose ADAMTS13 
activity remained <5%, with titers either similar or decreased when 
compared to those of the acute episode (Fig.6). 
 
Figure 6. Correlation between ADAMTS13 inhibitor titers at presentation and 
ADAMTS13 activity at initial clinical remission in patients with acquired TTP. 
Patients are grouped in 3 categories according to the level of ADAMTS13 activity at 
initial clinical remission: <5% (n = 13), between 15 and 40% (n = 12) and between 
50 and 100% (n =7). At presentation, the presence of high titers of ADAMTS13 
inhibitor, either alone or combined with IgG anti-ADAMTS13 antibodies, was more 
frequent in patients having undetectable ADAMTS13 activity (below 5%) at initial 
clinical remission when compared to patients having detectable ADAMTS13 activity. 
(*): significant statistical difference (P < 0.05) between both groups. 
When trying to correlate ADAMTS13 antibodies at presentation and 
ADAMTS13 activity at initial clinical remission; the presence of a high titer 
of ADAMTS13 inhibitor, either alone or combined with anti-ADAMTS13 
antibodies of the IgG class at presentation, was associated with the 
persistence of an undetectable ADAMTS13 activity (<5%) in initial clinical 
remission (Fig.6). 
 
4.4 Subclass distribution of IgG anti-ADAMTS13 antibodies  
The biological function of IgG antibodies is determined by their specificity, 
affinity and subclasses. The IgG subclasses have different capacities to 
bind to cell surface Fcγ receptors (FcγRs) or to activate complement 
proteins, thus mediating different immunological effector functions 
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(Jefferis et al, 1994). Due to our findings that about 92% of the TTP 
patients have IgG anti-ADAMTS13 antibodies, we decided to characterize 
the IgG subclass distribution to elucidate a possible role of these 
antibodies in the patho-mechanism leading to acquired TTP. 
 
4.4.1 Subclass distribution of IgG anti-ADAMTS13 antibodies  
The subclass distribution of anti-ADAMTS13 IgG antibodies was analyzed 
in the 58 patients who tested positive for anti-ADAMTS13 IgG antibodies 
in our in-house ELISA. From the 58 patients with acquired TTP tested, 44 
patients were analyzed during the first episode and 14 during a relapse. 
IgG4 was detected in 90% of the patients (52/58, 90%), followed by IgG1 
(30/58, 52%), IgG2 (29/58, 50%), and IgG3 (19/58, 33%). 
When patients were subdivided by clinical outcome, 38/44 (86%) patients 
analyzed during the first event had IgG4 antibodies. IgG4 was found either 
alone (8/38, 21%) or with other IgG subclasses (30/38, 79%). Among the 
30 patients in whom IgG4 was found with other IgG subclasses, the 
association with all four IgG subclasses (10/30, 33%) was the most 
prevalent finding, followed by association with IgG2 (7/30, 23%), IgG1 
(5/30, 17%) and IgG3 (1/30, 3%). IgG4 was also found with IgG1 and 
IgG2 (4/30, 13%) and with IgG1 and IgG3 (3/30, 10%) (Fig. 7). No IgG4 
was detected in 6/44 (14%) TTP patients who had predominantly IgG1 
with IgG3 (n = 2), IgG2 (n = 1) or IgG2 and IgG3 (n = 3) (Fig. 7).  
The IgG-subclass distribution in 14 patients analyzed during an acute 
relapsing event revealed IgG4 as the predominant IgG subclass (14/14, 
100%); IgG4 was found either alone (9/14, 65%) or associated with IgG2 
(3/14, 21%), IgG1 (1/14, 7%) or IgG1 and IgG2 (1/14, 7%), (Fig. 7).  
The IgG subclass distribution of 4/6 patients without detectable 
functional inhibitors showed IgG4 accompanied by IgG2 or IgG3 or IgG1 
and IgG3, or all of them. The remaining two patients had no IgG4, with 
IgG1 being the most representative subclass. 
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Figure 7. Subclass distribution of anti-ADAMTS13 IgG antibodies in patients 
with acquired TTP. 
Fifty-eight patients with acute acquired TTP were analyzed for different IgG 
subclasses. The histograms show the frequencies of patients positive for each 
combination of IgG subclasses. Black and white bars represent patients analyzed 
during the first TTP episode (n = 44) with or without IgG4, respectively. Grey bars 
represent patients analyzed during a relapsing event (n = 14). Plus and minus 
signs denote the presence and absence of the subclass, respectively. 
To assess the contribution of any subclass to total IgG (IgGsum), we 
calculated the relative concentration of each IgG subclass in a patient. Six 
of 58 patients were excluded from this calculation because their IgG4 OD 
values were outside the linear range. IgG4 was the most abundantly 
produced subclass, with levels ranging from 1% to 100% (Fig. 8A). IgG1 
was the second most common subclass, with levels ranging from 11% to 
92%, whereas, IgG2 and IgG3 formed only a small percentage of IgGsum, 
with levels ranging from 4% to 26% and 1% to 30% for IgG2 and IgG3, 
respectively (Fig. 8A). In contrast to IgG4, IgG1 was never found as a 
single subclass; however, in the absence of IgG4, IgG1 constituted more 
than 85% of IgGsum. The presence and abundance of IgG4 and IgG1 were 
inversely correlated (r2 = - 0.927, P < 0.01)  
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Figure 8. Relative concentrations of anti-ADAMTS13 IgG subclasses and total 
IgG anti-ADAMTS13 antibody titers within a patient. 
(A) The relative concentration of the different IgG subclasses was calculated for 
plasma of 52 TTP patients. The individual IgG subclass distribution of each patient 
is shown. Patients are numbered 1-52 according to decreasing levels of IgG4. IgG4 
and IgG1 are the dominating IgG subclasses. (B) Total IgG anti-ADAMTS13 
antibody titers corresponding to each patient [numbered from 1 to 52 as in (A)]. In 
both (A) and (B), individual patient numbers are shown in steps of five. 
Because of the dominant presence of IgG4 antibodies in our patient 
population, IgE anti-ADAMTS13 antibodies were also assayed, as the 
production of IgG4 and IgE is induced by the same cytokines [interleukin 
(IL)-4 and IL-13], released by T-helper 2 cells (Stavnezer, 1996). None of 
the 17 patients with IgG4 as the only positive subclass had IgE antibodies 
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against ADAMTS13, excluding a pathogenic role of IgE autoantibodies in 
TTP as described in, for example, bullous pemphigoid (Iwata et al, 2008) or 
SLE (Atta et al, 2010). 
 
4.4.2 Relation between the IgG subclass profile and the total anti-
ADAMTS13 IgG antibody titers and ADAMTS13:Ag levels 
When IgGtot was related to the IgG subclass profile, patients with IgG4 as 
the only subclass showed lower IgGtot titers (range 20-200) than patients 
with IgG4 combined with other IgG subclasses (Fig. 8B). The combination 
of IgG4 with one, two or more IgG subclasses was associated with the 
highest IgGtot titers (range 100-6400). This was even more pronounced in 
patients with undetectable IgG4 (range 1600-6400). Patients without 
detectable functional inhibitors generally had low IgGtot antibody titers 
(100-400), except for two patients who had undetectable IgG4 (1600 for 
both) (Fig. 8B).  
The relationship between ADAMTS13:Ag levels and the IgG subclass 
profile was variable, with a trend towards lower ADAMTS13:Ag levels with 
increasing numbers of IgG subclasses. Patients with the lowest IgG4 levels 
(< 10%) or highest IgG1 levels (> 85%) had significantly lower 
ADAMTS13:Ag levels than patients with the highest IgG4 levels or IgG4 as 
the only subclass present (P < 0.01 and P < 0.05, respectively; the six 
patients with IgG4 OD values outside the linear range were excluded from 
this analysis).  
 
4.4.3 Subclass distribution of anti-ADAMTS13 IgG antibodies and 
clinical outcome 
We observed that 4 patients who had very low (< 5%) or undetectable IgG4 
with high levels of IgG1 died during the first acute TTP event (Table 2). 
These patients also showed high anti-ADAMTS13 IgA antibodies titers, 
three of them in combination with anti-ADAMTS13 IgM antibodies. 
This observation prompted us to search for an association between levels 
of IgG4 and IgG1 and recurrence of TTP. We analyzed 40 patients who 
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were divided into three groups: those who had experienced only a single 
TTP episode [group 1; IgG4 and IgG1 median values were 44% 
(interquartile range (IQR) 30-85) and 50% (IQR 15-63), respectively], those 
who relapsed during 48 months of follow-up [group 2; IgG4 and IgG1 
median values were 91% (IQR 72-95.5) and 0% (IQR 0-15), respectively] 
and those who had had relapse(s) before [group 3; IgG4 and IgG1 median 
values were 100% (IQR 91.2-100) and 0% (IQR 0-0), respectively] (Fig. 9) 
(for inclusion criteria, see Methodology, chapter 3.9). High levels of IgG4 
were associated with relapse (P = 0.03 and P = 0.001 for comparison 
between groups 1 and 2 and groups 1 and 3, respectively).  
 
Figure 9. Levels of IgG1 and IgG4 anti-ADAMTS13 antibodies in 
patients with acute acquired TTP. 
(A) Patients who had experienced only a single TTP event. (B) Patients who 
relapsed during the 48 months of follow-up or had had relapse(s) including 
patients without further relapses during follow-up and patients lost to 
follow-up after the acute relapsing event.  
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Likewise, patients with undetectable or very low IgG1 levels experienced 
more TTP events than patients with detectable (moderate or low) levels (P = 
0.005 and P < 0.001 for comparison between groups 1 and 2 and groups 1 
and 3, respectively).  
Taken together, our findings suggest that patients with high levels of IgG4 
and undetectable IgG1 are more prone to relapse than patients with low 
levels of IgG4 and detectable IgG1. 
 
4.5 Detection of circulating ADAMTS13-anti-ADAMTS13 
antibody immune complexes in patients with acquired TTP 
During the establishment of our in-house ELISA to quantify ADAMTS13 
antigen levels (Rieger et al, 2006), we observed that removal from plasma 
of anti-ADAMTS13 IgG antibodies by Protein G also completely removed 
any measurable residual ADAMTS13 antigen, indicating that all 
ADAMTS13 was bound to IgG antibodies. These findings were the first 
evidence for the presence of soluble ADAMTS13-specific immune 
complexes (ICs) in plasma from patients with acquired TTP. 
These observations prompted us to establish two types of assays to 
experimentally detect circulating ADAMTS13-specific ICs: one based on 
co-immunoprecipitation of ADAMTS13 with IgG antibodies using Protein 
G and the second one based on ELISA methodology. 
 
4.5.1 Detection of circulating ADAMTS13-anti-ADAMTS13 antibody 
immune complexes by co-immunoprecipitation 
For co-immunoprecipitation (Co-IP) experiments, plasma samples from all 
those patients with acute acquired TTP (n=16) were included where 
sufficient amounts of plasma were still available. As negative controls, 
plasmas from healthy individuals, different batches of pooled NHP and 
human serum albumin (HSA, 50 µg/mL) spiked with recombinant 
ADAMTS13 (rADAMTS13, 2 µg/mL) were also analyzed. 
All samples were subjected to immunoprecipitation with Protein G and co-
isolated ADAMTS13 was detected by Western blot analysis using an 
affinity-purified polyclonal rabbit anti-human ADAMTS13 antibody. The 
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sensitivity of this antibody to detect rADAMTS13 in a blot is approximately 
0.5 ng. 
ADAMTS13 was not detectable in the protein G-bound total IgG derived 
from healthy individual plasmas, pooled NHP or HSA spiked with 
rADAMTS13 (Fig. 10A). ADAMTS13 was however detectable in most of the 
16 TTP-derived samples (Fig. 10B) suggesting the specific detection of 
circulating ADAMTS13-IgG ICs.  
 
Figure 10. Detection of circulating ADAMTS13-anti-ADAMTS13 antibody 
immune complexes (ICs) in TTP patients by co-immunoprecipitation. 
Circulating ADAMTS13-specific ICs were analyzed by co-immunoprecipitation of 
ADAMTS13 with Protein G-bound IgG followed by Western blot analysis to detect 
ADAMTS13. The position of ADAMTS13 in the gels was determined by loading 1 
ng of recombinant ADAMTS13 (rA13). (A) Healthy individuals (NP), different 
batches of pooled normal human plasma (NHP), human serum albumin (HSA; 50 
µg/mL) and HSA spiked with 2 µg/mL of recombinant ADAMTS13 (HSA + rA13). 
(B) TTP patients. Two batches of NHP served as negative control. The relative 
percentage of IgG1 and IgG4 antibodies and ADAMTS13:Ag values of the samples 
are also shown. Each lane contains equal amounts of total IgG.  
Except for one patient (Fig. 10B; TTP 4), circulating ADAMTS13-IgG ICs 
were detected in all plasma samples (n=9) where free ADAMTS13:Ag levels 
were not detectable (Fig. 10B). An interesting observation is that 3 
patients who had measurable residual ADAMTS13:Ag levels (levels 
between 361 – 415 ng/mL) showed also higher IC levels compared to those 
patients with no detectable protein (Fig. 10B; TTP 2, TTP 10 and TTP 16), 
suggesting that the ELISA employed to quantify ADAMTS13:Ag levels is 
 - 67 - 
also detecting circulating ADAMTS13-specific ICs at least to some extent, 
in line with a previous report (Rieger et al, 2006). 
No differences could be observed when the presence and relative amounts 
of circulating ADAMTS13-IgG ICs were compared with those of the 
subclasses of the free anti-ADAMTS13 IgG antibodies. Patients having 
mainly IgG1 antibodies (Fig. 10B; TTP 1 to 5) had similar amount of ICs as 
patients having mainly IgG4 antibodies (Fig. 10B; TTP 9 to 16). These 
observations may suggest that the formation and clearance of ADAMTS13-
IgG ICs is independent of the IgG subclass involved in IC formation.  
Patients with low levels of free IgG anti-ADAMTS13 antibodies (detectable 
only with a commercial ELISA kit) also contained ADAMTS13-IgG ICs (Fig. 
10B; TTP 6 to 8). 
 
4.5.2 Detection of circulating ADAMTS13-anti-ADAMTS13 antibody 
immune complexes by ELISA 
The positive findings obtained with the Co-IP experiments and considering 
our previous observation that an ADAMTS13:Ag ELISA was able to 
indirectly detect ADAMTS13-specific ICs, we aimed to establish an ELISA-
based assay that should detect and characterize the immunoglobulin 
fraction of the circulating ADAMTS13-specific ICs. 
For this, the basic set-up of the in-house ELISA to quantify ADAMTS13:Ag 
levels was modified at the detection step to visualize the antibody fraction 
of the immune complex. Briefly, a polyclonal rabbit anti-ADAMTS13 
antibody is used to capture any ADAMTS13-anti-ADAMTS13 antibody ICs 
present in the plasma and the immunoglobulin fraction of the IC is 
detected by means of enzymatically-labeled anti-human IgG1-4 or IgA 
antibodies. The major limitation of this ELISA is that only ICs bearing an 
ADAMTS13 with free available epitopes will be detected. 
The presence of circulating ADAMTS13-specific ICs was analyzed in 60 
healthy donor plasmas to establish assay cut-off values. Circulating 
ADAMTS13-specific ICs were also tested in a total of 57 out of 76 TTP 
patients for which plasma samples were available. The levels of 
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ADAMTS13-specific ICs were expressed as ratio between the OD values 
obtained with the tested plasma and OD values of a pooled NHP.  
Circulating IgG- and IgA-ADAMTS13 ICs were detected in 47/57 (82%) 
and 13/53 (25%) of the TTP patients, respectively. When the IgG subclass 
distribution of ADAMTS13-IgG-specific ICs were analyzed; 41/47 (87%) of 
the TTP patients showed an IgG4-IC, 19/47 (40%) an IgG2-IC, 15/47 
(32%) an IgG1-IC and only 7/47 (15%) of the patients an IgG3-IC (Fig. 11). 
Comparing the levels of ADAMTS13-specific ICs between TTP patients and 
healthy donors revealed a statistically significant difference for IgG1, IgG2, 
IgG4 and IgA ICs (P < 0.001 for IgG1, IgG2, IgG4 and IgA, respectively), 
but not for IgG3 (P = 0.456). 
 
Figure 11. Detection of circulating ADAMTS13-anti-ADAMTS13 antibody ICs 
in patients with acute acquired TTP by ELISA. 
Box plot of the distribution of circulating IgG1 to IgG4- and IgA-ADAMTS13 
specific ICs in plasma from 57 TTP patients. The IC levels are presented as ratio 
between the OD of the sample and the OD of a pooled NHP (dilution 1 to 20). The 
dashed lines represent the normal cut-off value for each ELISA. The bottom, 
median and top lines of the box mark the 25th, 50th, and 75th percentiles, 
respectively. The vertical line shows the range of values comprised between the 5th 
and 95th percentiles and the dots represent outlier values. The percentage of 
positive TTP patients for each subclass of ADAMTS13-specific IC is shown at the 
bottom. 
In 68% of the patients tested positive for IgG-ICs a correlation between the 
subclasses of the free IgG anti-ADAMTS13 antibodies found in the plasma 
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and the subclasses of the IgG-containing ICs was observed. Importantly, 
all patients that were tested negative for free IgG4 antibodies also tested 
negative for IgG4-containing ICs. In 8/12 (67%) of the TTP patients tested 
positive for free IgA anti-ADAMTS13 antibodies also tested positive for IgA-
containing ICs.  
Interestingly, in 2 out of 6 and 5 out of 41 patients tested negative for IgG 
and IgA anti-ADAMTS13 antibodies, respectively, circulating ADAMTS13-
specific ICs (involving IgG2, IgG4 or IgA) were detected by ELISA. This 
indicated that a negative finding of free anti-ADAMTS13 antibodies in 
plasma may be due to the sequestration of these antibodies in ICs. 
In only 6 patients circulating ADAMTS13-IgG-specific ICs were not 
detected although free IgG anti-ADAMTS13 antibodies and practically no 
ADAMTS13:Ag were present.  
Eight out of 9 patients who tested positive for free IgG anti-ADAMTS13 
antibodies only by the commercial ELISA were tested positive for IgG4-IC 
suggesting that our in-house ELISA is not detecting low levels of free IgG4 
antibodies. These observations confirm previous findings that the goat 
anti-human IgG antibody used to visualize IgG in the in-house ELISA 
detected IgG4 with ~50% lower sensitivity than IgG1-3 antibodies. 
Four patients tested negative for anti-ADAMTS13 antibodies also tested 
negative for all classes and subclasses of ICs (IgG1-4 and IgA). 
 
4.5.3 Detection of complement fixing immune complexes by binding 
to immobilized C1q 
The complement subcomponent C1q binds to the Fc region of complexed 
IgG or IgM thereby triggering the activation of the classical complement 
pathway. Based on these properties, we used a commercially available 
C1q binding ELISA to evaluate if ADAMTS13-containing ICs are able to 
activate complement. Plasmas derived from 37 TTP patients included in 
the current study and from 3 healthy individuals were tested. In 6 out of 
37 (16%) patients circulating ICs bound to immobilized C1q were detected 
(Fig. 12). Borderline and negative values were obtained for 6/37 (16%) and 
25/37 (68%) of the patients, respectively (Fig. 12). All 3 healthy 
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individuals tested also negative. Since C1q is efficient in binding ICs only 
when containing IgG subclasses 1 to 3, the results are in accordance with 
the observed high prevalence (87%) of circulating ADAMS13-IgG4-specific 
ICs. 
 
Figure 12. Detection of complement fixing ICs by binding to immobilized C1q 
The levels of circulating ICs (µg EQ/mL) binding to immobilized C1q was evaluated 
in 37 TTP plasma samples by ELISA. The negative cut-off value of the assay was 3.2 
µg Eq/mL, samples with 3.2-5.0 μg Eq/mL were judged as borderline and samples 
with values above 5.0 μg Eq/mL were judged as positive. 
 
4.6 Binding of human IgG4 to rabbit anti-ADAMTS13 antibody 
During the establishment of the ELISA to detect circulating ADAMS13-
IgG4-specific ICs, undesired high background signals were reached when 
testing either pooled NHP or individual healthy donor plasmas. These 
findings might have been caused by the potential presence of naturally 
occurring circulating ADAMS13-IgG4-specific ICs in the healthy 
population or by a propensity of human IgG4 present in normal plasma to 
bind rabbit IgG antibodies.  
The first possibility was explored comparing pooled NHP with an 
ADAMTS13-depleted pooled NHP (depleted-NHP) prepared as previously 
described (Rieger et al, 2006), and the second by using a commercially 
available purified human IgG4 (hIgG4) preparation in a concentration 
range comparable to the final amount of IgG4 present at each tested 
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dilution of pooled NHP. Interestingly, similar results were obtained with 
both set-ups (Fig. 13), indicating that hIgG4 is able to bind to coated 
rabbit IgG in a dose-dependent manner, thereby causing the high 
background signals in the ELISA.  
 
Figure 13. Binding of human IgG4 to coated rabbit IgG antibodies. 
Serial dilutions of pooled NHP and ADAMTS13-depleted NHP (indicated in blue 
color) as well as purified human IgG4 (hIgG4) at concentrations comparable to the 
final amount of IgG4 present at each tested dilution of pooled NHP (indicated in 
black color) were allowed to bind to coated rabbit IgG. As negative control (blank), 
blocking buffer was used as a sample. 
Similar results were obtained when rabbit IgG antibodies in solution were 
allowed to bind to coated hIgG4. Moreover, hIgG4 in solution was capable 
of competing with rADAMTS13 for binding to coated rabbit anti-
ADAMTS13 IgG (data not shown). 
This conclusion was further corroborated by pre-incubating pooled NHP, 
ADAMTS13-depleted-NHP and hIgG4 with a monoclonal anti-human IgG4 
(Fc-specific) antibody in a final concentration of 11 µg/mL. The binding of 
IgG4 to coated rabbit IgG was equally inhibited in all three samples but 
not in control samples pre-incubated with BSA (differences approximately 
5-fold; data not shown). These preliminary results suggested that hIgG4 is 
able to bind to coated rabbit IgG via its Fc fragment because the Fc-
specific anti-human IgG4 antibody was able to abrogate the binding.  
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Figure 14. Binding of rabbit IgG antibodies to coated human 
immunoglobulins. 
Horseradish peroxidase (HRP)-labeled whole rabbit IgG, IgG (Fab´)2 or IgG Fc 
antibodies were allowed to bind to coated purified human IgG1-4, IgM or IgA 
antibodies. (A) Binding of whole rabbit IgG to Igs. (B) Binding of rabbit IgG Fc to 
Igs. (C) Binding of rabbit IgG (Fab´)2 to Igs. 
We next explored the nature of the hIgG4-rabbit IgG interaction and also 
the potential binding of other human immunoglobulins (IgM, IgA or IgG1-
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3) to rabbit IgG. For this, HRP-labeled whole rabbit IgG, HRP-labelled IgG 
(Fab´)2 fragment and HRP-labelled IgG Fc fragment were allowed to bind 
to coated purified human IgG1-4, IgM or IgA antibodies. The results 
confirmed that the binding of rabbit IgG antibodies to human IgG4 is 
mediated via its Fc rather than its F(ab´)2 portion (Fig. 14). Interestingly, 
we also observed an increased dose-dependent binding of rabbit IgG (Fc 
fragment) to coated human IgG1 and to a lesser extent to IgG2, IgG3 and 
IgM. No binding was observed to IgA (Fig. 14). 
Because of these findings, we assayed for binding of human IgG1-3 to 
rabbit IgG antibodies. Different concentration of human IgG1-3 
(comparable to those of each tested dilution of pooled NHP) and diluted 
pooled NHP were allowed to bind to coated rabbit IgG antibodies. Neither 
IgG1, IgG2 or IgG3 had the ability to bind to rabbit IgG under the 
conditions used (data not shown). 
 
4.7 Detection of anti-ADAMTS13 antibodies and circulating 
ADAMTS13-immune complexes in a follow-up of a patient with 
refractory TTP 
The dynamic course of anti-ADAMTS13 antibodies and circulating 
ADAMTS13-IC during treatment was investigated in a patient suffering 
from refractory TTP (Scheiflinger et al, 2003). Throughout the follow-up 
until the decease of the patient at day 64, plasma samples were collected 
daily before treatment and ADAMTS13-related parameters were 
determined. ADAMTS13:Ac and ADAMTS13:Ag were undetectable at most 
time points. High inhibitor titers were measured during the first two weeks 
and declined to low levels thereafter. Anti-ADAMTS13 antibodies of the 
IgG, IgM and IgA class were detected concomitantly (Fig. 15). For IgG and 
IgA antibodies, high to moderate titers were found practically throughout 
the entire observation time.  
By contrast, IgM antibodies were detected only at the beginning and with 
low titers. The anti-ADAMTS13 IgG subclass profile showed prevalence of 
IgG1 (82%) and very low levels of IgG2 (7%) and IgG3 (11%) antibodies, 
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while IgG4 was undetectable. This antibody profile did not change during 
the course of the disease. 
The presence of ADAMTS13-specific IgG, IgM and IgA ICs was investigated 
by Co-IP and ELISA. The former method detected ADAMTS13-specific ICs 
for all the 3 classes of antibodies. By determining the relative amounts of 
circulating ICs through scanning of the luminograms (Fig. 16A-D), it 
appeared that the plasma concentration of the IgG-ICs is higher than that 
of the IgM- and IgA-ICs. Interestingly, ADAMTS13-specific ICs followed an 
inverse kinetics to that of the measured free antibody titers. ICs were 
detectable most of the time but became apparently undetectable when the 
titers of the free antibodies rose (Fig. 16A-D). Notably, low amounts of 
IgM-ICs were detected at most time points although no free IgM antibodies 
were detected after day 12 (Fig. 16A-D). 
 
 
Figure 15. Dynamic course of anti-ADAMTS13 antibodies in a patient with 
refractory TTP.  
Dynamic course of anti-ADAMTS13 antibody titers (IgG, IgM, IgA and functional 
inhibitor (BU/mL)) during the two months follow-up. The treatment regimen 
including plasma exchange (PEX), immunoadsorption (IAS), corticosteroids (CS), 
and splenectomy is shown above the diagram. 
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Figure 16. Dynamic course of circulating ADAMTS13-specific ICs in a patient 
with refractory TTP.  
Immunoblots showing the course of circulating (A) ADAMTS13-IgG ICs, (B) 
ADAMTS13-IgA ICs and (C) ADAMTS13-IgM ICs. Recombinant ADAMTS13 (rA13, 
1ng/well) was used as negative control. Pooled NHP (NHP), a single healthy donors 
(NP) and human serum albumin (HSA; 50 µg/mL) spiked with 2 µg/mL of rA13 
(SP) were used as negative controls. M denotes the molecular weight marker. Each 
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lane contains equal amounts of total IgG. The corresponding anti-ADAMTS13 
antibody titers are also shown in the lower panel of each blot. (D) Relative amount 
of circulating ADAMTS13-specific ICs after densitometric quantification using 
rA13 (1 ng) as standard. AU denotes arbitrary units. 
The presence of ICs was also analyzed by ELISA in the sample collected at 
day 1. Circulating IgG1-ICs, IgG3-ICs and IgA-ICs were detected. IgM-ICs 
were not investigated by ELISA. A correlation could again be observed 
when the classes and subclasses of free ADAMTS13 antibodies were 
compared with those of the immunoglobulin forming the ICs. 
 
4.8 Detection of anti-CD36 antibodies in TTP patients 
Previous studies have shown that approximately 70% of the TTP patients 
have autoantibodies against the membrane antigen CD36 (Tandon et al, 
1994;Schultz et al, 1998;Wright et al, 1999;Rock et al, 2005). In these 
studies, platelet lysates were used as source of human CD36 and the 
presence of anti-CD36 antibodies was evaluated by either Western blot 
with patient´s plasma as first antibody or by immunoprecipitation of 
patient´s plasma antibodies with platelet lysates-derived CD36. 
Alternatively, a Dot blot using purified platelet-derived CD36 as protein 
source was performed. 
The published high incidence of anti-CD36 antibodies in TTP patients 
prompted us to develop a more sensitive assay based on ELISA technique 
to detect these antibodies in the plasma from TTP patients. The source of 
human CD36 used to coat the ELISA plates was a commercially available 
full-length recombinant human CD36 (rCD36) expressed in human 
embryonic kidney cells (HEK 293).  
The presence of anti-CD36 antibodies was investigated in 57 of the 76 TTP 
patients included in the current study and in 36 additional TTP patients 
whose plasma samples became available at a later point in time.  
A total of 63 healthy donor samples were analyzed to establish assay cut-
off values. In the absence of any human-derived positive control, a 
monoclonal rat anti-human CD36 antibody directed against the 
extracellular part of human CD36 was used as positive control to allow 
following the assay performance. 
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Circulating anti-CD36 antibodies were detected in only 7/93 (8%) of the 
TTP patients and in 2/63 (3%) of the healthy donors (Fig.17). From the 57 
patients included in the study described in previous chapters, only 3 
patients tested positive. There was no statistically significant difference (P 
< 0.197) between healthy donors and TTP patients when the levels of anti-
CD36 antibodies (expressed as ratio between OD of the tested sample and 
the OD of a pooled NHP) were compared (Fig.17). 
 
Figure 17. Detection of anti-CD36 antibodies in patients with acquired TTP. 
Box plot of the distribution of anti-CD36 antibodies in plasma from 63 healthy 
donors (NP) and 93 patients with acquired TTP. The anti-CD36 antibodies levels 
are presented as ratio between the OD of the sample and the OD of a pooled NHP. 
The dashed line represents the normal ELISA cut-off value. The bottom, median 
and top lines of the box mark the 25th, 50th, and 75th percentiles, respectively. The 
vertical line shows the range of values comprised between the 5th and 95th 
percentiles and the dots represent outlier values. NS= non-significant statistical 
difference between both groups. 
For 3 out of the 7 TTP plasma samples tested positive for anti-CD36 
antibodies competitive inhibition experiments between immobilized rCD36 
and rCD36 in solution could be performed. Specificity of the detected anti-
CD36 antibody could be shown in 2 samples, whereas the third sample 
displayed inhibition also with different protein sources used as negative 
control (rADAMTS13 and BSA).  
In summary, we confirmed the detection of anti-CD36 antibodies in 2 out 
3 TTP patients by our in-house ELISA but not with the commercial kit. 
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The positivity of 4 TTP patients could not be confirmed with any additional 
assay due to unavailability of plasma sample.  
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5- DISCUSSION 
The pathogenesis of acquired idiopathic TTP is characterized by severe 
ADAMTS13 deficiency due to the presence of circulating autoantibodies 
directed against ADAMTS13 that may or may not inhibit its functional 
activity (Scheiflinger et al, 2003;Rieger et al, 2005;Shelat et al, 2006). The 
main goal of the present study was to characterize the immune response 
against ADAMTS13 in a well-defined cohort of 76 adult TTP patients who 
underwent a first acute episode (n=57) or who had an acute relapsing 
event (n=19). 
 
Characterization of the free anti-ADAMTS13 antibodies 
Anti-ADAMTS13 antibodies were identified in 71 out of the 76 (93%) TTP 
patients. IgG, IgM and IgA antibodies were detected in 92%, 7% and 17% 
of the patients, respectively (Fig. 5). The IgG and IgM findings are in 
agreement with a previous study of our group in which IgG and IgM 
antibodies were detected in 97% and 11% of the TTP patients, respectively 
(Rieger et al, 2005). Subsequent studies reported a similar prevalence of 
IgG (Tsai et al, 2006;Shelat et al, 2006;Scully et al, 2008;Pos et al, 2011) 
and IgM (Pos et al, 2011) antibodies in TTP patients. 
This is the first study on IgA antibodies against ADAMTS13 in TTP 
patients. The frequency rate of 17% for IgA antibodies found here (Ferrari 
et al, 2007) is very similar to the 19% of a more recent study conducted by 
Pos et al (Pos et al, 2011). Interestingly, one patient from our cohort with a 
positive functional inhibitor had detectable antibodies only of the IgA 
class, suggesting that IgA antibodies can also have inhibiting activity 
against ADAMTS13. High levels of IgA antibodies were recently found to be 
associated with mortality (Bettoni et al, 2011). In line with this 
observation, we observed that high levels of IgA antibodies were present in 
3 out of 4 death cases. Pathogenic IgA autoantibodies are described in 
patients suffering of SLE and antiphospholipid syndrome and they are 
considered a risk factor for development of thrombosis (Wilson et al, 
1998;Shen et al, 2008). The clinical significance and pathogenic potential 
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of IgA antibodies in acquired TTP is however unknown and further studies 
are needed to assess their contribution to the pathogenesis of TTP. 
Inhibitory antibodies were found in 92% of the patients while the rate of 
non-inhibitory antibodies in this study was only 8%. These data indicate 
that a majority of the anti-ADAMTS13 antibodies is inhibitory in vitro and, 
since most of them target domains that are required for ADAMTS13 
proteolytic activity (Klaus et al, 2004;Zheng et al, 2010), these antibodies 
are probably also inhibitory in vivo. On the other hand, the detection of 
non-inhibitory antibodies in samples from patients with acquired TTP may 
be assay dependent and their frequency of occurrence remains 
controversial. Depending on the study, the prevalence of non-inhibitory 
antibodies lies between 7% and 29% (Tsai et al, 2006;Shelat et al, 
2006;Scully et al, 2008). Since most of the functional assays used for 
functional inhibitor detection suffer from a lack of sensitivity, antibodies 
with a low affinity and/or concentration may be missed, thereby 
overestimating the rate of acquired TTP patients with non-inhibitory 
antibodies. 
Another novel finding of this study was the characterization of the 
subclasses of anti-ADAMTS13 IgG antibodies. The IgG subclass 
distribution of anti-ADAMTS13 IgG antibodies was investigated in 58 out 
of 76 TTP patients included in this cohort. In a remarkable number of 
patients (17/58), IgG4 was the only subtype that could be detected, 
implying that IgG4 plays a dominant role in the pathogenesis of 
autoimmune TTP. The second most frequent subtype was IgG1, while IgG2 
and IgG3 were less represented (Fig. 7). A similar prevalence of IgG 
subclasses in a cohort of 48 acquired TTP patients was recently reported 
(Pos et al, 2011). Importantly, IgG4 antibodies were found in all relapsed 
patients suggesting a chronic stimulation of the immune system since 
IgG4 is mainly produced under conditions of chronic antigen exposure 
driven by a T-helper 2 immune response (Aalberse et al, 2009). There was 
also an inverse correlation between the frequency and abundance of IgG4 
and IgG1 antibodies (P < 0.01) and we consider this inverse relation to be 
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an important factor in the pathophysiology of acquired TTP due to the 
distinct biological functions exerted by these two subclasses. IgG1 is 
known to bind to both complement C1q and FcγRs thus leading to 
activation of the classical complement pathway and immune and 
endothelial cells, whereas IgG4 has poor ability to induce both 
complement and cell activation (Jefferis et al, 1994). 
The ELISAs used in this thesis to detect anti-ADAMTS13 antibodies were 
developed in-house and utilized immobilized recombinant ADAMTS13 to 
bind the various antibodies. Compared to the method published 
previously by our group for the detection of anti-ADAMTS13 IgG and IgM 
antibodies (Rieger et al, 2005), we have introduced a slight modification to 
the basic set-up so as to allow the additional detection of the different IgG 
subclasses, IgA and IgE anti-ADAMTS13 antibodies. The method was able 
to detect both inhibitory and non-inhibitory autoantibodies. Thus, it 
appears suitable for treatment monitoring because it is easy to perform, 
the results can be available within a few hours, and seems to have a much 
greater sensitivity than the classical inhibitor assay due to the detection 
also of non-inhibitory antibodies. In the future, the sensitivity of the 
ELISA could be further improved by replacing the alkaline-phosphatase-
conjugated secondary antibodies by a horseradish peroxidase-conjugated 
one. 
Taken together, our findings indicate that the autoimmune response 
against ADAMTS13 is polyclonal and heterogeneous with different classes 
and subclasses of autoantibodies playing key roles in the patho-
mechanism of acquired TTP. Clearly, further studies are needed to 
investigate the specific pathogenic role of each antibody type. 
 
Anti-CD36 antibody incidence is not correlated with acquired TTP  
Based on reports on a high incidence of anti-CD36 antibodies in acquired 
TTP patients (Tandon et al, 1994;Schultz et al, 1998;Wright et al, 1999), 
we developed an ELISA assay to analyze our own cohort for presence of 
these autoantibodies. Anti-CD36 antibodies were found in only 8% of the 
TTP patients analyzed and in 3% of the healthy donor control group. This 
 - 82 - 
result was in contrast to the frequency of about 70% observed previously 
by other authors (Tandon et al, 1994;Schultz et al, 1998;Wright et al, 
1999).  
This gross discrepancy in the frequency of detected anti-CD36 antibodies 
is likely due to differences in the methods employed for antibody 
detection. We performed an ELISA using recombinant CD36 as protein 
source and the biotin-streptavidin system for detection, which is well-
known to confer a high sensitivity to the ELISA detection. In the past, 
Western blot analysis was employed, with platelet extracts as source for 
CD36 and patient´s plasma as a first antibody. This may well lead to a 
high incidence of false positives due to binding of antibodies to unrelated 
proteins. Furthermore, we have tested a total of 93 TTP plasma samples 
whereas in previous studies a range between 10 to 35 patients had been 
used (Tandon et al, 1994;Schultz et al, 1998;Wright et al, 1999;Rock et al, 
2005). Such differences in population number could also introduce a bias 
in the observed high frequency of positive samples. We are therefore 
confident that our data show that acquired TTP patients do not exhibit an 
increased incidence of anti-CD36 antibodies.  
 
Presence of ADAMTS13-specific circulating ICs in acquired TTP patients 
Elevated levels of soluble circulating autoantibody-antigen immune 
complexes are a hallmark of certain autoimmune diseases such as SLE, 
rheumathoid arthritis, antiphospholipid syndrome, vasculitis, and 
glomerulonephritis (Mayadas et al, 2009). Also acquired TTP has been 
thought to be an IC-mediated disease ever since the isolation of 
ADAMTS13-inhibiting IgG antibodies from plasma of TTP patients (Furlan 
et al, 1998). Early reports attributed the benefit of PEX therapy in TTP 
patients to the removal of potential circulating ICs (Bayer et al, 
1977;Bukowski et al, 1977) but the presence of circulating ICs in TTP 
patients remained controversial (Celada & Perrin, 1978;Neame & Hirsh, 
1978).  
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A previous study by our group showed that removal of anti-ADAMTS13 
IgG antibodies from plasma of TTP patients also removed any measurable 
residual ADAMTS13 antigen suggesting for the first time that the ELISA 
employed to quantify ADAMTS13 antigen levels is also detecting, at least 
to some extent, ADAMTS13-specific ICs (Rieger et al, 2006). Similar 
observations were recently reported by Yang et al (Yang et al, 2011) using 
a commercially available kit to quantify ADAMTS13 antigen levels. Based 
on these observations, we decided to investigate the presence of 
circulating ADAMTS13-specific ICs in more detail using two different 
approaches: one based on co-immunoprecipitation of ADAMTS13 with IgG 
antibodies using Protein G and the second one based on ELISA 
methodology.  
Co-immunoprecipitation experiments showed the presence of circulating 
ADAMTS13-IgG ICs in plasma of patients with TTP but not in healthy 
donors (Fig. 10). IgG-ICs were detected in patients with or without 
detectable free ADAMTS13 antigen, indicating that the absence of 
measurable ADAMTS13 antigen might be due to sequestration in ICs. 
These findings also suggest that our in-house ADAMTS13 antigen ELISA 
is detecting ICs only in those patients whose complexed ADAMTS13 still 
conserves available epitopes for binding to both the capture and detection 
anti-ADAMTS13 antibodies. The availability of free epitopes might indicate 
the presence of small-sized ICs. Moreover, IgG-ICs were detected in 
patients having either IgG4 or IgG1 anti-ADAMTS13 antibodies as 
predominant IgG subclasses, suggesting an apparently equal avidity of 
some IgG subclasses of antibodies for ADAMTS13. These experiments 
confirmed our previous findings and suggested that formation of 
circulating ADAMTS13-IgG-specific ICs is a common feature of acquired 
TTP. 
We found IgG4 as the predominant subclass of free autoantibodies in TTP 
patients. Since this IgG subclass is the least effective in terms of final 
effector functions under normal conditions, we reasoned that the lack of 
detection of other free IgG subclasses might be due to their sequestration 
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in ICs. Such circulating ICs (containing IgG1-3 or IgA antibodies) would 
also better explain the pathogenesis of TTP than the exclusive presence of 
rather harmless IgG4 antibodies. For their detection, we developed ELISA-
based assays where a polyclonal anti-ADAMTS13 antibody was used to 
capture the ICs through ADAMTS13 and the immunoglobulin constituents 
(IgG1-4 and IgA) of the ICs were detected by enzyme-labeled antibodies 
specific for the Ig classes and subclasses. The ELISA set-up used was 
clearly suitable and sufficiently sensitive for the detection of ICs. A 
limitation of this ELISA setup is however its underestimation of the real 
concentration of circulating ICs in case of large-sized ICs harboring more 
than one ADAMTS13 molecule and ICs with no free ADAMTS13 epitopes 
available.  
Characterization of circulating ICs by ELISA revealed the presence of IgG- 
and IgA-containing ICs in 81% and 23% of the 57 patients with TTP 
investigated, respectively. Moreover, in the patients tested positive for IgG-
ICs, a substantial overlap between free and IC-sequestered IgG subclasses 
was observed. IgG4-ICs were most frequent (72%), followed by IgG2-ICs 
(37%) and IgG1-ICs (26%) (Fig. 11). These findings suggested a correlation 
between free and complexed-IgG subclasses of anti-ADAMTS13 antibodies 
and did not support our hypothesis of a formation of ICs with a preference 
for certain IgG subclasses.  
Due to the high prevalence of free and complexed IgG4 autoantibodies, we 
investigated the ability of the ADAMTS13-specific ICs to fix complement. 
This was evaluated using an ELISA that takes advantage of the specific 
binding of the complement subcomponent C1q to the Fc region of 
complexed IgG1-3. Circulating ICs binding to C1q were detected only in 6 
out of 37 (16%) patients with TTP suggesting that the majority of the types 
of ICs detected in patients with TTP are not fixing complement. It remains 
possible though, that complement-fixing ICs did form but could not be 
detected because of their rapid deposition in tissues. 
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Inverse correlation of free and IC-sequestered anti-ADAMTS13 antibodies in 
a patient with acquired TTP 
We also analyzed the anti-ADAMTS13 antibody response and the 
concomitant appearance of circulating ICs during treatment of a patient 
with acquired TTP who died at day 64 after admission due to treatment 
refractoriness. This patient tested positive for the 3 classes of anti-
ADAMTS13 antibodies with IgG1 as the main IgG subtype. By Co-IP, we 
detected circulating IgG-, IgA- and IgM-ICs despite daily PEX therapy. 
Interestingly, the ICs followed an inverse kinetics to the measured free 
antibody titers, becoming apparently undetectable when the titers of the 
free antibodies and inhibitor activity rose. These data strongly suggest 
that samples from acquired TTP patients need to be analyzed not only for 
free but also for complexed anti-ADAMTS13 antibodies to obtain a full 
picture of the status of the disease.  
The IC ELISA revealed that for this patient the classes and subclasses of 
the immunoglobulin fraction forming the ICs correlated with those of the 
detected free antibodies. The patient had an IgG1-predominant immune 
response with detectable free and complexed-IgG1 antibodies and no 
detectable IgG4 (free or complexed) antibodies. These findings may be 
responsible, at least in part, for the treatment refractoriness and fatal 
outcome for this patient. 
Interestingly, free ADAMTS13 antigen was not detected in most samples 
by our in-house ELISA whereas circulating ICs could be demonstrated by 
Co-IP and ELISA, indicating that ADAMTS13, either newly synthesized or 
exogenously administrated by plasma infusion during PEX, was 
quantitatively sequestered by IC-formation. This mechanism may play an 
important role in the final response to treatment and should be 
particularly considered in patients refractory to treatment. The combined 
data of this study strongly suggest that samples from acquired TTP 
patients need to be analyzed not only for free but also for complexed anti-
ADAMTS13 antibodies to obtain a full picture of the status of the disease. 
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Interaction of human IgG4 with rabbit IgG  
A sequential set of experiments, aimed initially to assess the origin of 
undesired background signals in the ADAMS13-IgG4-specific IC ELISA, 
revealed the unexpected fact that human IgG4 (but not IgG1-3) antibodies 
specifically bind to the Fc region of rabbit IgG antibodies. Publications 
describing the binding of human IgG4 to IgG antibodies of different animal 
species (including rabbit) came out after our experiments were performed 
(Ito et al, 2010;Rispens et al, 2011). Ito et al (Ito et al, 2010) showed that 
human IgG4 antibodies strongly bind to mouse, rabbit, guinea pig, bovine 
and goat IgG antibodies, but do not bind to sheep, horse and rat IgG. 
Interactions between human IgG4 and animal IgGs should therefore be 
taken into account when a new assay is designed because they are a 
potential source of high background and interferences. 
 
Potential roles of anti-ADAMTS13 antibodies of the IgG4 and IgG1 subtypes 
and ADAMTS13-specific ICs in the pathogenesis of acquired TTP 
The relatively high incidence of IgG4 anti-ADAMTS13 antibodies and IgG4-
containing ADAMTS13-specific ICs is a novel and rather unexpected 
finding, as association of IgG4 antibodies with direct pathologic effects are 
described in only a few diseases including pemphigus (Mihai et al, 2007), 
sclerosing autoimmune pancreatitis and IgG4-related diseases (Okazaki et 
al, 2011). IgG4 antibodies are thought to be functionally monovalent and 
non-cross-linking antibodies (Aalberse et al, 2009) through a process 
described as “Fab-arm exchange of IgG4 half-molecules”, in which a 
heavy-light chain pair of one IgG4 molecule joins with another, unrelated, 
IgG4 half molecule, leading to a newly combined IgG4 molecule with two 
different antigen-binding sites (van der Neut et al, 2007). Such bi-specific 
molecules are unable to crosslink antigen and, consequently, only form 
small and relatively harmless ICs with a low potential for induction of 
immune activation. Furthermore, IgG4 fails to activate potentially 
dangerous effector mechanisms; it has low affinity for complement C1q, 
which is required for IC-binding to endothelial cells and the initiation of 
the classical complement cascade (Stokol et al, 2004), and binds to 
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cellular FcγRs with less efficiency than the other IgG subclasses (Jefferis et 
al, 1994).  
Moreover, the Fc region of human IgG4 antibodies can interact with its 
respective counterpart in other human IgG4 molecules (Rispens et al, 
2009). This phenomenon may contribute in vivo to an enhancement of the 
antigen binding capacity (avidity) of IgG4, thereby optimizing IgG4-derived 
responses and maybe, in the case of autoantibodies, to a pathogenic 
effect. 
A reduced number of patients presented with a predominant IgG1 
response. In these patients the formation of high levels of IgG1-ICs may 
mediate more severe effector functions. IgG1 is known to have the 
potential to bind complement C1q and to activate cellular FcγRs (Jefferis et 
al, 1994). Circulating IgG1-ICs can lead to endothelial cell activation, 
promoting inflammation and a pro-adhesive state, thus probably carrying 
a higher pathogenic potential when compared to IgG4-ICs. Furthermore, 
when present, IgA antibodies and IgA-ICs may also contribute to severity 
of the pathogenesis, because they have been shown to activate 
complement via the mannan-binding lectin pathway (Roos et al, 2001) and 
immune cells when binding to FcαRs (Monteiro, 2010), favoring an 
enhancement of complement-mediated inflammation and tissue damage. 
Although anti-ADAMTS13 IgG4 antibodies have yet to be shown to be 
functionally monovalent and to interfere with complement activation in 
vivo, it is tempting to speculate that IgG4 autoantibodies, to some extent, 
act as “protective” antibodies in TTP patients, inducing a milder and 
treatable form of TTP, whereas IgG1 (and IgA) anti-ADAMTS13 antibodies 
have a higher pathogenic potential due to IC-related effector functions. 
Even though our study is limited by the number of patients, and further 
studies are needed, we observed that patients are less likely to survive 
their first TTP event (four of seven patients died) if they have IgG1 and 
very low or undetectable IgG4 levels plus higher titers of other classes of 
anti-ADAMTS13 antibodies (particularly IgA antibodies), maybe due to 
formation of harmful ICs by these subclasses of antibodies. Similar 
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observations were reported recently (Bettoni et al, 2011), where the 
presence of IgG1, IgG3 and IgA anti-ADAMTS13 antibodies in acute phase 
were associated with clinical severity and in the particular case of IgA 
antibodies, also with mortality. 
The presence of increased levels of circulating ADAMTS13-specific ICs is 
likely to contribute to the pathogenic mechanisms leading to the onset of 
acquired TTP. Elevated levels of ICs are the main reason for systemic 
inflammatory manifestations associated with autoimmune diseases. Under 
normal conditions, ICs are quickly cleared by the reticuloendothelial 
system, but their continuous formation exceeds the clearance capacity of 
the system and the ICs build up in the circulation leading to endothelial 
cell activation and inflammation. The continuous presence of excessive 
amounts of circulating ICs might perpetuate a pro-inflammatory state 
promoting thrombosis and predisposing to relapse.  
Furthermore, as described for SLE (Chiang et al, 2011), ICs can also bind 
to B-cell receptors of auto-reactive B-cells resulting in signals leading to 
B-cell activation, proliferation and differentiation into autoantibody-
producing cells. This activating cycle might cause formation of more 
autoantibodies and thus more ICs leading to progression of a deleterious 
effect. 
While the amounts of circulating ICs should correlate with disease severity 
and activity, their quantification in plasma samples needs to consider 
several points: (i) the detected types of ICs may be irrelevant because 
harmful ICs could have already been deposited in tissues; (ii) the 
concentration of antigen, antibody and as a consequence ICs can change 
continuously during a chronic process, thus pathogenic ICs can form and 
deposit in a short period of time; (iii) the formation and clearance of ICs 
may not be in a steady state; and (iv) the setup of the assays does not 
allow discriminating between harmful and harmless ICs. Nonetheless, we 
believe that the detection and characterization of circulating ICs in 
patients with TTP will seed light onto the possible patho-mechanisms 
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underlying TTP development. Whether such data are also of use for 
clinical monitoring, however, remains to be seen. 
 
Prognostic marker for acquired TTP 
Beyond the characterization and elucidation of the role of anti-ADAMTS13 
antibodies in the pathogenesis of TTP, the identification of prognostic 
factors during the first acute episode would be of crucial importance for 
making decisions in the clinic. TTP is a severe disease and its acute events 
may be life-threatening in the absence of fast and appropriate treatment. 
In addition, relapse occurs in 30-50% of the patients who survive an 
initial episode of TTP, being more often during the first year after the onset 
(Willis & Bandarenko, 2005;George, 2009). However, identifying 
prognostic factors for both short-term and long-term outcome still remains 
very difficult considering the broad heterogeneity of patients with TTP. 
This heterogeneity includes the clinical background (idiopathic versus 
disease-associated TTP, sporadic versus recurrent TTP) and the 
ADAMTS13-specific parameters (undetectable versus detectable 
ADAMTS13 activity or antigen, presence versus absence of ADAMTS13 
inhibitor).  
Several studies have investigated the significance of ADAMTS13 activity 
and inhibitors levels to predict outcomes. Most concluded that severe 
ADAMTS13 deficiency in combination with the presence of antibodies 
against ADAMTS13 either at presentation and/or during clinical remission 
are associated with a higher risk of disease recurrence (Vesely et al, 
2003;Raife et al, 2004;Zheng et al, 2004;Peyvandi et al, 2004;Jin et al, 
2008;Peyvandi et al, 2008;Hovinga et al, 2010).  
We also have sought for prognostic factors that may help identifying 
patients at risk. We observed that anti-ADAMTS13 antibodies of the IgG 
class together with a high inhibitor titer at presentation were associated 
with persistence of undetectable ADAMTS13 activity in clinical remission 
(Fig. 6). Moreover, we were the first to investigate the possibility of an 
association between IgG subclasses and relapse, and found that high 
levels of IgG4 with undetectable IgG1 were statistically significantly 
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associated with a trend towards recurrence of TTP. This suggests that 
high levels of IgG4 could help to identify patients who are at risk of 
recurrence and could be used, in association with ADAMTS13 activity and 
inhibitors, as a prognostic marker to predict possible relapse.  
 
6- CONCLUSIONS 
The pathophysiology of acute acquired TTP is characterized by severe 
deficiency of ADAMTS13 (activity and antigen) due to the presence of 
different classes (IgG, IgM and IgA) and subclasses (mainly IgG4 and IgG1) 
of inhibiting anti-ADAMTS13 antibodies. An immune response 
characterized by high levels of IgG4 predicts, at least partially, a more 
treatable form of TTP than if IgG1 antibodies are present. Antibodies 
against ADAMTS13 are also involved in immune-complex formation 
(mainly IgG4-containing immune complexes). Immune complexes might 
contribute to ADAMTS13 depletion from the circulation and probably to 
organ damage due to tissue deposition.  
Measurement of inhibitory activity; free anti-ADAMTS13 antibodies as well 
as ADAMTS13-specific circulating ICs should be performed in patients 
presenting with acute acquired TTP. This information will help to better 
understand the course of the disease, especially in cases of refractory 
patients which may benefit of a more aggressive therapy. 
Levels of IgG4 autoantibodies could be a recurrent predicting biomarker, 
although prospective trials with well-characterized patients are needed to 
substantiate our preliminary observations. The contribution made by IgG4 
antibodies and IgG4-ICs to the overall pathologic mechanism in acquired 
TTP needs further investigation. We believe that the results of this study 
contributed to a better understanding of the pathogenesis leading to 
acquired TTP and the prognostic markers here identified might help to 
recognize patients at risk of disease recurrence or having a poor 
prognosis. 
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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and
inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode
of thrombotic microangiopathy with undetectable ADAMTS13 activity
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To study both the pathophysiologic and
the prognostic value of ADAMTS13 in
thrombotic microangiopathies (TMAs), we
enrolled a cohort of 35 adult patients
combining a first acute episode of TMA,
an undetectable (below 5%) ADAMTS13
activity in plasma, and no clinical back-
ground such as sepsis, cancer, HIV, and
transplantation. All patients were treated
by steroids and plasma exchange, and an
18-month follow-up was scheduled. Re-
mission was obtained in 32 patients
(91.4%), and 3 patients died (8.6%) after
the first attack. At presentation, ADAMTS13
antigen was decreased in 32 patients
(91.4%), an ADAMTS13 inhibitor was detect-
able in 31 patients (89%), and an anti-
ADAMTS13 IgG/IgM/IgA was present in 33
patients (94%). The 3 decedent patients were
characterized by the association of several
anti-ADAMTS13 Ig isotypes, including very
high IgA titers, while mortality was indepen-
dent of the ADAMTS13 inhibitor titer. In
survivors, ADAMTS13 activity in remission
increased to levels above 15% in 19 patients
(59%) but remained undetectable in 13 pa-
tients (41%). Six patients relapsed either
once or twice (19%) during the follow-up.
High levels of inhibitory anti-ADAMTS13 IgG
at presentation were associated with the
persistence of an undetectable ADAMTS13
activity in remission, the latter being predic-
tive for relapses within an 18-month delay.
(Blood. 2007;109:2815-2822)
© 2007 by The American Society of Hematology
Introduction
Thrombotic microangiopathies (TMAs) are defined by the associa-
tion of acute mechanical hemolytic anemia, thrombocytopenia, and
visceral ischemic manifestations related to the formation of platelet
thrombi in the microcirculation.1 Clinically, TMA includes mainly
the thrombotic thrombocytopenic purpura (TTP) and the hemolytic
uremic syndrome (HUS) characterized by a multivisceral ischemia
and a renal ischemia, respectively.2 Although mechanisms for HUS
remain very heterogeneous, pathophysiology for most forms of
TTP is related to a severe deficiency of a plasma metalloprotease,
ADAMTS13 (a disintegrin and metalloprotease with throm-
bospondin type 1 repeats).3-6 Physiologically, ADAMTS13 is the
specific cleaving protease for von Willebrand factor (VWF), a large
multimeric glycoprotein crucial for both platelet adhesion and
aggregation in the high stress–associated hemodynamic conditions
of the microcirculation.7 A severe enzymatic deficiency of
ADAMTS13 causes highly adhesive unusually large multimers of
VWF to accumulate in plasma, which may spontaneously bind to
platelets and thus induce the formation of platelet thrombi in the
microcirculation. In rare cases, clinically relevant ADAMTS13
severe deficiency is related to compound heterozygous or homozy-
gous mutations of the ADAMTS13 gene (Upshaw-Schulman
syndrome).8-10 In most cases, severe ADAMTS13 deficiency is
secondary to the development of anti-ADAMTS13 autoantibodies
(auto-Abs).11-12 Anti-ADAMTS13 auto-Abs can be detected in
vitro either functionally because of their inhibitory effect on
ADAMTS13 enzymatic activity13-14 or, more recently, physically
as immunoglobulin G (IgG) or IgM by enzyme-linked immunosor-
bent assay (ELISA).15-16 In more than 80% of acquired TTP,
anti-ADAMTS13 antibodies are inhibitory IgG.11-12 In some cases,
the mechanisms for acquired TTP may be different, involving either
anti-ADAMTS13 noninhibitory IgG or IgM15-16 or circulating inhibitors
not related to an IgG or an IgM.17 However, although most undetectable
ADAMTS13-associated TMA overlaps with the clinical entity named
TTP, some exceptions remain, consisting of either clinical TTP with
detectable ADAMTS13 activity or clinical HUS with undetectable
ADAMTS13 activity.18,19 This observation is currently motivating
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experts in the field to reconsider a new classification of TMA more
focused on pathophysiological mechanisms instead of clinical
symptoms.3,20
Beyond the elucidation of pathophysiological mechanisms, a
second step crucial for TMA characterization is the identification of
prognostic factors. Indeed, TMAs are severe diseases with acute
events that may be life-threatening in the absence of fast and
appropriate treatment (plasmatherapy) and with a global mortality
rate that still remains close to 10%.21,22 In addition, in patients who
achieved remission after an acute event, the risk of relapse is
estimated to be at least 11%, with extreme rates reported at 73% as
a function of the clinical background.2,3 However, identifying
prognostic factors for both short-term and long-term outcome still
remains difficult considering the broad heterogeneity of TMA
patients. This heterogeneity including both the clinical background
(idiopathic versus disease-associated TMA, sporadic versus recur-
rent TMA) and the ADAMTS13 plasmatic features (undetectable
versus detectable ADAMTS13 activity, presence versus absence of
an ADAMTS13 inhibitor) is well emphasized as a limit to
determine clear prognostic factors in the recent literature.3,23-27
More specifically, the first acute TMA episode, classically
described as a “storm in a blue sky,” remains a crucial challenge for
physicians in terms of both pathophysiologic and prognostic issues.
The first TMA attack is always a trauma whether it is idiopathic and
then a first step within an autoimmune disease or whether it is
associated with a preexisting clinical context and then a crucial turn
in the course of the latter. More pathophysiologic explanations
and prognostic markers are obviously needed. Undetectable
ADAMTS13 activity–associated TMA, in addition to being a
homogeneous entity, has the advantage of offering an exciting
biologic parameter on which to focus, especially thanks to the
recent advances in both ADAMTS13 antigen (ADAMTS13Ag)
and auto-Ab characterization.16 Thus, in the current study, we
chose to focus on both a pathophysiologic and a prognostic analysis
(initial outcome and 18-month follow-up) of a homogeneous
cohort of adult patients characterized by 3 criteria: (1) a first
episode of acute TMA; (2) an undetectable ADAMTS13 activity;
and (3) no severe clinical background that could, in itself, influence
the prognosis (ie, severe sepsis, cancer, HIV infection, or organ
transplantation). Standard clinical and biologic features as well
as specific VWF/ADAMTS13-related parameters (VWF antigen
[VWFAg], ADAMTS13 activity and antigen, ADAMTS13 inhibitors,
and anti-ADAMTS13 IgG/IgM/IgA) were evaluated at presenta-
tion in all patients. In patients who achieved remission, ADAMTS13
activity was reevaluated during the follow-up. Thus, we evaluated
the correlation of ADAMTS13-related parameters at presentation
with the initial clinical and biologic outcome (mortality versus
remission, recovery versus nonrecovery of ADAMTS13 activity in
remission) as well as with the relapse rate during the follow-up.
Patients, materials, and methods
Patients
All adult patients (more than 18 years old) admitted in the 10 participating
French centers with a clinical diagnosis of acute TMA between January
2003 and December 2004 were eligible and tested for ADAMTS13 activity
in plasma. Diagnostic criteria for acute TMA were as follows: (1)
microangiopathic hemolytic anemia (hemoglobin level below 120 g/L
[12 g/dL]), negative direct antiglobulin test, at least 2 schistocytes per
high-power field in the peripheral blood smear, lactate dehydrogenase
above 450 U/L, and undetectable serum haptoglobin; (2) thrombocytopenia
(platelet count below 150  109/L); (3) no requirement for fever,
neurologic symptoms, or renal failure. For each patient, a questionnaire was
completed, allowing initial clinical and laboratory evaluation. Inclusion
criteria combined both a first acute event of TMA and an ADAMTS13
activity in plasma below 5%. Exclusion criteria were severe sepsis, cancer,
HIV infection, organ or hematopoeitic stem cell transplantation, and
disseminated intravascular coagulation. As a first intention treatment, all
enrolled patients received both steroids (1 mg prednisone per kilogram of
body weight daily) and plasma exchange (exchanging 1.0 to 1.5 times the
predicted plasma volume of the patient) at the discretion of the attending
physician. Evaluation for the initial outcome (achievement of remission or
death) and an 18-month follow-up were performed. Patients were enrolled
after appropriate consent was obtained in agreement with the institutional
review board of Assistance Publique-Hoˆpitaux de Paris (Comite´ Consultatif
pour la Protection des Personnes dans la Recherche Biome´dicale, Ile-de-
France–Paris–Saint Antoine) and the Declaration of Helsinki.
Clinical definition
Idiopathic TMA was defined as TMA occurring in patients with no apparent
preexisting disease. Remission was defined by a normal platelet count
(above 150 109/L) and no plasma exchange treatment for 30 days (day 1
starting on remission) or more.
Sample collection
Before any treatment was initiated, venous blood was collected into 1:10
final volume of 3.8% sodium citrate. Platelet-poor plasma was obtained by
centrifugation at 2500g for 20 minutes, and aliquoted samples were stored
at 80°C before being tested. Plasma samples were collected both at
presentation and in remission (between day 1 and day 7 of remission
according to the previous definition).
VWFAg
VWF antigen (VWFAg) levels in plasma were measured using an
enzyme-linked immunosorbent assay (ELISAAsserachrom VWF; Diagnos-
tica Stago, Asnie`res, France).
ADAMTS13 activity ELISA
Measurement of ADAMTS13 activity in plasma was performed as previ-
ously described18 with minor modifications. Briefly, the method relies on
the hydrolysis of a constant amount of wild-type recombinant VWF used as
substrate by serial dilutions of tested plasma used as ADAMTS13 provider.
Plasma samples treated with Pefabloc (Roche Applied Science, Indianapo-
lis, IN) (2 mM final) for 10 minutes were serially diluted from 1:10 to 1:640
in 5 mM Tris-HCl, pH 8, 1.5 M urea. Aliquots of 90 L were preincubated
with 10 L of 100 mM BaCl2 for 5 minutes at room temperature. This
mixture (60 L) was added into wells of microtitration plates to 40 L
wild-type recombinant VWF (0.05 IU) previously dialyzed against 5 mM
Tris-HCl, pH8, 1.5 M urea. Incubation was performed for 48 hours at 37°C.
The proteolysis was stopped by addition of 5 L of 200 mM EDTA in water.
The residual VWFAg contained in the hydrolysate was thus estimated by a
2-site ELISA using the anti–C-terminal VWF MoAb 453 for coating and a
pool of immunoperoxidase-conjugated anti–N-terminal VWF MoAbs for
staining.28 Normal pooled plasma (NPP) was arbitrarily defined as contain-
ing 100% of ADAMTS13 activity and used as an internal control.
ADAMTS13 inhibitor assay
Patient plasma was heat treated at 56°C for 30 minutes to inactivate any
endogeneous ADAMTS13 activity. Circulating inhibitor for ADAMTS13
was assayed by measuring the residual ADAMTS13 activity in mixtures of
TMA patient plasma and NPP at 3 distinct volume-volume ratios: 1:1, 2:1,
and 3:1 as previously described.18 Titer was semiquantitatively defined as
high, medium, or low for a residual ADAMTS13 activity below 10% in 1:1,
2:1, and 3:1 mixtures, respectively.
ADAMTS13 inhibitor assay was systematically performed in addition
to the ADAMTS13 activity assay in all patients.
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Anti-ADAMTS13 antibody ELISA
Anti-ADAMTS13 IgG, IgM, and IgA were tested in all patients at
presentation. Anti-ADAMTS13 IgG and IgM antibodies were detected as
published by Rieger et al.16 Briefly, microtiter plates were coated with an
anti-His tag antibody (overnight incubation), nonspecific binding sites were
blocked for 2 hours at room temperature with PBS-BSA, and recombinant
His-tagged ADAMTS13 was added and incubated for 3 hours at room
temperature. Serial dilutions of plasma samples were incubated overnight at
4°C. After washing, plates were incubated with an alkaline phosphatase–
conjugated goat anti–human IgG, IgM, or IgA antibody (Sigma, Saint
Louis, MO) for 2 hours at room temperature. After washing, the enzyme
substrate p-nitrophenyl phosphate (PNPP) was added and incubated
45 minutes. Absorbance was read at 405 nm. Anti-ADAMTS13 IgG/IgM/
IgA antibodies titers were calculated according to Rieger et al.16 In patients
whose anti-ADAMTS13 IgG titer was lower than the detection limit of our
developed ELISA (IgG negative), anti-ADAMTS13 IgGs were retested
using the TECHNOZYME ADAMTS13-INH commercial kit (Techno-
clone, Vienna, Austria) to improve sensitivity in the detection (IgG positive
if above 15 U/mL). The IgG anti-ADAMTS13 ELISA using the commercial
kit was performed according the manufacturer’s instructions.
ADAMTS13 Ag ELISA test
ADAMTS13 Ag was measured using a recently developed ADAMTS13 Ag
ELISA.29 Briefly, microtiter plates were coated with a polyclonal rabbit IgG
against human ADAMTS13. Dilutions of plasma samples were incubated
overnight at room temperature. After washing, plates were incubated with a
horseradish peroxidase–conjugated polyclonal rabbit IgG against human
ADAMTS13 for 2 hours at room temperature. After washing, a chromo-
genic substrate (Sure Blue TMB Microwell Peroxidase Substrate; KPL,
Gaithersburg, MD) was added. The color reaction was stopped by 1N HCl
solution, and absorbance was read at 450 nm. The reference interval for the
ELISA is 740 to 1420 ng ADAMTS13 per milliliter, and the limit of
quantification is 62.5 ng ADAMTS13 per milliliter. Samples with antigen
levels under the limit of quantification are expressed as less than 62.5 ng
ADAMTS13 per milliliter.
Statistical analysis
Statistics were performed using the computer-assisted program Statview
(Abacus Concepts, Berkeley, CA). Means and standard deviations (SD)
were calculated for each continuous variable. Comparisons were performed
using an independent sample t test for continuous parametric variables and
a 2 test for categoric variables. Relationships between ADAMTS13-related
parameters and other variables were studied using univariate and multivari-
ate analysis with both linear and logistic regression analysis.
Results
Patients
Over a 24-month period, 755 adult patients with a clinically
suspected acute TMA were enrolled in our national registry and
screened for ADAMTS13 activity. A total of 658 patients exhibited
a normal or partially decreased ADAMTS13 activity, and 97
patients had an undetectable ADAMTS13 activity. Among the
latter, 47 patients had previously been included in our registry
because of 1 or several acute TMA episodes, while 50 patients had
a first TMA episode. Among the latter, 15 had exclusion criteria
such as cancer, HIV, severe sepsis, organ transplantation. Thus,
finally, a cohort of 35 consecutive patients with a first acute episode
of TMA associated with an undetectable ADAMTS13 activity
(below 5%) in plasma was enrolled. Demographic, clinical, and
standard biologic features of each patient are presented in Table 1.
Mean age was 36 years (SD 12.7), and the sex ratio was 2.5:1
(25 women and 10 men). Twenty-two patients exhibited an
idiopathic TMA, while 13 patients had a TMA associated either
with pregnancy (n 6), the postpartum state (n 1), oral contra-
ceptives (n 1), Crohn disease (n 1), psoriasis (n 1), chronic
hepatitis C (n 1), diabetes (n 1), or hypertension (n 1). At
inclusion during the acute TMA, fever was present in 5 patients
(14.3%), and neurologic symptoms including either headache,
altered mental status, aphasia, or convulsions were observed in 18
patients (51.4%); anemia (mean hemoglobin level  SD, 71 18
g/L and thrombocytopenia (mean platelet count  SD, 17 
109/L  13  109/L) were present in all patients. The mean
creatinine level was 111 52 M, and only 3 patients exhibited a
creatinine level higher than 200 M. Three patients (8.6%) died of
acute multivisceral TMA involvement with acute renal failure
within a delay of 10 days of extensive plasma exchanges. Remis-
sion was obtained in 32 patients (91.4%) with the classical “steroids
plus plasma exchanges” protocol described in “Patients” within a mean
delay of 4 1 weeks; no survivor patient exhibited a flare-up
episode. The 18-month follow-up showed that 6 patients relapsed.
VWF- and ADAMTS13-related parameters in patients
at presentation
Results of both VWFAg and ADAMTS13Ag are presented in
Figure 1. VWFAg levels were higher than 100 IU/dL in 32 patients
(91.4%), including 11 patients with levels higher than 200 IU/dL
(31.4% of total). ADAMTS13Ag levels were decreased in 32
patients (91.4%) (including 7 patients with undetectable levels) and
normal in 3 patients (8.6%). However, statistical analysis showed
no correlation between VWFAg and ADAMTS13Ag levels.
Titrations for both ADAMTS13 inhibitor and anti-ADAMTS13
IgG, IgM, and IgA are presented in Figure 2. An ADAMTS13
inhibitor was detected in 31 patients (89%), while an anti-
ADAMTS13 IgG (titer ranging from 25 to 6400) and/or IgM (titer
from 20 to 3200) and/or IgA (titer from 200 to more than 10 000
arbitrary units) were detected in 33 patients (94%) (Figure 2). A
mild correlation between ADAMTS13 inhibitor titer and anti-
ADAMTS13 Ig titer was present with an overlapping between both
parameters in 29 of 35 patients (inhibitory anti-ADAMTS13 Ig,
83%). In contrast, in the absence of ADAMTS13 inhibitor, an
anti-ADAMTS13 Ig was detected in 4 of 35 patients (noninhibitory
anti-ADAMTS13 Ig, 11.5%). Plasma of 2 patients inhibited
ADAMTS13 activity despite the absence of anti-ADAMTS13
IgG/IgM/IgA (Figure 2). Statistical analysis showed no correlation
between ADAMTS13Ag levels and either ADAMTS13 inhibitor
or anti-ADAMTS13 IgG/IgM/IgA titers, respectively.
Analysis of decedent patients
Three patients died after the first acute TMA episode (patients 15,
17, and 22; Table 1). Table 1 indicates their specific clinical
characteristics, and Table 2 indicates their main VWF/ADAMTS13
features. All patients had an idiopathic TMA, none of them had
fever at presentation, while 2 of them exhibited neurologic
symptoms (altered mental status and aphasia). In all of them, the
platelet count was lower than 15 109/L and the hemoglobin level
lower than 65 g/L. Interestingly, all of them also had a significant
alteration of renal function (creatinine level higher than 175 M),
and 2 of them were older than 60 years. (Table 1). Analysis of the
VWF/ADAMTS13 features (Table 2) shows a remarkably in-
creased VWFAg level in 2 patients (350 and 540 IU/dL in patients
15 and 22, respectively) and a remarkably decreased ADAMTS13Ag
in 2 patients (less than 62.5 ng/mL in patients 15 and 17). An
ADAMTS13 inhibitor was either detectable in 2 patients (low or
high titer) or not detectable in 1 patient. Interestingly, all patients
were characterized by the association of several anti-ADAMTS13
ADAMTS13-DEFICIENT THROMBOTIC MICROANGIOPATHIES 2817BLOOD, 1 APRIL 2007  VOLUME 109, NUMBER 7
Ig isotypes (2 patients with IgG, IgM, and IgA and 1 patient with both
IgG and IgA) with very high Ig titers, especially for IgA (Table 2).
Analysis of ADAMTS13 in survivors at initial clinical remission
ADAMTS13 activity measured at initial clinical remission showed
3 distinct courses: It either remained undetectable (below 5%) in 13
patients (41%) or became detectable but partially decreased (15%
to 40%) in 12 patients (38%) or normal (50% to 100%) in 7 patients
(21%). ADAMTS13 inhibitors in remission were still detectable
only in patients whose ADAMTS13 activity remained below 5%,
with titers either similar or decreased when compared with those of
the acute episode (Figure 3).
Correlation between ADAMTS13 parameters at presentation
and ADAMTS13 activity at initial clinical remission is presented in
Figure 4. Neither ADAMTS13 Ag levels nor the presence of an
ADAMTS13 inhibitor (independently of the titer) nor the presence
of anti-ADAMTS13 IgG, IgM, or IgA at presentation were
predictive of the course of ADAMTS13 activity in remission. In
contrast, the presence of a high titer of ADAMTS13 inhibitor,
either alone or combined with an anti-ADAMTS13 IgG, was
associated with the persistence of an undetectable ADAMTS13
activity (below 5%) in remission (Figure 4).
Table 1. Demographic, clinical, and standard biologic features of each TMA patient (n 35)
Pt
no.
Age,
y Sex Context Fever CNS symptoms
Platelet count,
 109/L
Hb level,
g/L
Creatinine
level, M
Initial
outcome
No. of
relapses*
1 21 M Idiopathic No None 10 63 116 R 0
2 19 F Idiopathic No None 3 44 88 R 0
3 27 M Idiopathic Yes None 10 69 85 R 0
4 35 F Idiopathic Yes None 21 42 90 R 0
5 57 F Idiopathic No Aphasia 28 51 92 R 0
6 41 F Idiopathic No Aphasia 27 81 83 R 1
7 53 F Idiopathic Yes Aphasia 10 50 77 R 0
8 35 F Idiopathic No None 9 62 81 R 0
9 39 M Idiopathic No None 10 91 85 R 0
10 50 F Idiopathic No None 15 80 87 R 0
11 29 F Idiopathic No None 30 70 90 R 0
12 34 F Idiopathic No AMS 15 80 83 R 0
13 40 M Idiopathic Yes None 15 57 100 R 1
14 31 M Idiopathic No Headache 23 110 159 R 2
15 61 M Idiopathic No AMS 4 62 240 D —
16 38 F Idiopathic No None 5 81 100 R 2
17 45 M Idiopathic No None 9 60 175 D —
18 28 M Idiopathic Yes AMS 15 72 88 R 0
19 39 F Idiopathic No Aphasia 17 85 105 R 0
20 16 F Idiopathic No None 10 70 100 R 0
21 26 F Idiopathic No None 12 68 81 R 1
22 70 F Idiopathic No Aphasia 13 52 195 D —
23 30 F Pregnancy No None 11 83 82 R 0
24 29 F Pregnancy No Aphasia 7 67 139 R 0
25 27 F Pregnancy No None 20 100 300 R 0
26 24 F Pregnancy No Headache 35 81 79 R 0
27 34 F Pregnancy No None 10 71 82 R 1
28 33 F Pregnancy No AMS 36 67 85 R 0
29 23 F Postpartum No Headache 11 64 81 R 0
30 43 F Contraceptives No AMS 11 72 76 R 0
31 23 F Crohn No AMS 27 44 78 R 0
32 45 M Psoriasis No None 17 116 90 R 0
33 59 F HCV No Convulsions 14 70 95 R 0
34 29 F Diabetes No Headache 20 73 97 R 0
35 31 M Hypertension No AMS 80 106 210 R 0
Patients 15, 17, and 22 are dead.
Pt indicates patient; CNS, central nervous system; Hb, hemoglobin; M, male; R, remission; F, female; AMS, altered mental status; D, death; —, not applicable; HCV,
hepatitis C virus.
*During an 18-month follow-up.
Figure 1. von Willebrand factor antigen (VWFAg) and ADAMTS13 antigen
(ADAMTS13Ag) levels in plasma in a cohort of 35 patients with acute TMA.
Normal ranges are indicated by dashed lines (50 to 100 UI/dL for VWFAg and 740 to
1420 ng/mL for ADAMTS13Ag). Each TMA patient is represented by a circle. All but 3
patients exhibited a VWFAg level higher than 100 IU/dL, while all but 3 patients had a
decreased ADAMTS13Ag level. Statistical analysis showed no correlation between
VWFAg and ADAMTS13Ag levels.
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Follow-up of the survivors
Of the 32 patients who achieved clinical remission after the first
acute TMA episode, 6 patients relapsed either once (patients 6, 13,
21, and 27; Table 1) or twice (patients 14 and 16; Table 1) during
the 18-month follow-up. Delay for relapses ranged from 5 to
17 months after the first acute TMA episode, and 50% of relapses
occurred as soon as the first year. Interestingly, all relapses were
associated with an undetectable ADAMTS13 activity and an
ADAMTS13 inhibitor titer similar to that at first diagnosis (data
not shown).
Both the mean age (36 years old) and the sex ratio (2:1
female-male) of relapsing patients were similar to those of the
cohort; all but 1 patient whose acute TMA occurred during
pregnancy (patient 27) had an idiopathic TMA, and both their
clinical and standard biologic parameters at presentation were
similar to the ones of nonrelapsing patients (Table 1). VWF/
ADAMTS13-related parameters of the 6 relapsing patients are
presented in Table 3. At presentation of the initial acute TMA
episode, VWFAg levels were either normal or moderately in-
creased (70 to 250 IU/dL), ADAMTS13Ag levels were either
decreased or normal (75 to 1010 ng/mL), an ADAMTS13 inhibitor
was detected in 5 of 6 patients, while an anti-ADAMTS13 IgG
was present in all patients. Interestingly, at initial remission,
ADAMTS13 activity was still undetectable (below 5%) in 5 pa-
tients together with ADAMTS13 inhibitor titers either identical or
decreased when compared with inhibitor titers of the initial acute
phase (Table 3).
The relapse rate was significantly higher in patients whose
ADAMTS13 activity at initial remission was still undetectable
(below 5%) (5 of 13; 38.5%) when compared with patients whose
ADAMTS13 activity at initial remission was detectable (above
15%) (1 of 19; 5%).
Discussion
In adult patients, an autoimmunization against ADAMTS13 induc-
ing a severe ADAMTS13 functional deficiency in plasma has been
described as a key mechanism for most undetectable
ADAMTS13-associated TMA.3
The first goal of the current study was to explore the pathophysi-
ology for ADAMTS13 severe deficiency in a cohort of adult
patients who underwent a first acute episode of TMA. Because
none of these patients had ever received plasma infusions before,
any potential alloimmunization against ADAMTS13 and variations
in anti-ADAMTS13 auto-Abs titers after plasmatherapy30 could be
excluded. Interestingly, this study is the first one to show anti-
ADAMTS13 IgA in TMA patients. In all cases, however, these
IgAs were associated with IgG. In our cohort, a circulating
inhibitor against ADAMTS13 was detected with a lower frequency
(89%) than an anti-ADAMTS13 IgG/IgM/IgA (94%) as previously
reported by Rieger at al,16 who recently demonstrated a higher
sensitivity of IgG/IgM detection (97%) versus inhibitor detection
(83%) in 59 patients with an undetectable ADAMTS13-associated
acute TMA. This discrepancy between inhibitors and Ig rates is,
however, not surprising considering the broad range (50% to
almost 90%) of circulating ADAMTS13 inhibitors reported in
TMA patients3,11-13,18,31,32 and the established variability of sensitiv-
ity of the miscellaneous methods used for the detection of these
inhibitors.14
In our cohort, the overlapping rate between ADAMTS13
inhibitors and anti-ADAMTS13 IgG/IgM/IgAwas 83%, correspond-
ing to inhibitory IgG/IgM/IgA, while the rate for noninhibitory
IgG/IgM/IgA was 11.5%. These proportions are in agreement with
the literature15,16,33 and confirm that most anti-ADAMTS13 auto-
Figure 2. ADAMTS13 inhibitor and anti-ADAMTS13 IgG/IgM/IgA in a
cohort of 35 patients with acute TMA. Each TMA patient is represented
by a symbol. Black circles are for patients with IgG, gray circles for patients
with IgA, white circles for patients with IgM, and black triangles for patients
with no detectable IgG/IgM/IgA. IgG/IgM/IgA titers are expressed as the
reciprocal of patient plasma dilution. An isolated IgG was detected in 26
patients, the combination IgG and IgM in 1 patient, the combination IgG
and IgA in 4 patients, and the combination of IgG, IgM, and IgA in 2 patients
(indicated by numbers referring to patients in Table 1). Two patients had
neither an IgG, IgM, nor IgA. ADAMTS13 inhibitors are expressed as
semiquantitative titers: 4 patients had no detectable ADAMTS13 inhibitor,
14 patients a low titer, 5 patients a medium titer, and 12 patients a high titer.
Twenty-nine patients had both an ADAMTS13 inhibitor and an anti-
ADAMTS13 IgG/IgM/IgA (inhibitory anti-ADAMTS13 antibodies), and 4 pa-
tients had an anti-ADAMTS13 IgG/IgA with no ADAMTS13 inhibitor
(noninhibitory anti-ADAMTS13 antibodies). Two patients had no IgG/IgM/
IgA but an ADAMTS13 inhibitor.
Table 2. Main VWF/ADAMTS13 features of the 3 decedent patients
Patient
no.
VWFAg,
IU/dL
ADAMTS13Ag,
ng/mL
ADAMTS13
inhibitor titer
Anti-ADAMTS13
IgG titer*
Anti-ADAMTS13
IgM titer*
Anti-ADAMTS13
IgA titer*
15 350  62.5  1600 0 	 10 000
17 150  62.5  6400 3200 	 10 000
22 540 85  1600 20 3 200
 indicates negative;, high;, low.
*1/dilution.
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Abs are functional (inhibitory) in vitro and potentially in vivo.
However, the decrease of ADAMTS13Ag plasma levels found in
91.4% of patients in our cohort suggests that the formation of
immune complexes that may be rapidly cleared in vivo also
strongly participates in ADAMTS13 deficiency whatever the
inhibitory or noninhibitory capacity of ADAMTS13 auto-Abs, as
previously reported.34,35 Also, in addition to the inhibitory effect on
ADAMTS13 function, the residual levels of both ADAMTS13
activity and ADAMTS13Ag in plasma may be influenced by
several other parameters—either Ig related (ie, the affinity for
ADAMTS13, the epitope(s) on ADAMTS13,36-38 a proteolytic
degradation of ADAMTS1339) or non-Ig related (ie, a decreased
liver synthesis,40 an inactivation by thrombin or plasmin,41 or an in
vitro inhibition by hemoglobin,17 the latter being excluded in our
patients). Finally and interestingly, we found that anti-ADAMTS13
IgG associated with a high inhibitor titer at presentation was
predictive of a nonrecovery of ADAMTS13 activity in clinical
remission (Figure 4). The pathophysiology for this discrepancy
between clinical remission and ADAMTS13-related biologic remis-
sion in some patients remains, however, unclear.
The second goal of our study was to search for prognostic
factors among ADAMTS13-related parameters at presentation.
The originality and strength of the current study was to specifically
include patients with a first acute TMA episode associated with an
undetectable ADAMTS13 activity and to exclude patients whose
clinical background in itself could have influenced the prognosis
(cancer, HIV infection, organ transplantation, severe sepsis).
These exclusion criteria may therefore explain the mortality rate
of 8.6%, which is lower than most rates reported in the litera-
ture.3,21,22 Interestingly, a detailed analysis of the 3 decedent
patients reveals a specific association between mortality and the
combination of several Ig isotypes (IgG, IgM, and IgA) with the
presence of very high IgA titers in all patients (Table 2). The
association of both an IgG and an IgM has already been described
in a 70-year-old patient with a fatal TTP.15 The presence of
anti-ADAMTS13 IgA has never been described in any patient to
date, and both their etiology and their potential toxicity remain
unknown. However, IgAs are known to be associated with a bad
prognosis with several pathological conditions such as nephropa-
thies,42 myeloma,43 celiac disease,44 and heparin-induced thrombo-
cytopenia.45 In our patients, the role of anti-ADAMTS13 IgA
toxicity on renal tissue may be questionable, because all of them
had a severe alteration of renal function as soon as at presentation.
Also, in our 3 decedent patients, the inhibitory function of the
anti-ADAMTS13 IgG/IgM/IgA does not appear closely related to
mortality although ADAMTS13Ag levels were severely decreased.
This last point underlines that an immune-depletion mechanism
leading to a severe ADAMTS13 quantitative deficiency is the most
important mechanism for the severe ADAMTS13 enzymatic
deficiency identified in the decedent patients. The high titers of the
anti-ADAMTS13 IgG/IgM/IgAs are likely to be strongly involved
in the formation of immune complexes, but a particularly high
affinity of these IgG/IgM/IgAs to ADAMTS13 may also be
hypothesized. Hence, both the high titer and the potential high
affinity of the anti-ADAMTS13 IgG/IgM may also explain the lack
of response to the first intention treatment (steroids and plasma
exchanges) that led to a fatal outcome with a dramatic multivisceral
involvement in our 3 patients. Retrospectively, in these patients, the
indication of a first-line immunosuppressive treatment associated
with plasmatherapy is debatable.
In our cohort, however, 32 patients of 35 (91.4%) achieved
remission within 3 to 5 weeks with a treatment associating steroids
and plasma exchanges. No patient required an additive treatment
(ie, splenectomy or immunosuppressive agents) to induce remis-
sion. This good response to plasmatherapy alone may be explained
by both the exclusion of TMA associated with sepsis, cancer, organ
transplantation, HIV, and enrollment during a first acute TMA
episode. Indeed, TMA refractory to plasmatherapy has been
described mainly either in the previous clinical contexts or,
independently of these specific clinical backgrounds, preferentially
in patients with a recurrent disease.3
Using an 18-month follow-up of the 32 patients who achieved
remission, we found a global relapse rate of 19%. Although relapse
rates previously reported are very heterogeneous and look very
dependent on the clinical background,3,23 the relapse rate of our
cohort is, however, in agreement with data from the literature: In
Figure 4. ADAMTS13-related parameters at presentation in 32 surviving TMA
patients. The level of ADAMTS13 activity in survivors at initial clinical remission
defines 3 groups of TMA patients: below 5% (group 1, n  13, black histograms),
15% to 40% (group 2, n  12, dashed histograms), and 50% to 100% (group 3,
n  7, white histograms). At presentation, the percentage of patients with either a
decreased ADAMTS13Ag level, an ADAMTS13 inhibitor (independently of the titer),
or the presence of an anti-ADAMTS13 IgG, IgM, or IgA was not significantly different
between the 3 groups. In contrast, at presentation, the presence of either a high titer
of ADAMTS13 inhibitor or a highly inhibitory anti-ADAMTS13 IgG was significantly
(*P  .05) more frequent in group 1 when compared with group 2 and group 3,
respectively.
Figure 3. ADAMTS13 inhibitor titer. Titer is shown in the acute phase (A) and in
remission (B) in 32 surviving TMA patients. The level of ADAMTS13 activity in
survivors at initial clinical remission defines 3 groups of TMA patients: below 5%
(group 1, n  13, black histograms), 15% to 40% (group 2, n  12, dashed
histograms), and 50% to 100% (group 3, n  7, white histograms). The percentage of
patients with either high, medium, low, or negative ADAMTS13 inhibitor titers within
each group is presented both in the acute phase (A) and in remission (B). In group 1,
ADAMTS13 inhibitor titers remained identical or decreased in remission when
compared with the acute phase. In groups 2 and 3, all ADAMTS13 inhibitors, when
present in the acute phase, disappeared in remission.
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adult idiopathic TMA, data from the Oklahoma TTP-HUS registry
report a relapse rate of about 20%2; in adult TMA occurring
concomitantly with another clinical condition (especially preg-
nancy and autoimmune diseases), the risk of relapse is reported to
be higher than 25%.46,47 Also in agreement with these data, of our 6
relapsing patients, 5 had an idiopathic TMA while 1 had a pregnancy-
associated TMA, and 50% of relapses occurred within the first year.
Interestingly, the relapse rate was significantly higher in patients
whose ADAMTS13 activity in remission was still undetectable
(38.5%) when compared with patients who recovered a detectable
ADAMTS13 activity in remission (5%). This observation is in
agreement with a previous report from our group showing that most
patients with multirelapsing TTP becoming progressively refrac-
tory to plasmatherapy were characterized by a persistent undetect-
able ADAMTS13 activity during remission.48 However, the predic-
tive value for relapse of an undetectable ADAMTS13 activity in
remission remains debatable: Indeed, in our cohort, 1 patient
(patient 21) who recovered a detectable ADAMTS13 activity in
remission (15%) relapsed 16 months after the initial episode, while
8 patients with a still undetectable ADAMTS13 activity in
remission did not relapse during the 18-month follow-up. On one
hand, in our study, the positive predictive value for relapsing in a
delay of 18 months of an undetectable ADAMTS13 activity in
remission (number of relapsing patients with an undetectable
ADAMTS13 activity in remission/total number of patients with an
undetectable ADAMTS13 activity in remission) is only 38.5%.
These data are not surprising considering that even patients with an
inherited, and thus persistent, severe ADAMTS13 deficiency
(Upshaw-Schulman syndrome) exhibit greatly heterogeneous clini-
cal phenotypes in terms of both severity and frequency of
relapses.49,50 Indeed, similar to the incomplete penetrance and
variable expressivity related to gene modifiers observed in most
thrombotic diseases,51 both specific environmental and genetic
backgrounds are likely to associate synergistically with persistent
acquired ADAMTS13 severe deficiency in the trigger of TMA
relapses. On the other hand, the negative predictive value for
relapse of a detectable ADAMTS13 activity in remission (number
of nonrelapsing patients with a detectable ADAMTS13 activity in
remission/total number of patients with a detectable ADAMTS13
activity in remission) is 94.7%, which means that recovering a
detectable ADAMTS13 in remission may be considered as a good
prognostic factor (lower risk of relapse) in patients after a first
acute TMA episode.
In conclusion, this study emphasizes that the pathophysiology
for a first TMA attack related to an undetectable ADAMTS13
activity mainly involves anti-ADAMTS13 IgG combining both an
inhibitory and an immune complex–depletion mechanism. Among
ADAMTS13-related parameters at presentation, the combination
of several anti-ADAMTS13 Ig isotypes (IgG, IgM, and IgA),
including very high IgA titers, is linked to a higher risk of mortality.
In survivors, highly inhibitory anti-ADAMTS13 IgGs at presenta-
tion are associated with the persistence of an undetectable
ADAMTS13 activity in remission, the latter being predictive for
relapses within 18 months. Similarly to other autoimmune dis-
eases,52 the role of anti-ADAMTS13 auto-Abs in acquired TMA as
prognostic markers needs to be further addressed using longitudi-
nal studies involving large numbers of patients, ideally as soon as
the first TMA attack.
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Table 3. Main VWF/ADAMTS13 features at presentation and at initial remission of the first TMA attack
of the 6 relapsing patients during the 18-month follow-up
Patient
no.
VWFAg,
IU/dL
ADAMTS13
Ag, ng/mL
ADAMTS13
inhibitor titer
Anti-ADAMTS13
IgG titer, 1/dilution
ADAMTS13 activity, %;
inhibitor in remission
6 140 450  200  5; 
13 180 145  800  5; 
14 245 75  400  5; 
16 140 1010  800  5; 
21 70 300  1600 15; 
27 140 160  200  5; 
Anti-ADAMTS13 IgM titer and anti-ADAMTS13 IgA titer equal 0 for all patients listed in this table.
 indicates high;, medium;, low;, negative.
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Summary. Background: ADAMTS13-neutralizing IgG auto-
antibodies are the major cause of acquired thrombotic
thrombocytopenic purpura (TTP). Objective: To analyze the
IgG subclass distribution of anti-ADAMTS13 antibodies and a
potential relationship between subclass distribution and disease
prognosis. Methodology: An enzyme-linked immunosorbent
assay-based method was used to quantify the relative amounts
of IgG subclasses of anti-ADAMTS13 antibodies in acquired
TTPplasma.Results: IgG4 (52/58, 90%)was themost prevalent
IgG subclass in patients with acquired TTP, followed by IgG1
(52%), IgG2 (50%), and IgG3 (33%). IgG4 was found either
alone (17/52) orwith other IgG subclasses (35/52). IgG4was not
detected in 10% of the patients. There was an inverse
correlation between the frequency and abundance of IgG4
and IgG1 antibodies (P < 0.01). Patients with high IgG4 levels
and undetectable IgG1 are more prone to relapse than patients
with low IgG4 levels and detectable IgG1. Conclusions: All IgG
subclasses of anti-ADAMTS13 antibodies were detected in
patients with acquired TTP, with IgG4, followed by IgG1,
antibodies dominating the anti-ADAMTS13 immune response.
Levels of IgG4 could be useful for the identiﬁcation of patients
at risk of disease recurrence.
Keywords: ADAMTS13, anti-ADAMTS13 antibodies, IgG
subtypes, thrombotic thrombocytopenic purpura.
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a life-
threatening thrombotic microangiopathy (TMA) character-
ized by microangiopathic hemolytic anemia, thrombo-
cytopenia with renal impairment or neurologic
abnormalities due to the deposition of platelet, and von
Willebrand factor (VWF)-rich thrombi in the microcircula-
tion [1]. ADAMTS13 (a disintegrin-like and metalloprotease
with thrombospondin type 1 motif) regulates the size,
and therefore the thrombogenic potential, of VWF by
cleaving the peptide bond between Tyr1605 and Met1606 in
the A2 domain of VWF subunits. Congenital or acquired
ADAMTS13 deﬁciency is the major risk factor for
TTP [2,3].
Autoantibodies against ADAMTS13 are believed to cause
ADAMTS13 deﬁciency in acquired idiopathic TTP [4,5]. The
antibody response to ADAMTS13 includes neutralizing or
non-neutralizing antibodies [4–6]. Neutralizing antibodies
block the proteolytic activity of ADAMTS13 towards VWF
and are detected with in vitro functional assays. Non-neutral-
izing antibodies can only be identiﬁed by enzyme-linked
immunosorbent assay (ELISA) [7]. Such antibodies may
contribute to increasing ADAMTS13 clearance from the
circulation or may interfere with ADAMTS13 interaction with
cells or other plasma proteins [6]. Principally, the ELISA assay
detects neutralizing or non-neutralizing antibodies against
ADAMTS13. Such antibodies are predominantly of the IgG
class and, to a lesser extent, of the IgM class [7,8]. We have also
identiﬁed IgA anti-ADAMTS13 antibodies in some patients
with acquired TTP [8], but their clinical signiﬁcance is
unknown.
The biological function of IgG antibodies is determined
by their speciﬁcity, afﬁnity, and subclass. IgG subclasses
have different capacities to bind to cell surface Fcc receptors
(FccRs) or to activate complement proteins [9], thus
mediating different immunologic effector functions. We
characterized the ADAMTS13-speciﬁc IgG antibody sub-
class distribution to elucidate the role of IgG anti-ADAM-
TS13 autoantibodies in the pathologic mechanism leading to
acquired TTP.
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Materials and methods
Patients
Fifty-eight patients diagnosed with acute acquired TTP were
analyzed. Fifty-three had idiopathic TTP, and ﬁve had TTP
associated with pregnancy (n = 2), the postpartum state
(n = 1), systemic lupus erythematosus (SLE) (n = 1), or
cancer (n = 1).
Forty-four patients were analyzed during the ﬁrst episode of
TTP, and 14 during relapse. Four of the 44 patients analyzed
during the ﬁrst episode died, eight were lost to follow-up, and
11/32 who achieved clinical remission relapsed during the 36-
month follow-up (follow-up, 36–77 months). The 14 patients
studied during an acute relapse had a documented positive
history of TTP with at least one previous TTP episode. Five of
14 patients who were included in the 36-month follow-up had
no new relapses, and nine were lost to follow-up.
Inclusion criteria Patients had to meet the following
inclusion criteria: (i) presence of microangiopathic hemolytic
anemia (hemoglobin level < 12 g dL)1), direct antiglobulin
test-negative, at least two schistocytes per high-power ﬁeld in
the peripheral blood smear, lactate dehydrogenase
levels > 450 IU L)1, and undetectable serum haptoglobin;
(ii) thrombocytopenia (platelet count < 150 · 109 L)1); and
(iii) severely reduced (< 10%) plasma ADAMTS13 activity
levels. Fever, neurologic symptoms or renal failure were not
obligatory.
Clinical and laboratory data The patients demographic
and clinical features and ADAMTS13-related laboratory
ﬁndings are summarized in Table 1. The clinical
characteristics and laboratory ﬁndings of some of these
patients have been described previously [7,8].
Remission was deﬁned as a normal platelet count
(> 150 · 109 L)1) and no plasma exchange treatment for 30
consecutive days (day 1 of remission) or more. Relapse or
recurrence was deﬁned as the reappearance of clinical mani-
festations and/or laboratory data compatible with TTP after
remission had been achieved.
Plasma samples Frozen plasma samples from TTP patients
were obtained from the Central Haematology Laboratory,
University of Bern, Switzerland (Center 1) and Service
dHematologie biologique, Hoˆspital Antoine Be´cle`re, Paris,
France (Center 2). Patients were enrolled after giving consent
according to the Declaration of Helsinki. This study was
approved by the institutional review board.
Determination of the activity, inhibitors and antigen of
ADAMTS13
ADAMTS13 activity (ADAMTS13:Ac) and functional AD-
AMTS13 inhibitors were measured in patients plasma at
Centers 1 and 2 as previously described [10,11]. ADAMTS13
antigen (ADAMTS13:Ag) levels were analyzed in patients
plasma by ELISA [12].
Determination of total IgG, IgG subclass, IgM, IgA and IgE
anti-ADAMTS13 antibodies by ELISA
Total IgG (IgGtot) and IgG subclass, IgM, IgA and IgE anti-
ADAMTS13 antibodies were analyzed by ELISAas previously
described [7], with minor modiﬁcations. Brieﬂy, microtiter
plates (Nunc-Immuno Maxisorp, Roskilde, Denmark) were
coated with anti-His tag antibody (2 lg mL)1) (Penta-His;
Qiagen, Hilden, Germany). The non-speciﬁc binding sites were
blocked. Recombinant His-tagged ADAMTS13 (2 lg mL)1)
was added. Diluted patients plasma and negative controls
(pooled normal human plasma; Baxter BioScience, Vienna,
Austria) were incubated overnight at 4 C. Bound antibodies
were detected using an alkaline phosphatase (AP)-conjugated
goat anti-human IgG, IgM, IgA or IgE antibody (Sigma, St
Louis, MO, USA) or mouse monoclonal anti-human IgG1,
IgG2, IgG3 and IgG4 antibodies (Zymed Laboratories, San
Francisco, CA, USA). Finally, the enzyme substrate p-nitro-
phenylphosphate (Sigma) was added, and the absorbance was
read at 405 nm with a reference ﬁlter of 620 nm on an iEMS
microplate reader (Labsystems, Helsinki, Finland). Between
each step, the plates were washed with phosphate-buffered
saline containing 0.1% (v/v) Tween-20 (pH 7.4).
The speciﬁcity of the AP-conjugated mouse monoclonal
anti-human IgG1–IgG4 and goat anti-human IgE antibody
detection was checked. No cross-reactivity was observed at any
concentration with any class or subclass of antibodies.
Data analysis and statistical calculations
IgGtot and IgG subclass, IgM, IgA and IgE anti-ADAMTS13
antibodies were expressed as antibody titers, and the cut-off
Table 1 Demographic and clinical features and ADAMTS13-related
laboratory findings of patients with acute acquired thrombotic thrombo-
cytopenic purpura (TTP)
Sex, F/M 41/17
Median age, years (range) 38 (16–75)
Median platelet count, · 109 L)1 (range) 12 (3–82)
No. of patients/total
Idiopathic TTP 53/58
TTP with associated conditions 5/58
ADAMTS13:Ac (< 10%)/n 58/58
ADAMTS13 functional inhibitor/n 52/58
ADAMTS13:Ag (ng mL)1)
Undetectable (< 65) 14
65–100 10
101–740 32
Normal levels (740–1420) 2
IgG anti-ADAMTS13/n 58/58
IgM anti-ADAMTS13/n 4/58
IgA anti-ADAMTS13/n 10/47
n, number of patients tested; ADAMTS13:Ac, ADAMTS13 activity;
ADAMTS13:Ag, ADAMTS13 antigen.
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levels were calculated as previously described [7]. Samples
above the cut-off level were judged to be positive. The IgG
subclass optical density (OD) values were normalized by the
corresponding normalization factor, calculated as described
below. To ensure speciﬁcity of the anti-ADAMTS13 antibody
detection, the positivity of samples was conﬁrmed by compet-
itive inhibition experiments, using puriﬁed recombinant
ADAMTS13.
Quantification and normalization of the absorbances
measured in IgG subclass ELISA
We used ELISA with subclass-speciﬁc antibodies to estimate
the relative amounts of the different IgG subclasses, ﬁrst
because of the absence of a true standard, and second because
of the differences in the development time between the IgG
subclasses due to differences in the detection sensitivities of the
secondary antibodies used. To minimize these differences, the
relative OD values of the IgG subclass ELISA were compared
under standardized conditions.
The time-dependent OD signal generated from each IgG
subclass (puriﬁed human IgG1–IgG4, lambda chain; Sigma)
coated on an ELISA plate in a concentration range of 0.125–
1 lg mL)1 was analyzed. The corresponding OD values
generated were recorded every 5 min up to 75 min, and plotted
against time. Slopes for each concentration and subclass were
calculated. The corresponding means ± standard deviations
of the slopes from four independent experiments were plotted
and analyzed by linear regression for each individual IgG
subclass. The regression parameters obtained were used to
calculate the OD values of each subclass at a coating
concentration of 0.5 lg mL)1 (linear range). The OD value
of IgG4 was set to 1, resulting in normalization factors for
IgG1, IgG2 and IgG3 of 9, 0.7 and 0.4, as compared with IgG4.
Coating efﬁciency was evaluated in each experiment by ELISA
using an AP-conjugated goat anti-human lambda light chain
antibody (Sigma) to ensure uniform IgG1–IgG4 concentra-
tions.
The calculated normalization factors were used to normalize
the OD values in patients with more than one IgG subclass of
anti-ADAMTS13 antibodies. Samples were normalized by
multiplying the OD values corresponding to each positive
subclass by the corresponding calculated normalization factor.
With this approach, an estimate was obtained of the relative
contributions of the different IgG subclasses to the total anti-
ADAMTS13 IgG in patient plasma. Without the normaliza-
tion procedure, IgG1 levels would have been underestimated as
compared with IgG2–IgG4 levels, as inferred from the
normalization factor values. Samples with normalized OD
values above the linear range were excluded (six patients) from
analyses.
Positive normalized OD values of each subclass were
summed (IgGsum, total absorbance), and the proportion of
each individual subclass was calculated as a percentage of the
total absorbance (assumed to be 100%) to obtain the IgG
subclass percentage distribution in a single patient.
Statistical analysis
Statistical analyses were performed with SIGMASTAT ver-
sion 3.5 (Systat Software, San Jose, CA, USA). Data are
presented as the median and the interquartile range (IQR). The
statistical signiﬁcance of the differences between medians of
IgG1 and IgG4 values were assessed by the Mann–Whitney
rank sum test, and the correlation by the Spearman rank test.
To assess the strength of the relationship between IgG4 levels
and recurrence, 40 patients were divided into three groups
according to clinical outcome. The ﬁrst group comprised 18
patients who had experienced only a single TTP event, the
second comprised nine patients who relapsed during the
36 months of follow-up, and the third comprised 13 patients
who had had relapse(s), ﬁve of whom had had no further
relapses during follow-up, and eight of whom were lost to
follow-up after the acute relapsing event. Deceased patients,
patients lost to follow-up after the ﬁrst TTP event and patients
with IgG4 OD values above the linear range were excluded
from this analysis (18 patients). P-values < 0.05 were consid-
ered to be statistically signiﬁcant.
Results
ADAMTS13:Ac, functional ADAMTS13 inhibitor and
ADAMTS13:Ag levels
All patients (n = 58) had ADAMTS13:Ac values < 10%.
The corresponding ADAMTS13:Ag levels showed a variable
distribution, from undetectable to normal levels (Table 1),
similar to earlier ﬁndings [12]. A functional inhibitor was found
in 52 patients (89%; Table 1).
Anti-ADAMTS13 antibody profiles
Analysis of the anti-ADAMTS13 antibody proﬁle in acquired
TTP patients revealed anti-ADAMTS13 IgG antibodies in all
of the patients, including the six with severe ADAMTS13
deﬁciency without functional inhibitors. Titers ranged from 20
to 6400. Additionally, low titers of anti-ADAMTS13 IgM
antibodies were detected in four patients (7%) and of anti-
ADAMTS13 IgA antibodies in 10/47 patients (21%), with
titers ranging from 200 to > 10 000 (Table 1). The anti-
ADAMTS13 IgA antibody titer was not determined in 11
patients, owing to insufﬁcient plasma.
Subclass distribution of IgG anti-ADAMTS13 antibodies
The subclass distribution of anti-ADAMTS13 IgG antibodies
was analyzed in 58 patients with acquired TTP: 44 during the
ﬁrst episode, and 14 during relapse. IgG4 was detected in 90%
of the patients (52/58, 90%), followed by IgG1 (30/58, 52%),
IgG2 (29/58, 50%), and IgG3 (19/58, 33%) (Fig. 1A).
When patients were subdivided by clinical outcome, 38/44
(86%) patients analyzed during the ﬁrst event had IgG4
antibodies. IgG4 was found either alone (8/38, 21%) or with
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other IgG subclasses (30/38, 79%). Among the 30 patients in
whom IgG4 was found with other IgG subclasses, the
association with all four IgG subclasses (10/30, 33%) was the
most prevalent ﬁnding, followed by associations with IgG2 (7/
30, 23%), IgG1 (5/30, 17%), and IgG3 (1/30, 3%). IgG4 was
also found with IgG1 and IgG2 (4/30, 13%) and with IgG1 and
IgG3 (3/30, 10%) (Fig. 1B). No IgG4 was detected in 6/44
(14%) TTP patients who had predominantly IgG1 with IgG3
(n = 2), IgG2 (n = 1), or IgG2 and IgG3 (n = 3) (Fig. 1B).
The IgG subclass distribution in 14 patients analyzed during
an acute relapsing event revealed IgG4 as the predominant IgG
subclass (14/14, 100%); IgG4 was found either alone (9/14,
65%) or associated with IgG2 (3/14, 21%), IgG1 (1/14, 7%), or
IgG1 and IgG2 (1/14, 7%) (Fig. 1C).
Patients having TTP associated with pregnancy (n = 2) and
the postpartum state (n = 1) had IgG4 accompanied by IgG2,
IgG1, or IgG3. The patient with TTP associated with SLE had
all four IgG subclasses, whereas the patient with TTP
associated with cancer had no IgG4.
The IgG subclass distribution of 4/6 patients without
detectable functional inhibitors showed IgG4 accompanied by
IgG2, IgG3, or IgG1 and IgG3, or all of them. The remaining
two patients had no IgG4, with IgG1 being the most
representative subclass (Fig. 2A; individual patient num-
bers 21, 29, 31, 41, 48, and 52).
To assess the contribution of any subclass to IgGsum, we
calculated the relative concentration of each IgG subclass in a
patient. Six of 58 patients were excluded from this calculation
because their IgG4 OD values were outside the linear range.
IgG4 was the most abundantly produced subclass, with levels
ranging from 1% to 100% (Fig. 2A). IgG1 was the second
most common, with levels ranging from 11% to 92%, whereas
IgG2 and IgG3 formed only a small percentage of IgGsum
(levels ranging from 4% to 26% and 1% to 30% for IgG2 and
IgG3, respectively) (Fig. 2A). In contrast to IgG4, IgG1 was
never found as a single subclass; however, in the absence of
IgG4, IgG1 constituted more than 85% of IgGsum. The
presence and abundance of IgG4 and IgG1 were inversely
correlated (r2 = ) 0.927, P < 0.01) (Fig. 2A). Patient num-
bers 1–3, 6–8, 11, 13, 16, 18, 25, 26 and 38 represent those
patients analyzed during an acute relapsing event (Fig. 2A,B).
IgE anti-ADAMTS13 antibodies were also assayed, because
production of IgG4 and IgE is induced by the same cytokines
[interleukin (IL)-4 and IL-13], released by T-helper 2 (Th2)
cells [13]. None of the 17 patients with IgG4 as the only positive
subclass had IgE antibodies against ADAMTS13, excluding a
pathogenic role of IgE autoantibodies in TTP as described in,
for example, bullous pemphigoid [14].
Relationship between the IgG subclass profile and the total
anti-ADAMTS13 IgG antibody titers and ADAMTS13:Ag
levels
When IgGtot was related to the IgG subclass proﬁle, patients
with IgG4 as the only subclass showed lower IgGtot titers
(range 20–200) than patients with IgG4 combined with other
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Fig. 1. Subclass distribution of anti-ADAMTS13 IgG antibodies in pa-
tients with acquired thrombotic thrombocytopenic purpura. Fifty-eight
patients with acute acquired TTP were analyzed for different IgG sub-
classes. (A) The histogram represents the overall frequencies of the four
anti-ADAMTS13 IgG subclasses. (B) Patients analyzed during the first
TTP episode (n = 44). (C) Patients analyzed during a relapsing event
(n = 14). (B, C) Histograms showing the frequencies of patients positive
for each IgG subclass combination. Plus signs denote the presence of the
subclass; minus signs denote the absence of the subclass.
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IgG subclasses (Fig. 2B). The combination of IgG4 with one,
two or more IgG subclasses was associated with the highest
IgGtot titers (range 100–6400). This was evenmore pronounced
in patients with undetectable IgG4 (range 1600–6400). Patients
without detectable functional inhibitors generally had low
IgGtot antibody titers (100–400), except for two patients who
had undetectable IgG4 (1600 for both) (Fig. 2B).
The relationship between ADAMTS13:Ag levels and the
IgG subclass proﬁle was variable, with a trend towards lower
ADAMTS13:Ag levels with increasing numbers of IgG
subclasses. Patients with the lowest IgG4 levels (< 10%) or
highest IgG1 levels (> 85%) had signiﬁcantly lower ADAM-
TS13:Ag levels than patients with the highest IgG4 levels or
IgG4 as the only subclass present (P < 0.01 and P < 0.05,
respectively; the six patients with IgG4 OD values outside the
linear range were excluded from this analysis).
Subclass distribution of anti-ADAMTS13 IgG antibodies and
clinical outcome
Four patients (n = 4) who had very low (< 5%) or
undetectable IgG4 with high levels of IgG1 died during the
ﬁrst acute TTP event (Table 2). These patients also showed
high anti-ADAMTS13 IgA antibody titers, three of them in
combination with anti-ADAMTS13 IgM antibodies.
The association between levels of IgG4 and IgG1 and the
recurrence of TTP was analyzed in 40 patients, who were
divided into three groups: those who had experienced only a
single TTP episode [group 1; IgG4 and IgG1 median values
were 44% (IQR 30–85) and 50% (IQR 15–63), respectively];
those who relapsed during the 36 months of follow-up
[group 2; IgG4 and IgG1 median values were 91% (IQR 72–
95.5) and 0% (IQR 0–15), respectively]; and those who had
had relapse(s) before [group 3; IgG4 and IgG1 median values
were 100% (IQR 91.2–100) and 0% (IQR 0–0), respectively]
(Fig. 3) (for inclusion criteria, see Materials and methods,
Statistical analysis). A second analysis was performed in
parallel, in which the six patients with IgG4 OD values outside
the linear range (most likely with underestimated IgG4 levels)
were included. Three of these patients were included in
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Fig. 2. Relative concentrations of anti-ADAMTS13 IgG subclasses and
total IgG anti-ADAMTS13 antibody titers within a patient. (A) The
relative concentrations of the different IgG subclasses were calculated for
plasma of 52 TTP patients. The individual IgG subclass distribution of
each patient is shown. Patients are numbered 1 to 52 according to
decreasing levels of IgG4. IgG4 and IgG1 are the predominant IgG
subclasses. (B) Total IgG anti-ADAMTS13 antibody titers corresponding
to each patient [numbered from 1 to 52 as in (A)]. In both (A) and (B),
individual patient numbers are shown in steps of ﬁve, and patients 21, 29,
31, 41, 48 and 52 have no detectable functional inhibitors.
Table 2 ADAMTS13 laboratory findings and clinical outcome in patients with very low (< 5%) or undetectable levels of IgG4 and high levels of IgG1
Patient
no.*
ADAMTS13:Ac
(U mL)1)
ADAMTS
13 inhibitor
ADAMTS
13:Ag (ng mL)1)
IgG anti-ADAMTS
13 (titer)
IgM anti-ADAMTS
13 (titer)
IgA anti-ADAMTS
13 (titer)
IgG1
(%)
IgG4
(%) Outcome
49 < 0.05 +++ < 65 6400 3200 > 10 000 92 0 Death
50 < 0.05 + < 65 3200 0 0 92 0 Remission
48 < 0.05 ) < 65 1600 0 > 10 000 91 0 Death
52 < 0.05 ) < 65 1600 50 800 85 0 Death
46 < 0.05 + < 65 3200 0 3200 88 1 Remission
45 < 0.05 + 83 1600 20 3200 78 3 Death
47 < 0.05 + 560 200 0 0 71 0 Remission
ADAMTS13:Ac, ADAMTS13 activity; ADAMTS13:Ag, ADAMTS13 antigen. *Patients numbers correspond to the individual numbers in Fig. 2.
All patients had idiopathic thrombotic thrombocytopenic purpura.
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group 1, two in group 2, and one in group 3. High levels of
IgG4 were associated with relapse (P = 0.03 and P = 0.001
for comparison between groups 1 and 2, and groups 1 and 3,
respectively). Similar P-values were obtained when patients
with IgG4 OD values outside the linear range were included
(P = 0.017 and P < 0.001 for comparison between groups 1
and 2, and groups 1 and 3, respectively).
Likewise, patients with undetectable or very low IgG1 levels
experienced more TTP events than patients with detectable
(moderate or low) levels (P = 0.005 and P < 0.001 for
comparison between groups 1 and 2, and groups 1 and 3,
respectively). P-values of 0.004 and < 0.001 for comparison
between groups 1 and 2, and groups 1 and 3, respectively were
obtained when patients with IgG4 OD values outside the linear
range were included.
Taken together, our ﬁndings suggest that patients with high
levels of IgG4 and undetectable IgG1 are more prone to relapse
than patients with low levels of IgG4 and detectable IgG1.
Discussion
We investigated the IgG subclass distribution of anti-
ADAMTS13 IgG antibodies in patients with acquired TTP,
using an ELISA as described [7], but slightly modiﬁed, with
anti-human IgG1–IgG4 antibodies as detecting antibodies. We
reasoned that, because the various IgG subclasses differ in their
biological functions, the characterization of the subclass proﬁle
of anti-ADAMTS13 antibodies could provide insights into the
pathophysiology of acquired TTP.
IgG4 was the only subtype detected in a remarkable number
of patients (17/58), implying a dominant role for IgG4 in this
autoimmune disease. The second most frequent subtype was
IgG1, and IgG2 and IgG3 were less represented. Our ﬁndings
indicate that the autoimmune response against ADAMTS13 is
polyclonal and heterogeneous.
IgG1 and IgG4 also predominated in patients with inhibitors
in acquired and in congenital hemophilia A [15], in blistering
skin diseases [16], and in other autoimmune diseases [17].
Interestingly, and inexplicably, absolute levels of IgG1 and
IgG4 were always inversely correlated.
IgG4 is predominantly produced after prolonged antigenic
stimulation [18]. The strong bias towards production of IgG4
autoantibodies against ADAMTS13 therefore suggests chronic
antigenic stimulation of the immune system when systemic
tolerance mechanisms fail.
Although our study is limited by the number of patients, and
further studies are needed, we observed that patients are less
likely to survive their ﬁrst TTP event (four of seven patients
died) if they have IgG1 and very low or undetectable IgG4 levels
plus higher titers of other classes of anti-ADAMTS13
antibodies (particularly IgA). Our ﬁndings are supported by
a recent report of a TTP patient with high IgG1 levels who died
during a relapsing event, although IgG4 antibodies were not
investigated [19]. IgG1 is known to activate the classical
complement pathway, and binds to activating FccRs expressed
on innate immune effector cells, whereas IgG4 fails to activate
complement, and binds to cellular FccRs with less efﬁciency
than IgG1 [9]. Furthermore, IgA antibodies may also contri-
bute to the severity of the pathogenesis, because they have been
shown to activate complement via the mannan-binding lectin
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Fig. 3. Levels of IgG1 and IgG4 anti-ADAMTS13 antibodies in patients
with acute acquired thrombotic thrombocytopenic purpura (TTP) pa-
tients. (A) Patients who had experienced only a single TTP event. (B)
Patients who relapsed during the 36 months of follow-up. (C) Patients
who had had relapse(s), including patients without further relapses during
follow-up and patients lost to follow-up after the acute relapsing event.
IQR, interquartile range.
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pathway [20], favoring an enhancement of complement-medi-
ated inﬂammation.
IgG4 antibodies are thought to be functionally monovalent
[18,21] through a process described as in vivo Fab arm
exchange of IgG4 half-molecules, in which a heavy–light
chain pair of one IgG4 molecule joins with another, unrelated,
half IgG4 molecule, leading to a newly combined IgG4
molecule with two different antigen-binding sites [22]. Such
hybrid molecules are unable to crosslink antigen and,
consequently, to form large immune complexes. However,
only large immune complexes can crosslink FccRs, thereby
activating innate immune effector cells [23]. Functional
monovalency might decrease the pathologic potential of
IgG4 antibodies and might, during contact with antigen,
result in only small and relatively harmless immune complexes
with a low potential for induction of immune activation [24].
Although anti-ADAMTS13 IgG4 antibodies have yet to be
shown to be functionally monovalent and to interfere with
complement activation in vivo, it is tempting to speculate that
IgG4 autoantibodies, to some extent, act as protective
antibodies in TTP patients, inducing a milder and treatable
form of TTP, whereas IgG1 (and IgA) anti-ADAMTS13
antibodies might have higher pathogenic potential, particu-
larly in the absence of IgG4.
Relapse occurs in 30–50% of the patients who survive an
initial episode of TTP, beingmore frequent during the ﬁrst year
after the onset [25,26]. Several studies have investigated the
signiﬁcance of ADAMTS13 activity and inhibitors in predict-
ing outcomes. Most concluded that severe ADAMTS13
deﬁciency and the presence of antibodies against ADAMTS13
at presentation and/or remission are associated with a higher
risk of disease recurrence [8,25,27]. We investigated the
possibility of an association between IgG subclasses and
relapse, and found that high levels of IgG4 with undetectable
IgG1 were statistically signiﬁcantly associated with a trend
towards recurrence of TTP. This suggests that high levels of
IgG4 could help to identify patients who are at risk of
recurrence, and could be used, in associationwithADAMTS13
activity and inhibitors, as a prognostic marker to predict
possible relapse.
In conclusion, we found that the subclass proﬁle of anti-
ADAMTS13 IgG antibodies in patients with acquired TTP is
dominated by IgG4 and IgG1 antibodies with inversely
correlated titers. An immune response characterized by high
levels of IgG4 predicts, at least partially, a more treatable form
of TTP than if IgG1 antibodies are present. We conclude that
IgG4 levels could be a recurrent predicting biomarker, although
prospective trials with well-characterized patients are needed to
substantiate our preliminary observations. The contribution
made by IgG4 and IgG1 autoantibodies to the pathologic
mechanism in acquired TTP needs further investigation.
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Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by the 
presence of neutralizing and/or non-neutralizing anti-ADAMTS13 autoantibodies 
which are predominantly of the IgG class and less frequently of the IgM and/or IgA 
classes [1-4]. However, the extent to which these antibodies circulate in plasma in 
their free form or as a complex with ADAMTS13 and how this proportion changes 
over time is unclear. We and others have recently reported indirect detection by an 
ADAMTS13 antigen (ADAMTS13:Ag) ELISA of IgG ADAMTS13-specific immune 
complexes (ICs) in plasma from patients with acquired TTP [5,6]. In the present study 
we used another more direct method for detecting ICs and compared the levels of 
free anti-ADAMTS13 antibodies, ADAMTS13:Ag, ADAMTS13 activity 
(ADAMTS13:Ac) and inhibitor with those of ICs. 
Samples from a patient with acquired idiopathic TTP, whose case history has in 
part been described [1], were analyzed. Treatment modalities of this patient are 
summarized in Fig. 1A. The patient presented with undetectable ADAMTS13:Ac and 
ADAMTS13:Ag, but also without ADAMTS13:Ac inhibition as determined by the CBA 
assay [1,5,7]. Re-assessment of the inhibitor with the more sensitive fluorometric 
FRETS-VWF73 assay [7] revealed low level inhibition of ADAMTS13:Ac, 
corresponding to ~0.8 BU/mL. 
Fig. 1B summarizes the dynamic course of ADAMTS13:Ac, ADAMTS13:Ag, and 
ADAMTS13 inhibitor during the 64 days’ follow-up until the patient’s death. Analyses 
of specific IgG, IgM and IgA anti-ADAMTS13 antibodies by ELISA [8] detected IgG 
and IgA antibodies at most time points, whereas IgM antibodies were only 
measurable until day 12 (Fig. 1C-E, Supplementary Fig. 1). The anti-ADAMTS13 IgG 
subclass profile on admission (82% IgG1, 7% IgG2, 11% IgG3, no IgG4) did not 
change significantly during the course of the disease (not shown). The IgG and IgA 
2 
antibody titers decreased during periods of transient response to plasma exchange 
(PEX) treatment, but this drop was not always accompanied by a recovery in 
ADAMTS13:Ac and ADAMTS13:Ag levels. This lack of ADAMTS13 activity recovery 
and the presence of high levels of IgG1 combined with undetectable IgG4 have been 
described as indicators of poor prognosis and increased risk of mortality in patients 
with acquired TTP [6,8] and may, at least in part, explain the poor outcome of the 
patient. 
The presence of ICs was demonstrated by co-immunoprecipitation of 
ADAMTS13 with immunoglobulins, using protein G for the isolation of total IgG, and 
anti-IgA- and anti-IgM-specific affinity matrixes for isolation of total IgA and IgM, 
respectively (Fig. 1C-E). Interestingly, ADAMTS13-specific IgG-ICs were detectable 
in significant amounts at most times during the 2-month follow up, particularly when 
the free IgG antibody titers and inhibitor were low. By contrast, IgG-ICs became 
almost undetectable when the free IgG antibody titers and ADAMTS13 inhibitor were 
high (Fig. 1B, C). Thus, IgG-ICs followed an inverse kinetics to both the free IgG 
antibody in plasma and the inhibitory titer. Similar trends were seen for the IgA- and 
IgM-specific ICs, but with an apparently lower total concentration than IgG-ICs (Fig. 
1D, E). Notably, low amounts of IgM-ICs were detected at most time points although 
no free IgM antibodies were detected after day 12 (Fig. 1E), suggesting that all free 
IgM antibodies had been complexed by ADAMTS13. Overall it appears that anti-
ADAMTS13 antibodies are not detected by ELISA when they are part of an immune 
complex and the inhibitor titer measured correlates with the amount of free anti-
ADAMTS13 antibodies. 
In the patient studied, samples from most time points were devoid of free 
ADAMTS13:Ag but contained circulating ICs, indicating that ADAMTS13, either newly 
synthesized or exogenously administered by plasma infusion during PEX, had been 
quantitatively sequestered through formation of ICs. ADAMTS13:Ag was also 
undetectable in samples that had high levels of free anti-ADAMTS13 antibodies but 
lacked circulating ICs (Fig. 1; days 8-11 and 16-21), suggesting that ICs that had 
formed were already cleared at these time points. 
Considering that the patient was receiving daily PEX, the plasma concentration of 
antibodies and antigen changed continuously throughout therapy, thereby influencing 
the dynamic processes of formation, biological activity, deposition and clearance of 
ICs. Under normal conditions, ICs are thought to be quickly cleared by the reticulo-
3 
endothelial system, and only a continuous formation eventually exceeds the 
clearance capacity of the system, causing a build-up of ICs in the circulation. There, 
IgM- or IgG-containing ICs can either activate the complement classical pathway or 
bind to cellular Fc receptors [9,10]. Circulating IgA-ICs have the potential to activate 
complement via the mannan-binding lectin pathway and immune cells when binding 
to Fcα receptors. These features can lead to endothelial cell activation, promoting 
inflammation and disturbing the hemodynamic flow, which in turn may contribute to 
enhanced VWF-dependent platelet adhesion and aggregation. The continuous 
presence of excessive amounts of circulating ICs might therefore perpetuate a pro-
inflammatory state promoting thrombosis and predisposing to relapse.  
In conclusion, our study on the dynamic course of the ADAMTS13-specific 
autoantibody response in a patient with refractory TTP suggests that in addition to a 
characterization of the whole panel of autoantibodies against ADAMTS13, circulating 
ADAMTS13-specific ICs also need to be determined to obtain a full picture of the 
status of the disease. Formation of ADAMTS13-specific ICs capturing all freely 
available ADAMTS13 should be particularly considered in patients who are refractory 
to treatment. Future studies on a representative cohort of patients with acquired TTP 
will show whether our observation of an inverse correlation of free and IC-
sequestered anti-ADAMTS13 antibodies in a single patient is a general phenomenon.  
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Figure 1. Course of ADAMTS13-related variables in a patient with acquired 
idiopathic TTP. (A) Treatment regimen over 64 days until the patient’s death. IAS, 
5 
immunoadsorption (on staphylococcal protein A Sepharose columns); PEX, plasma 
exchange (40 mL fresh-frozen plasma/kg body weight); CS, corticosteroids 
(prednisone 100,50,25,12.5 mg/day). The date of splenectomy is also indicated. The 
following ADAMTS13-related variables were determined at the time points indicated: 
(B) ADAMTS13:Ac (FRETS-VWF73, U/mL), ADAMTS13:Ag (ng/mL, reference range 
740–1420 ng/mL) and ADAMTS13 inhibitor (BU/mL); (C) IgG anti-ADAMTS13 
antibodies (titer) and IgG-ICs (arbitrary units), (D) IgA anti-ADAMTS13 antibodies 
(titer) and IgA-ICs (arbitrary units); (E) IgM anti-ADAMTS13 antibodies (titer) and 
IgM-ICs (arbitrary units). ADAMTS13-specific ICs were analyzed by co-
immunoprecipitation of ADAMTS13 with either Protein G Sepharose or anti-IgA- or 
anti-IgM-specific affinity matrixes. Plasma-bound antibodies were eluted and co-
immunoprecipitated ADAMTS13 was analyzed by Western blot using an affinity-
purified polyclonal rabbit IgG anti-human ADAMTS13 antibody. The relative amount 
of ICs (expressed in arbitrary units) was quantified by densitometry analysis and 
rADAMTS13 (A; 1 ng) as standard. Two pooled normal human plasmas (N1, N2) 
were used as a negative control. The insets in Fig. 1C-E show a section of the 
respective blots. The entire blots and a detailed description of the method are 
depicted in Supplementary Fig. 1. 
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Figure S1 
 
 
 
Figure S1. Detection of circulating ADAMTS13-specific ICs at different time 
points by co-immunoprecipitation and Western blotting. Circulating ADAMTS13-
specific ICs were analyzed by co-immunoprecipitation of ADAMTS13 with either 
Protein G Sepharose (GE Healthcare, Buckinghamshire, England) or anti-IgA- or 
anti-IgM-specific affinity matrixes (BAC CaptureSelect, Naarden, The Netherlands). 
Patient plasma (200 µl) was incubated with 100 µl of beads at room temperature for 
60 min. Bound antibodies were eluted by adding sample loading buffer (Thermo, 
Rockford, IL, USA) and heating at 95°C for 10 min. The co-immunoprecipitated 
ADAMTS13 was analyzed by Western blot using an affinity purified polyclonal rabbit 
IgG anti-human ADAMTS13 antibody (Baxter Innovations, Vienna, Austria) in 
8 
combination with a peroxidase-conjugated goat anti-rabbit IgG (Jackson 
Immunoresearch, West Grove, PA, USA) and a chemiluminescent substrate 
(Thermo). Immunoreactive bands were visualized with the Fusion FX7 image system 
(Vilber Lourmat, Germany) and the relative amount of ICs (expressed in arbitrary 
units) was quantified by densitometry analysis and rADAMTS13 (rA13; 1 ng) as 
standard. Pooled normal human plasma (NP) was used as a negative control. The 
average background signal intensity from the NP was subtracted from the signal 
intensities of the samples. M denote molecular marker. Each lane contains equal 
amounts of total IgG. The anti-ADAMTS13 antibody (IgG, IgA and IgM) titers of the 
samples are shown below the diagram. 
